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Abstract 
Venous Thromboembolism (VTE) is a significant preventable complication that causes 
morbidity and mortality not only in hospitalised patients, but also in healthy individuals. 
Pharmacological and mechanical prophylactic methods are available. Pharmacological 
methods, although are effective in reducing the incidence of VTE, the bleeding risk 
associated with their use is a major drawback. Besides pharmacological methods, clinical 
practice guidelines also recommend the use of mechanical methods (NICE, 2010b). The 
rationale for using mechanical methods is to increase venous return and decrease the risk 
of venous stasis, one of the compounding factors for VTE. As with pharmacological 
methods, mechanical interventions are also associated with side effects. Electrical 
stimulation is an alternative method, which has been shown to be effective in improving 
blood flow (Faghri et al., 1997, Lindstrom et al., 1982, Nicolaides et al., 1972). This 
method however, has not gained widespread use mainly due to the elevated discomfort 
associated with its use at high intensities. The limited number of available electrical 
stimulation devices, are complex in structure and restricts mobility. Therefore, 
developing an alternative technique that is effective and easy to use is justifiable. It is 
among our intentions in the studies presented in this thesis, to investigate the 
effectiveness of a novel electrical stimulation technique. The studies outlined in this 
thesis were carried out on healthy adult volunteers, with the intention of investigating the 
efficacy of a custom built neuromuscular electrical stimulation device (THRIVE) in 
enhancing lower limb blood flow and supporting the development of a prototype to a 
commercial medical device (geko™ T-1). The device activates foot and calf muscle 
pumps of the lower leg using OnPulse™ Technology; a software that ensures safe and 
controlled delivery of electrical impulses. The effect of the novel device on cardiac 
function was initially investigated, where the electrical stimulation device was applied 
bilaterally for 30 minutes at two pulse width settings 400µs and 600µs on 10 healthy 
subjects lying supine. A significant difference in cardiac output was reported following 
echocardiography assessments, p ≤ 0.05. Similarly, a significant increase in skin 
microcirculatory velocity together with arterial peak velocity and blood volume flow was 
reported, p ≤ 0.05. Further investigations were then performed on 10 healthy subjects 
seated in an airline seat for a period of 4 hours, to explore the systemic effect of the 
electrical stimulation device applied for a period of 5 minutes on specific blood 
coagulation parameters. A series of lower limb circulatory dynamic assessments were 
performed at baseline and at 1, 2, 3 and 4 hours. Blood coagulation parameters and blood 
clotting time were measured through analysis of blood withdrawn from three anatomical 
sites (arm, right leg and left leg). Results obtained have shown a highly significant 
increase in lower limb blood perfusion, p ≤ 0.001. An enhanced fibrinolytic activity, 
characterised by a significant drop in tissue plasminogen antigen levels was seen. No 
major effects on vital signs were reported. Finally, a comparison of the effectiveness of 
the novel device with two leading mechanical prophylaxis devices, Huntleigh Flowtron™ 
Universal and Kendall SCD™ was performed on 10 healthy subjects. Each device was 
fitted for a period of 30 minutes followed by a 10 minute recovery phase, in a sequential 
manner. Colour flow Doppler ultrasound in addition to skin microcirculatory and vital 
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sign assessments were carried out to further assess the comparative efficacy. Results 
obtained demonstrate that the novel device is significantly more effective in increasing 
microcirculatory velocity, p ≤ 0.001 in comparison to the IPC devices investigated. 
Venous blood flow measurements were also significantly higher for the geko™ T-1 
device compared to the IPC devices. Furthermore, a significant increase in both arterial 
blood velocity and volume was reported following the use of the geko™ T-1 device.  
The safety and tolerability to the device was also of prime concern. Results showed that 
the device was well tolerated throughout, as indicated by the minimal discomfort 
sensation perceived by the subjects using visual analogue scale (VAS) and verbal rating 
score (VRS) in all studies. In conclusion, the results obtained in this thesis indicate that 
the geko™ T-1 device investigated has a potential use in the prevention of deep vein 
thrombosis and other peripheral vascular disorders due to significant effects on 
circulatory dynamics in arterial, venous, and microcirculatory systems. 
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Chapter 1. Introduction 
Venous thomboembolism (VTE), comprising deep vein thrombosis (DVT) and 
pulmonary embolism (PE) is a major health problem that received a burst of attention in 
the press and clinical forums. In the year 2003, the American Public Health Association 
declared DVT a public health crisis. Studies from the United States have estimated the 
annual incidence of VTE to be approximately 150 per 100 000 of the population (Heit et 
al., 2001, Tsai et al., 2002). In the year 2005, the House of Commons Select Committee 
for Health, published a critical report stating that 25 000 patients in England die annually 
from VTE. The figure reported, is higher than the combined total deaths from breast 
cancer, AIDS, and road traffic injuries (Welch, 2010). However, unlike other diseases, 
VTE is largely preventable through the use of appropriate prophylactic measures in 
patients at higher risk. Since the year 2005, tremendous efforts and resources have been 
devoted to tackle this issue. Specialised teams have been established in the majority of 
hospitals throughout the UK, and risk assessments of VTE upon hospital admission have 
become mandatory. The National Institute of Clinical Excellence also addressed this 
problem by establishing guideline CG-92 in 2010 for the management of VTE. The 
guideline states assessment of patients upon hospital admission to identify those at 
increased risk for developing VTE and selecting the appropriate pharmacological and/or 
mechanical prophylaxis measures as required during their hospital stay and until recovery 
(NICE, 2010b). Indeed financial penalties for poor compliance have been enforced by the 
Department of Health, via the Commissioning for Quality and Innovation (CQUIN) 
target system (NICE, 2010b).   
Prevention of VTE is therefore possible, through the use of the appropriate prophylaxis. 
Prophylaxis measures are broadly categorised as mechanical and pharmacological 
prophylaxis. Both strategies are effective in reducing the risk of VTE significantly 
compared to no prophylaxis (NICE, 2006). However, unlike pharmacological 
prophylaxis, mechanical methods are not associated with bleeding complications or other 
contraindications. They have enjoyed wide popularity, as they can be used as adjunct to 
pharmacological methods or as an alternative, for those patients with a particularly high 
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risk of bleeding. Commonly used mechanical methods include graduated compression 
stockings and intermittent pneumatic compression devices, which although effective they 
are unsatisfactory for a number of reasons. Electrical stimulation is an alternative 
prophylaxis method that is used during operative procedures under general anaesthesia 
and has been shown to effectively activate the calf muscle pump, thereby preventing 
DVT (Lindstrom et al., 1982, NICE, 2006, Nicolaides et al., 1972). However, electrical 
stimulation devices used earlier were associated with a number of shortcomings that are 
mainly associated with the selection of intensity currents. Whereby, the use of a low 
intensity current that stimulates muscles with a low level of contraction may not be 
sufficiently effective in promoting circulation to reduce DVT. On the contrary, the use of 
higher intensity currents that will induce higher levels of contraction will cause the 
muscles to contract sufficiently resulting in involuntary movements of the limb, which 
might be undesirable in certain clinical settings and exquisitely painful as well.  
Objectives of the Thesis  
After considering the short comings associated with the current prophylaxis measures, it 
is among the intention of our research, to provide a novel alternative prophylaxis method 
for the prevention of DVT, and or other circulatory disorders in the lower limb. A series 
of clinical trials were designed, conducted and presented in this thesis, with the aim of 
investigating the effectiveness of a novel electrical stimulation device in improving lower 
limb blood flow and supporting the development of the system. Increasing lower limb 
blood flow improves venous return and thereby reduces venous stasis. Since stasis is one 
of the compounding factors in the development of DVT, the risk of developing 
thrombosis should theoretically be reduced. 
The proposed technique stimulates the motor nerves innervating the lower limb muscles 
at low intensity settings to promote blood circulation. The electrical stimulation is applied 
to the lateral popliteal nerve, in the region of the popliteal fossa that initiates isometric 
contraction of both the posterior and anterior lower limb muscle groups. This will result 
in the activation of venous muscle pump of the lower leg, in contrast to previous studies 
conducted, where activation of muscle pump was achieved by direct stimulation of the 
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calf through placing electrodes over the muscles themselves (Faghri et al., 1997, 
Lindstrom et al., 1982, Nicolaides et al., 1972). Clinical trials carried out to evaluate this 
novel technique are described in detail subsequently. The thesis is structured as follows:  
Chapter 2: Background  
In this chapter the circulatory system will be described and the anatomy and physiology 
of important blood vessels in the lower limb will be covered. The importance of 
haemostasis in the regulation of blood flow and in the prevention of coagulation will also 
be discussed. Following this general background, the concept of Venous 
Thromboembolism will be presented, outlining the factors leading to its development and 
evaluating methods of prevention.  
Chapter 3: Description of the novel device investigated 
This chapter includes a description of the stages of the development of the novel 
electrical stimulation device. The chapter will also include an overview of the devices 
used in the studies presented and how they were developed. 
Chapter 4: Cardiac Study  
The cardiac study focuses on investigating the effect of the novel electrical stimulation 
device initially termed THRIVE device, at two different pulse width settings in 
enhancing lower limb blood flow in healthy subjects lying supine. The study was also 
designed to evaluate the effect of using the novel electrical stimulation device on specific 
cardiac parameters.  
Chapter 5: THRIVE Study  
THRIVE study is the second clinical trial conducted with the intention of evaluating the 
haematological effects of the novel device (THRIVE), by investigating specific 
coagulation factors during the period of prolonged sitting. Assessment of the 
effectiveness of the novel device in enhancing lower limb blood flow at the vascular and 
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micro vascular level was also performed. Furthermore, the tolerance and acceptance of 
the subjects to the device under study were evaluated. 
Chapter 6: geko™ versus IPC Comparison Study  
The prototype of the electrical stimulation device used in the previous studies had gained 
CE marking at this stage and is now termed geko ™. The intention of the study presented 
in this chapter, was to evaluate the performance of the novel device (geko™) in relation 
to commonly used mechanical prophylaxis devices in hospital settings. Therefore in this 
chapter, the effectiveness of the geko™ device in enhancing lower limb blood flow, will 
be compared to two commonly used intermittent pneumatic compression devices. Non-
invasive assessments of blood flow at the vascular and micro vascular level was 
performed to healthy subjects lying supine. The tolerance and acceptance of the subjects 
to the devices tested was also evaluated.   
Chapter 7: Discussion & Conclusion 
In this chapter the results presented in the studies described earlier was analysed with 
reference to findings of previous research using similar techniques. The discussion 
focuses on evaluating the effects of the novel electrical stimulation from five 
perspectives: 1) Cardiac performance, 2) Tissue perfusion, 3) Blood coagulation, 4) 
Safety, and 5) Tolerance and Acceptance.  
Chapter 8: Future Options 
This chapter will describe briefly the potential studies that will be performed using the 
novel device investigated earlier.  
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Chapter 2. Background 
2.1. The Circulatory System 
The circulatory system consists of two loops that begins and ends at the heart. In addition 
to the heart, the circulatory system is composed of a vast array of blood vessels. The 
blood vessels form a tube-like network allowing the blood to flow from the heart to the 
tissues and back to the heart again. There are three major types of blood vessels: arteries, 
capillaries and veins. Arteries and veins share the same general structure. They have 
walls consisting of three concentric layers (tunica). The inner most and thinnest layer is 
the tunica intima, which consists of endothelial cells that is in direct contact with the 
blood flow. The tunica intima restricts the entry of substances into the vessel wall, 
control blood vessel diameter and regulate coagulation. In addition to endothelial cells, 
the tunica intima also consist of a sub-endothelial layer, composed mostly of connective 
and an internal elastic lamina that separates it from the tunica media layer. (Concepts, 
2012, Standring et al., 2008). Tunica media is the thickest layer and is composed of 
muscle tissues, elastic fibres as well as collagen. The tunica externa is the outermost 
layer and consists of connective tissues, nerves and vessel capillaries especially found in 
large blood vessels (Standring et al., 2008). Arteries have thick walls to help withstand 
high pressures. The lumen part of the arteries decreases in size moving down the arterial 
tree. Veins on the other hand are smaller than arteries. They have a bigger lumen and 
thinner walls to facilitate the flow of blood under a lower pressure in comparison to that 
of the arteries. In comparison to the structure of arteries and veins, capillaries are smaller 
blood vessels with a simpler structure. They consist of a layer of squamous epithelium, 
though some capillaries have connective tissues as well. Capillaries have a very small 
lumen, which allows the exchange of nutrients between blood and tissues, refer to Figure 
1. 
Blood circulation starts at the arteries, which carry blood away from the heart. Arteries 
are further categorised into: pulmonary arteries and systemic arteries. Pulmonary arteries 
are responsible for carrying deoxygenated blood from the heart to the lungs, where it gets 
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oxygenated. Likewise, systemic arteries deliver oxygenated blood to the rest of the body. 
The main, largest systemic artery is the aorta, which originates from the heart and 
branches into smaller arteries. The aorta is the first blood vessel to carry blood as it 
leaves the heart before it begins its circulatory journey throughout the body (Weber, 
2006). The aorta then branches out into smaller arteries that supply blood to the head, the 
heart itself and to lower regions in the body. 
 
Figure 1:  Structural differences between the blood vessels. Arteries and veins have 
walls consisting of three concentric layers. Veins are smaller than arteries with a 
bigger lumen and thinner walls. Capillaries are smaller blood vessels consisting 
of a layer of squamous epithelium with a very small lumen.  
Arteries then branch to further smaller arteries termed arterioles, which regulate the flow 
of blood into various tissues. As it emerges from the heart, the aorta has a diameter of 
approximately 3cm. The diameter then decreases along the arterial tree reaching a 
diameter of 0.5cm in the arteries, which then further decreases into a diameter of 10µm in 
the arterioles. The smaller diameter of the arterioles provides a significant resistance to 
the flow of blood that creates a pressure gradient in the circulatory system. Hence, 
maintaining adequate blood flow to the entire body. Following blood flow in the 
arterioles, blood reaches the capillaries. 
 
Artery Vein Capillary
lumen 
tunica intima
tunica media
tunica externa
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Figure 2:  Sequence of Blood Flow. Blood circulation starts at the aorta followed by 
arteries and arterioles. It then reaches the capillaries, which drain into venules 
followed by the veins to be taken back to the heart.  
Capillaries connect arterioles to venules, they are approximately 4-8µm in diameter, and 
are composed of thin walls of endothelium. They are divided into two types, continuous 
and fenestrated capillaries. Continuous capillaries are responsible for the diffusion of 
water, small solutes and lipid soluble materials into the surrounding interstitial fluid, but 
prevent the loss of blood cells and plasma proteins. Unlike continuous capillaries, 
fenestrated capillaries contain pores across the endothelial lining that facilitates rapid 
exchange of water and solutes between plasma and interstitial fluid. The flow of blood 
through the capillaries is regulated by structures composed of muscle fibres termed 
precapillary sphincters that open and close allowing blood to flow when necessary. Blood 
received from the capillaries drain into venules in order to be transported back to the 
heart (Figure 2). Venules are usually 10-30µm in diameter that branch into larger veins, 
which are approximately 0.5cm in diameter. Veins eventually carry blood to the largest 
vein in the body, the vena cava that have a lumen diameter of 3 cm (Schneider et al., 
2003). Veins have thin walls in comparison to arteries of similar size. However, the wall 
thickness of a vein is not correlated exactly to the size of the vein, and usually varies in 
different regions. For instance, the walls of leg veins are thicker than veins of similar size 
in the arm. In summary the circulation process in the body begins in the aorta, then the 
arteries which drain into arterioles. Blood then reaches the capillaries that further drain 
into venules, which in turn drain into veins and finally reach the vena cava.  
As large blood vessels branch into smaller vessels, their total cross sectional area, the 
space through which blood flows, increases. In consequence, the blood pressure and 
velocity drops (Figure 3). The peak of pressures in the arteries is the systolic blood 
Aorta
Artery Arteriole Capillary Venule Vein
3 cm
0.5cm 10μm 4 – 8 μm 10 - 30μm 0.5cm
Direction of  Blood Flow
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pressure; the minimum is the diastolic pressure. As the blood begins its circulatory 
journey, the blood is driven through the arterial system by the heart. However, as the 
blood reaches the venous system, it is no longer moved by the heart. Instead it is the force 
of the muscle pumps surrounding the veins that pushes the blood, through the veins and 
back to the heart.   
 
Figure 3:  Blood Flow versus Total Cross Sectional Area adapted from (Shephard 
and Vanhoutte, 1980). The relationship between blood flow velocity (solid 
line) and total cross-sectional area (dotted line) of blood vessels is inverse. The 
greater the cross-sectional area, the slower the blood flows and vice versa.   
2.2. Anatomy of the Venous System 
The peripheral venous system acts both as a reservoir to hold excessive blood and as a 
conduit to return blood from the capillary network to the heart down a pressure gradient. 
A large part of the blood flow volume, passes into the peripheral venous system of the 
lower extremities, which in turn consists of three major types of veins: deep veins, 
superficial veins and perforating veins.  
2.2.1. The Deep Veins 
The deep veins of the lower extremity are the most important part of the venous system, 
as they are the major venous return circuit for the circulatory system. The entire venous 
blood eventually passes through the deep veins on its way back to the right atrium of the 
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heart.  The deep veins of the lower extremity are divided into several segments and have 
the same names as their adjacent artery, refer to Figure 4. Starting at the ankle and 
moving upwards, the major deep veins are called the tibial veins that further divide into 
three pairs. Tibial veins then converge together forming a single vein called the popliteal 
vein, which stretches to the top of the knee joint. The popliteal vein then passes through 
the thigh, where it is known as the femoral vein. The femoral vein then reaches the area 
of the hip joint and becomes known as the common femoral vein. After passing the hip 
joint, the common femoral vein then becomes the external iliac vein and then the common 
iliac vein, which is located in the area surrounding the waistline (Fronek and Bergan, 
2007, Ombrellaro, 2006). 
 
Figure 4:  Venous System of the Lower Extremity. With permission of (Maggisano 
and Harrison, 2004). The major deep veins include the tibial veins that converge 
forming the popliteal vein, which stretches to the top of the knee joint. Femoral 
vein from the thigh reaches the area of the hip joint and becomes known as the 
common femoral vein. The common femoral vein then becomes the external iliac 
vein and then the common iliac vein, located in the waistline area. 
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2.2.2. The Superficial Veins 
As the name implies, the superficial veins are located superficially in the subcutaneous 
adipose layer. These veins include the visible veins that lie right underneath the skin. The 
superficial veins are located in the fatty tissue layer between the muscle and the skin. 
Two major superficial veins in the leg are known: the Lesser Saphenous Vein (LSV), 
which usually runs from the ankle to the knee and the Great Saphenous Vein (GSV) that 
originates on the dorsum of the foot and ascends through the thigh to the groin. In the 
groin, the GSV then joins the common femoral vein of the deep venous system. 
Similarly, the LSV (Figure 4) originates laterally from the dorsal venous arch of the foot 
and travels subcutaneously behind the lateral malleolus at the ankle. It then crosses the 
back of the leg reaching the knee, then joins the deep venous system through connecting 
to the popliteal vein (Fronek and Bergan, 2007, Ombrellaro, 2006). 
2.2.3. The Perforating Veins 
Perforating veins are branches that penetrate the muscle in several places. These veins 
cross the aponeurosis linking the superficial with the deep veins. This linkage is essential 
for a normal venous outflow from the leg. A confusing aspect to the perforating veins is 
their flow direction. Some perforating veins produce a normal flow, from the superficial 
to the deep circulation. Others on the other hand, conduct an abnormal outflow from the 
deep circulation to the superficial circulation. This action is termed perforating vein 
reflux. Thus, any perforator vein may demonstrate a bidirectional blood flow. In the leg, 
there are several perforators distributed at the ankle, calf, knee, and groin area. Perforator 
veins include, Cokett’s, Boyd’s, Dodd’s and Hunterian perforators (Figure 5) (Bergan, 
2007 , Brown and Pease, 2009).  
2.3. Venous Pressure  
Unlike arterial pressure, which is generated by muscle contractions of the heart, pressure 
in the venous system is influenced by gravitational forces. The effect of gravitational 
force is apparent when a person changes from supine to standing position. When a person 
is lying down, the head, heart and feet are all at the same level. The hydrostatic pressure 
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is nearly the same for all parts of the body, and the pressure within the blood vessels 
depends on the force generated by the heart. 
 
Figure 5:   Perforating Veins of the Lower Leg. With permission of (Brown and 
Pease, 2009). Cockett’s are located at the ankle/calf connecting the great 
saphenous vein to posterior tibial. Boyd’s perforators located around the knee 
connects GSV to the popliteal vein. Dodd’s and Hunterian perforators located at 
the distal and proximal thigh respectively connects the great saphenous vein to 
the femoral vein.  
However, large hydrostatic changes occur when a person is standing. The only point in 
which the pressure remains constant is the hydrostatic indifferent point (zero reference 
pressure level). All pressure down this point is increased by 1 mmHg for each 13.6 mm 
distance below/ or decreased above the heart. Therefore, in an adult who is standing, the 
venous pressure in the feet is approximately +90 mmHg and -30 mmHg in the head. 
(Schneider et al., 2003). The gravitational force helps pull blood downward to the lower 
extremities. The force of gravity will also make it more difficult for the blood to flow 
upward to return the blood to the heart. However, this is made possible through the action 
of the muscle pump system.  
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2.4. The Muscle Pump System 
Peripheral veins, especially those found in the legs and arms, contain one way valves, 
that are delicate but strong and consisting of two small leafs. The valve, when competent, 
stops backflow and therefore directs the blood flow towards the heart. The venous return 
process takes place through the regulated contraction and relaxation of muscles 
surrounding the veins, which in turn alternately opens and closes proximal and distal 
valves. For instance considering the muscle pumping action in the leg, upon muscle 
contraction, the deep veins of the legs are compressed causing the proximal valve leaflets 
to open propelling blood to the central circulation; the distal valves close obstructing the 
flow into the vein (Figure 6). During muscle relaxation, the superficial leg veins drain 
into the deep veins. Upon relaxation, the distal valves open allowing the blood to flow 
and fill the venous segment. Initially during this process, the proximal valve closes 
during the refill process, but then opens as the volume and pressure increases in the vein 
(Klabunde, 2011). Therefore, it is through this compression and relaxation cycle, that 
venous return is achieved. Hence, failure in the pumping cycle as a result of weakness in 
the muscles, incompetent valves, or thrombus formation in the blood vessels, leads to an 
insufficient venous return.   
  
 
  
 
 
Figure 6:  Muscle Pump Contraction and Relaxation adapted from (Klabunde, 
2010).  Muscle contraction causes the distal valve leaflets to open propelling 
blood to the central circulation and the proximal valves closes obstructing the 
flow into the vein Upon relaxation the distal valves closes during the refill 
process, and the proximal valves opens allowing the blood to flow and fill the 
venous segment.  
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2.5. Haemostasis 
Haemostasis is a complex process involving a series of biochemical reactions to prevent 
excessive blood loss in the body. It is achieved through the interaction of three major 
constituents: clotting factors, endothelium and platelets. Each constituent in the system 
interacts and influences the other constituents. Under normal circumstances, haemostatic 
balance is maintained through the efficient interaction of all constituents in favour of 
anticoagulation status. Haemostasis can be broken down into two phases: primary phase 
involving the aggregation of platelets to the vessel wall and secondary phase that 
involves the formation of fibrin through a cascade of reactions including clotting factors 
(coagulation pathway).  
2.5.1. Primary Haemostasis  
The intact endothelium reduces the incidence of clotting by providing a physical barrier 
while secreting a series of biochemical mediators that inhibit clot formation. These 
mediators include vaso-relaxants such as Nitric Oxide (NO) and prostaglandin I2 (PGI2) 
commonly referred to as prostacyclin and vaso-constrictors such as Endothelin.  The 
release of NO and vaso-constrictors from endothelial cells contributes to the relaxation of 
the underlying vascular smooth muscle, thereby dilating the blood vessel. PGI2 is a 
prostaglandin derived from arachidonic acid (AA) through an endoperoxide (EPO) 
intermediate (Pettigrew, 2001). Prostaglandin I2 and nitric oxide increase intracellular 
levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate 
(cGMP) in platelets, which inhibit platelet activation, adhesion to the endothelium as well 
as aggregation. Adenosine, which is synthesised from adenosine triphosphate (ATP) and 
adenosine diphosphate (ADP) by endothelial cells, also increases intracellular cAMP 
levels in platelets (Figure 7).  
Following endothelium disruption, primary haemostasis begins. The initial phase of 
haemostasis results in the formation of a primary platelet plug and encompasses the 
reactions of platelets, the endothelium together with a plasma protein. Endothelial 
disruption, caused by an injury to the blood vessel exposes the collagen found in the 
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subendothelium. The injury causes temporary vaso-constriction, of which not only 
prevents blood loss, but also slows the blood flow enhancing the adherence of platelets to 
the exposed sub-endothelium surfaces and to other platelets. The binding of platelets to 
the subendothelium, depends on the presence of collagen in the vessel wall, glycoprotein 
membrane receptors embedded in the surface of platelets, together with a plasma protein 
called von Willebrand Factor (vWF) (Welch, 2010).  
Once platelets bind to the vessel wall, they become activated. Activation of platelets 
causes them to change their shape, activate the collagen receptors on their surface, 
synthesise and release a number of compounds. The compounds released by activated 
platelets include Endoperoxide, Thromboxane A2 (TXA2) together with ADP. The 
endoperoxide derived from arachidonic acid in platelets is converted to the prostaglandin 
TXA2. Both TXA2 formed and ADP act as platelet agonists binding to receptors on the 
surfaces of other platelets, causing them to activate and promote aggregation (Figure 7) 
(Pettigrew, 2001).  
 
Figure 7:  Platelet Antithrombotic and Prothrombotic action adapted from 
(Pettigrew, 2001). Nitric oxide (NO) and prostacyclin (PGI2) synthesised from 
endothelial cells increase intracellular levels of cyclic adenosine monophosphate 
(cAMP) and cyclic guanosine monophosphate (cGMP) in platelets, which inhibit 
platelet activation, adhesion to the endothelium, and aggregation. Adenosine, 
which is synthesised from adenosine triphosphate (ATP) and adenosine 
diphosphate (ADP) by endothelial cells, increases intracellular cAMP levels in 
platelets. Activated platelets synthesise and release a number of compounds, 
including Endoperoxide (EPO), Thromboxane A2 (TXA2), and ADP.  Both 
TXA2 and ADP bind to receptors on the surfaces of other activate and promote 
platelet aggregation. 
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Following platelet aggregation a platelet plug is formed, however, this plug is temporary 
and is not strong enough. The plug will break apart and will be washed away by red 
blood cells, unless it becomes strengthened. This is made possible through the formation 
of an insoluble fibrin net during the secondary haemostasis phase.   
2.5.2. Secondary Haemostasis (Coagulation Pathway) 
Secondary haemostasis involves a complex coagulation cascade that ultimately results in 
the conversion of a soluble clot to an insoluble fibrin clot. The coagulation cascade is 
further divided into two pathways:  intrinsic and extrinsic. Each pathway is initiated by a 
distinct mechanism and both converge together leading to fibrin clot formation.  
2.5.2.1. Intrinsic Pathway  
The intrinsic pathway also known as ‘contact activation pathway’, is initiated by the 
blood coming into contact with exposed collagen in the blood vessel i.e. elements that lie 
within the blood itself that cause damage to the blood vessel wall. Following damage to 
the vessel wall, a series of clotting factors are activated. The end result of this cascade is 
the activation of Factor X, which is an enzyme responsible for converting pro-thrombin 
to thrombin, the key initiator of clot formation. Thrombin converts fibrinogen to fibrin, 
which form a loose meshwork stabilising the clot (Figure 8).  
2.5.2.2. Extrinsic Pathway 
The extrinsic pathway also known as Tissue Factor (TF) pathway is triggered by tissue 
damage outside of the blood vessel, usually as a result of trauma or mechanical injury. 
Damage to the tissues stimulates the activation of tissue factor released by damaged 
tissue cells. Tissue factor is a membrane bound glycoprotein and is the primary initiator 
of blood coagulation. Following the activation of TF, a series of clotting factor activation 
takes place, eventually leading to the formation of Factor X. At this point, both the 
intrinsic and extrinsic pathway converges and the subsequent steps are similar. Formation 
of Factor X promotes the conversion of prothrombin to thrombin. Thrombin is the key 
step in clot formation as it mediates the transformation of fibrinogen to fibrin clot 
(Figure 8).  
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Figure 8:  Coagulation Cascade. The coagulation cascade has two pathways, the 
intrinsic pathway; triggered by damage to the blood vessels and the extrinsic 
pathway that is triggered by damage to the tissue outside blood vessel. Both 
pathways eventually lead to the formation of a blood clot.  
Following tissue repair via fibrin clot formation, the clot must then be dissolved in order 
for normal blood flow to resume. The dissolution of the clot occurs through a process 
called fibrinolysis. Fibrinolysis is the body’s natural mechanism that is responsible for 
the degradation and removal of fibrin clots, hence restoring obstructed circulation. 
Plasminogen, a precursor molecule of plasmin that is produced by the liver, plays a key 
role in the fibrinolysis process (Chromogenix, 1995). The plasma concentration of 
plasminogen is about 100 – 150 mg/mL and the half-life in the circulation is about 2.8 
days (Collen et al., 1972). The primary activator of plasminogen is tissue plasminogen 
activator (tPA), a product of endothelial cells, which activates plasminogen and converts 
it to plasmin. Plasma concentrations of tPA measured as tPA antigen is about 5-10 µg/L 
and varies greatly under different physiological conditions (Nordenhem and Wiman, 
1998). In the plasma, tPA occurs mainly as a complex together with its principle 
plasminogen activator inhibitor, PAI-1 (Peterson et al., 2000). Plasminogen activator 
inhibitor is the most important inhibitor of tPA. Under normal physiological conditions, 
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the concentration of PAI-1 in the plasma is about 10µg/L (Urden et al., 1972). A 
decreased fibrinolytic activity, is mainly due to increased levels of PAI-1 (Wiman and 
Hamsten, 1991). Furthermore, elevated plasma concentrations of tPA antigen, which is 
usually found as a bound complex of tPA/PAI-1 also correlates with a decreased 
fibrinolytic activity. Therefore, there is a strong positive correlation between plasma PAI-
1 levels and tPA antigen (Nordenhem and Wiman, 1998).  
Following injury, active tPA is released from vascular endothelial cells, it then cleaves 
plasminogen to plasmin, which then digests the fibrin (Figure 9). The net result of this 
process is soluble degradation products to which neither plasminogen nor plasmin can 
bind to in addition to D-Dimer. After the release of plasminogen and plasmin, they are 
rapidly inactivated by their respective inhibitors. 
 
Figure 9:  Schematic Representation of Fibrinolysis. Adapted from (Chromogenix, 
1995). Tissue plasminogen activator (t-PA) is produced by vascular endothelial 
cells and is released into the circulation following stimulation. Inhibition of this 
process can occur through plasminogen activator inhibitor (PAI) or through 
plasmin inhibitor. Free t-PA together with complexed t-PA/PAI is cleared from 
the circulation by the liver. 
D-dimer is the final degradation product formed as a result of the action of plasmin on 
cross-linked fibrin. It consists of two identical sub-units derived from two fibrin 
molecules. In an efficient fibrinolytic activity and in the presence of increased fibrin 
formation, an increased level of D-dimer will be present in the plasma. Hence, D-dimer 
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levels are increased by any condition in which fibrin is formed and degraded by plasmin 
(Hager and Platt, 1995).  
2.6. Coagulation Assessment 
It is clear from the above overview, that a range of factors are involved in the coagulation 
process. Therefore, assessing specific coagulation factors can provide an indication of 
abnormality in the coagulation process. Coagulation assessment is performed by 
quantitatively measuring different factors at different stages of the coagulation pathway. 
For the purpose of simplification, the coagulation cascade will be divided into four 
stages: 1.Platelet aggregation stage, 2. Thrombin formation, 3. Fibrin formation and 4. 
Fibrinolysis.  
2.6.1. Platelet Aggregation Stage 
Assessing platelet aggregation stage involves measuring prostacyclin and von Willebrand 
factor (vWF). As mentioned earlier, prostaglandin (PGI2) is an inhibitor of platelet 
aggregation and a promoter of vasodilation. However, a key drawback of PGI2 is its short 
half life; since its activity disappears within 10 minutes of yielding a stable product (6-
keto PGF1α). Therefore, it is possible to use a surrogate concentration of PGI2 by 
measuring the concentration of its stable product 6-keto PGF1α. This provides an idea of 
the platelet aggregatory level in a blood vessel, where  decreased levels of prostaglandin 
have been found to be associated with vascular dysfunction and an indicator of 
pulmonary hypertension (Christman et al., 1992).  
The second marker of platelet aggregation is von Willebrand factor, which as mentioned 
earlier is secreted from endothelial cells into the plasma and into the sub-endothelial cell 
matrix. Once released, vWF appears to play a major role in mediating platelet 
aggregation at the site of injury and also binds to and stabilises Factor VII that is essential 
for the formation of fibrin. Raised levels of vWF have been proposed as a possible 
indicator of endothelial dysfunction, which predisposes thrombosis (Badimon et al., 
1992, Blann, 1993, Boneu et al., 1975). Raised vWF levels have also been associated 
with an increase in thromboembolic events, as supported by Koster et al., who found that 
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vWF levels increased in patients with a history of deep vein thrombosis (Koster et al., 
1995).  
2.6.2. Thrombin Formation  
Thrombin formation is a result of complex enzymatic mechanisms taking place. 
Therefore, assessment of thrombin formation is  useful in the clinical diagnosis of venous 
thromboembolism and is made possible through measuring the Endogenous Thrombin 
Potential (ETP). ETP indicates the thrombin generation capacity of the plasma, which is 
considered to be one of the main determinants of haemostasis and thrombosis (Hemker 
and Beguin, 1995). Substances that have the ability to reduce the thrombin generation 
capacity in plasma such as anticoagulants have an antithrombotic and haemorrhagic 
effect. On the contrary, all conditions that increase thrombin generation such as 
deficiencies of anti-thrombin result in thrombosis.  
2.6.3. Fibrin Formation 
As mentioned earlier, following the formation of thrombin, fibrin is formed from its 
precursor fibrinogen. With the advancement of technology, it is now possible to get a 
quick measurement of the clotting time (fibrin formation), through the use of an 
Automated Coagulation Timer technology (ACT). Using a photo optical system, ACT 
detects the clot formation of a freshly withdrawn blood sample and displays the results in 
seconds.  
Additionally, it is also possible to get a detailed analysis of the dynamics of fibrin 
formation, stabilisation, as well as fibrin dissolution through the use of a Rotational 
Thromboelastometry (ROTEM®) technique. In comparison to ACT, ROTEM® is more 
advanced in the sense that it can measure both the intrinsic and extrinsic coagulation 
pathways, providing detailed information about the journey of a clot. The key parameters 
measured using ROTEM® include, Clotting Time (CT), Clot Formation Time (CFT), 
Maximum Clot Firmness (MCF) and Maximum Clot Lysis (ML).  
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2.6.4. Fibrinolysis  
In addition to using the ROTEM® technique to measure the clot lysis time, it is also 
possible to get an indication of the clot lysis (fibrinolysis) by measuring the concentration 
of specific markers. These include Tissue Plasminogen Activator (tPA) and D-dimer 
levels. As mentioned earlier, tPA is the primary initiator of fibrinolysis. An adequate 
amount of tPA is essential for maintaining the endothelium in a non-thrombogenic state. 
For instance, a deficiency in tPA will result in a reduced capacity to degrade fibrin, 
resulting in thrombosis. Furthermore, D-dimer, the final degradation product of fibrin can 
be measured, providing a quick indication of abnormal clotting. An elevated level of D-
dimer is an indication of the presence of abnormally high levels of cross-linked fibrin 
degradation products. This implies that a significant clot formation and clot breakdown 
have been taking place in the body.   
2.7. Venous Thromboembolism 
Venous thromboembolism (VTE) has evoked great interest over the past few years in 
many fields; such as the media, airline industry and public health institutions. Venous 
thrombosis is characterised by the formation of a blood clot (thrombus) in a vein, which 
if left untreated may cause partial or complete obstruction to blood flow.VTE 
incorporates Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). DVT is the 
term used to describe the formation of a blood clot in the deep veins. If the blood clot is 
left untreated, it may break into fragments called emboli, and travel to the lungs forming 
PE. Although clots can form in the upper extremities, the most common site for thrombus 
formation is the deep veins of the calves, thigh and pelvis (Welch, 2010).  
2.7.1. Epidemiology of VTE 
The precise incidence of VTE is unknown, as most studies are limited by the inaccuracy 
of clinical diagnosis. Epidemiological studies have been carried out worldwide, with the 
majority of the reports from the United States. Based on these reports, the annual 
incidence of VTE in the United States was found to range between 70 to150 per 100 000 
persons (Anderson et al., 1991, Heit et al., 2001, Silverstein et al., 1998, Tsai et al., 
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2002). In Europe, data from studies carried out in France and Sweden reported an 
occurrence rate of VTE 160 to180 per 100 000 persons (Cohen et al., 2007). Although 
such data has contributed greatly to our understanding of the epidemiology of VTE, the 
total burden of this disease on the health care system remains underestimated. This is 
mainly due to the absence of data on the undiagnosed or misdiagnosed VTE cases 
together with the unrecognised VTE related deaths. Therefore, in an attempt to describe 
the health burden of VTE within the European Union (EU), a study carried out by the 
VTE Impact Assessment group in Europe (VITAE) investigated the annual number of 
non fatal incidents and recurrent VTE events, as well as VTE related deaths in six 
countries within the EU. The VITAE study estimated that the total number of non fatal 
VTE events is almost 460 000 for DVT and 300 000 cases for PE out of approximately 
760 000 events. The total VTE related deaths is estimated 370 000 out of which 26 000 
are treated and 215 000 are not treated (Cohen et al., 2007). Hence, based on those 
figures it is in no doubt that VTE is an important public health issue that requires greater 
attention in an attempt to reduce the health burden of this disease.   
2.7.2. Risk Factors of VTE  
The underlying aetiology for the development of VTE was described by ‘Virchow’s 
Triad’, outlined by Rudolph Virchow in 1856, who proposed that three main factors are 
associated with thrombosis: 1. venous stasis 2. damage to the vein wall and 3. blood 
hyper-coagulability. Thus, it is believed that any risk factor that induces VTE can be 
characterised by the existence of one or more of the components of Virchow’s Triad.  
The presence of risk factors plays an important role in assessing the probability of 
developing VTE. Moreover, risk factor assessment permits successful 
thromboprophylaxis and prevent further development of complications associated with 
VTE. Hence, reduce the health burden of the disease. A summary of some of the risk 
factors predisposing to thrombosis is found in the sections below. It is essential to 
recognise that the predictive values of these risk factors are not equal. Prior to providing 
prophylaxis, physicians should consider both the strength of individual risk factors and 
the cumulative weight of all risk factors. A range of risk factors with their corresponding 
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odds ratios are listed in Table 1. Strong risk factors that have an odds ratio of greater 
than 10 justify prophylaxis against VTE.  
Strong Risk Factors (Odds Ratio >10) 
Hip fracture 
Hip or knee arthroplasty 
Major general surgery 
Major general trauma 
Spinal cord surgery 
Moderate Risk Factors (Odds Ratio2-9) 
Chemotherapy 
Congestive heart or respiratory failure 
Hormone replacement therapy  
Malignancy 
Oral contraceptive therapy 
Stroke 
Pregnancy/postpartum 
Previous venous thromboembolisma 
Weak Risk Factors (Odds Ratio< 2) 
Bed rest > 3 days 
Immobility due to sitting (prolonged travel) 
Advanced age 
Laproscopic surgery 
Obesity 
Pregnancy/antepartum 
Varicose veins 
Table 1:  Risk Factors for VTE. (Anderson and Spencer, 2003) 
2.7.2.1. Advance Age 
Venous thromboembolism is a major health problem, mainly affecting the elderly 
population. The risk of VTE is quite low before the age of 40. For instance, in persons 15 
years old or younger, there is less than 5 cases per 100 000 of the population annually 
(Anderson et al., 1991, White et al., 2003).  However, it increases dramatically after the 
age of 75. As found by Kniffin et al., the annual rate of DVT in the United States 
increases from 180 per 100 000 persons at the age of 65 to 69 years to 310 by the age of 
85 to 99 years (Kniffin et al., 1994). The increased risk with advanced age is mainly due 
to the presence of additional factors and / or complications that might lead to changes in 
the venous system and hence, result in thrombosis. 
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2.7.2.2. Prolonged Travel 
There has been much debate in the media regarding the development of VTE following 
long hours of travel. Deep vein thrombosis have been incorrectly termed ‘Economy Class 
Syndrome’, as some of the DVT cases have been reported in airline passengers who 
travelled in economy class. However, DVT is not restricted to airline traveller nor to 
travellers on economy class. It can affect people using any other forms of travel including 
cars, trains or any vehicle. A number of studies have been carried out to determine the 
actual incidence of DVT following long haul flights (Belcaro et al., 2001, Ferrari et al., 
1999, O'Keeffe and Baglin, 2003). For instance when investigating the incidence of VTE 
within 24 hours of travelling for long hours in the LONFIT 1 study, it was found that the 
incidence was 0% (0/355) in patients without any risk factors for VTE. In comparison, in 
higher risk patients 2.8% developed DVT following long hours of travel (Belcaro et al., 
2001). High risk patients were defined as those with a pre-history for DVT, have limited 
mobility due to bone or joint problems, have severe obesity and exhibit a coagulation 
disorder. Furthermore, in a randomised trial, it was reported that 10% of passengers 
undertaking long flights (>8 hours) developed asymptomatic calf DVT detected with 
duplex ultrasound (Scurr et al., 2001).  
 
A number of factors associated with air travel are thought to play a contributory role in 
the development of DVT. During periods of quiet sitting a number of rheological and 
biochemical changes have been reported to occur in the limb. Prolonged sitting in a 
cramped position with limited space results in restriction of the natural venous pumps. In 
the sitting position blood flow velocity is reduced by two-thirds compared with lying in 
the supine position (Delis et al., 2004, Wright and Osborn, 1952). Cramped position may 
also cause venous stasis and further induce endothelial damage by compression of the 
popliteal vein at the edge of the seat.  
2.7.2.3. Ethnicity 
Racial and ethnic differences have been shown to influence incidence rates of VTE. In a 
study carried out in California, it was found that the annual incidence of DVT was 23 per 
100 000  in Caucasians, 29.3 in African Americans, 13.9 in Hispanics, and 6 in Asians 
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(Bulger et al., 2004). Similarly, studies of hospitalised patients in North America and 
Hong Kong have also shown that Asian patients, including those of Chinese origin have a 
significantly lower incidence rates than people of African origin. The reason behind such 
differences has not been found, but it has been suggested that it could be due to certain 
genetic traits that increase the risk of developing VTE. As reported by Joynt et al., 2009, 
Chinese people tend to have a low level of Factor V Leiden gene mutation, which is a 
factor responsible for increased coagulation (Joynt et al., 2009). Furthermore, it has been 
found that Asian people tend to have lower mean fibrinogen and a decreased hyper 
coagulation Factor VIIc and VIIIc concentrations, which are associated with an increased 
risk to DVT if present in high concentrations (Ho et al., 2000, Ho et al., 1995). 
2.7.2.4. Pregnancy & Oestrogen Therapy 
Women face several conditions in their lifetime that increase their risk of developing 
VTE. These conditions include pregnancy, use of oral contraceptives as well as hormone 
replacement therapy (HRT). In comparison to non pregnant women, VTE have been 
shown to increase during pregnancy by 4 to 5 fold (Heit et al., 2005, James, 2009). 
Pregnancy is associated with hyper-coagulation as well as venous stasis, which occur by 
the end of the first trimester. Pregnancy is also associated with endothelial damage to 
pelvic vessels, which usually takes place during vaginal or abdominal delivery. Hence, as 
all initiating factors for thrombosis are present, this sets the scene for thrombosis to take 
place.  
Further epidemiological studies have clearly established an association between the use 
of oral contraceptives and VTE (Bulger et al., 2004). The risk has been found to be 
dependent on the oestrogen dose, with preparations containing greater than 50µg of 
oestrogen being associated with the highest risk. Thus, although the doses of oestrogen in 
oral contraceptive formulations have now been reduced to 30µg, the reduction in 
oestrogen dose has not reduced the thrombotic risk. Several studies have shown that oral 
contraceptives with a reduced dose of oestrogen (< 50µg) are associated with a 3 to 6 fold 
increase in relative risk of VTE (World Health Organization, 1995).  The risk is highest 
during the first year of using contraceptives and is heightened with prolonged use 
(Herings et al., 1999).  
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Similarly as with oral contraceptives, the use of hormone replacement therapy has been 
found to increase the risk of VTE. The increased risk is also associated with the dose of 
oestrogen present in the hormonal replacement therapy, which is one-fifth the dose found 
in the oral contraceptives. However, published data has shown a 2 to 4 fold increase in 
relative risk of VTE in current users of HRT as compared with non-users, with a 
heightened risk observed during the first year of use (Bloemenkamp et al., 1995).    
2.7.2.5. Obesity 
Obesity is defined as excessive accumulation of fat and is described by a body mass 
index (BMI) equal to or above 30 kg/m
2
 (World Health Organization, 2006). Although it 
has not consistently been identified as an independent risk factor for VTE, obesity is an 
important modifiable risk factor. Several studies have reported an increased risk of DVT 
within the obese populations. For example, in an epidemiological study including 106 
patients, (Samama, 2000) reported a 2 fold increase in risk of DVT occurrence among 
patients with a BMI  greater than 30kg/m
2
.  
The patho-physiological correlation between thrombosis and BMI has been extensively 
studied. There are a number of studies substantiating a positive correlation between BMI 
and several coagulation factors such as Factor VII, Factor IX and D-dimer levels (De 
Lorrenzo et al., 1998, Serrano, 1998, Shippinger et al., 1998). Furthermore, it has been 
established that obese people tend to have a further increased thrombotic risk when 
exposed to additional risk factors such as oral contraceptives. For instance, in a single 
study examining the correlation between obesity and oral contraceptive use, a 1.8 to 3 
fold increased risk of DVT was found among oral contraceptive users (Nightingale et al., 
2000). This was confirmed by Abdollahi et al., who reported a 10 fold increased risk of 
DVT among obese women using oral contraceptives as compared to women of normal 
weight who did not use oral contraceptives (Abdollahi et al., 2003). 
It is clear from the above figures, that the presence of various risk factors influence the 
development of VTE. It has been shown that the greater the number of risk factors, an 
individual holds, the greater the likelihood for developing VTE. For example, in a 
community review carried out on 1231 consecutive patients treated for VTE, 96% were 
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found to have at least one risk factor and the risk increases with the number of risk 
factors an individual holds (Anderson and Spencer, 2003, Anderson et al., 1991). 
2.7.2.6. Surgery  
As a result of an accumulation of risk factors, hospitalised patients have more than a 100 
fold increased risk of VTE (Heit et al., 2001). Hospitalised patients might be subjected to 
prolonged immobility, surgical procedures, or paralysis as a result of anaesthesia. Such 
factors will induce changes in all three components of the Virchow’s Triad. Surgical 
procedures result in vessel wall damage and hyper coagulability. Similarly, prolonged 
immobility deprives the veins of the legs of activity resulting in venous stasis (Welch, 
2010). The type of surgical procedures performed determines the risk of VTE, as certain 
procedures increase the risk of VTE, refer to Table 2. Patients having spinal cord surgery 
have the highest risk (60-80%) for developing DVT, compared to 10-20% for general 
medical patients. It is therefore necessary to carry out a pre-assessment of the VTE risks, 
bleeding risks, and the type of thromboprophylaxis that can be provided.  
Condition DVT Prevalence (%) 
General Medical Patients 10-20 
General Surgery 15-40 
Major Gynaecological Surgery 15-40 
Major Urological Surgery 15-40 
Neurosurgery 15-40 
Stroke 20-40 
Congestive Heart Failure 20-40 
Hip/Knee arthroplasty, 40-60 
Major Trauma 40-80 
Spinal Cord Surgery 60-80 
Table 2:  Risk of DVT in hospitalised patients in the absence of 
thromboprophylaxis. (Geerts et al., 2008, Spyropoulos, 2005). 
2.8. VTE Prophylaxis 
VTE is a major health problem, however unlike other diseases; it is preventable through 
the use of appropriate thromboprophylaxis. The House of Commons Health Committee 
in the year 2005 reported that an estimated 25 000 people in the UK die from preventable 
hospital acquired VTE each year (House of Commons Health Committee, 2005). The 
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reported number includes patients admitted to the hospital for medical care as well as 
surgery. The reason behind such a high incidence has been attributed to the inconsistent 
use of thromboprophylactic measures in hospital settings. Therefore, to tackle this 
problem the National Institute for Health and Clinical Excellence (NICE) issued 
Guideline CG92 in the year 2010 (NICE, 2010b). The guideline provides 
recommendations for assessing and reducing the risk of VTE in patients in hospitalised 
settings. It also outlines the most cost effective prophylaxis methods that may be used for 
VTE prophylaxis taking into account the risks associated with the various prophylaxis 
measures used (NICE, 2010b). Current preventative measures available fall into two 
categories: a) pharmacological and b) mechanical methods.  
2.8.1. Pharmacological Prophylaxis 
Pharmacological prophylaxis involves the use of medicinal agents in the management of 
VTE. A range of antithrombotic agents are available, and are classified based on their 
mechanism of action. The most widely used agents are anticoagulants, which block the 
production and activation of clotting factors. Three classes of anticoagulants are 
available, vitamin K antagonists, heparins and direct thrombin inhibitors. Depending on 
the patient’s condition, these drugs are usually given prior to, during, or following 
surgical procedures.  
2.8.1.1. Vitamin K Antagonists (VKAs) 
Vitamin K antagonists (VKAs) are commonly referred to as ‘oral anticoagulants’, 
examples include Warfarin and Coumarin that have been available for more than 50 
years. VKAs are blood thinning agents that have no direct effect on clot synthesis; 
therefore they do not break clots. The aim of using VKAs is to prevent further clot 
progression (Baker et al., 2004). VKAs act by lowering the amount of active vitamin K 
available for the activation of certain clotting factors. However, a major side effect to 
VKAs is bleeding and the need for constant monitoring. Hence, in certain conditions, it 
might be more beneficial to replace the use of VKAs by other agents.  
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2.8.1.2. Heparins 
Heparin is an anticoagulant that has been discovered to exhibit antithrombotic properties 
over 90 years ago.  It has been extensively used as a treatment for VTE for the past 50 
years. Heparin prolongs bleeding time and increases vessel wall permeability (Hirsh et 
al., 2001, Hirsh and Raschke, 2004). Three types of heparins are in use: i) Unfractionated 
Heparin (UFH), ii) Low Molecular Weight Heparin (LMWH), iii) Synthetic Penta-
saccharides (Factor Xa inhibitors) 
i) Unfractionated Heparin (UFH)  
Unfractionated heparin is a naturally occurring glycosaminoglycan derived from either 
pig intestine or bovine lung tissue, with a molecular weight ranging between 5 000 to 35 
000 daltons (Scottish Intercollegiate Guidelines Network, 2011). UFH acts by 
inactivating the activation of clotting factors, mainly thrombin and Factor Xa. This 
results in the inhibition of fibrin formation. UFH is administered parenterally either 
through intravenous infusion that has an immediate effect (30 min), or a subcutaneous 
injection with a delayed (2 hrs), but a more prolonged effect (10 hrs) (Scottish 
Intercollegiate Guidelines Network, 2011). Although UFH is an effective form of 
antithrombotic treatment, however, as with Warfarin it is associated with a bleeding risk 
in addition to other complications. Therefore, another type of heparin (LMWH) may be 
used instead. 
ii) Low Molecular Weight Heparin (LMWH) 
Low molecular weight heparin is largely taking over as the agent of choice for both 
prevention and treatment of VTE. It is synthesised from UFH through a depolymerisation 
reaction resulting in the production of smaller molecules ranging between 4000 to 6000 
daltons in size (Raskob et al., 2001). LMWH is equally effective as UFH, although it is 
more expensive. However, its long term use allows outpatient management and reduces 
hospital stay, which makes it more economical in the long run (Hirsh et al., 2001). 
Examples of commercially available LMWH include: Ardeparin, Dalteparin, 
Enoxaparin Sodium, Rivaparin and Tinzaparin. The effectiveness of LMWH in reducing 
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the risk of VTE has been investigated through a meta- analysis performed by Mismetti et 
al in the year 2000 that showed that both UFH and LMWH are equally effective at 
reducing the incidence of VTE, but LMWH is safer with a 52% lower bleeding risk 
(Mismetti et al., 2000). The mechanism of action of LMWH is similar to that of UFH 
however; LMWH has the advantage of having a greater bioavailability following 
subcutaneous injection. Hence, LMWHs are more effective as antithrombotic agents 
when given a once or twice daily dose in comparison to a twice or three times daily 
dosage for UFH.  
iii) Synthetic Penta - saccharides (Factor Xa inhibitors) 
Despite the proven efficacy of LMWH, synthetic penta - saccharides have been shown to 
be more effective than LMWH in reducing asymptomatic form of DVT (Bounameaux 
and Perneger, 2002). An example of a synthetic penta-saccharide is Fondaparinux, which 
contains the same penta-saccharide sequence found in UFH and LMWH. Fondaparinux 
acts as a catalyst, enhancing the inhibition of Factor Xa, which in turn inhibits thrombin 
formation (Hyers, 2003). It is rapidly absorbed following subcutaneous administration 
and has a long half life of approximately 17 hours, allowing a once daily dosing with a 
rapid onset of action (Hyers, 2003). Evaluation of the side effects have shown that in 
addition to the risk of bleeding Fondaparinux holds, it may also result in 
thrombocytopenia (Papadopoulos et al., 2007).  
Another antithrombotic agent that inhibits Factor Xa is Danaparoid, a low molecular 
weight heparin. It is mainly used in practice as an alternative treatment in patients who 
develop heparin-induced thrombocytopenia (HIT) from heparin therapy. Danaparoid is 
also safe for use during pregnancy, as it does not cross the placenta. However, a major 
disadvantage is its prolonged half life that ranges from 17 to 28 hours.  
2.8.1.3. Direct Thrombin Inhibitors (DTIs) 
Direct thrombin inhibitors are agents that are capable of inhibiting both circulating 
thrombin and clot-bound thrombin. As Danaparoid, DTIs are also used an alternative 
treatment in patients who develop heparin induced thrombocytopenia. Despite this 
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advantage, the major drawback of DTIs is their bleeding risk (Hyers, 2003). The first 
DTIs to be used medically was Hirudin; a 65 amino acid polypeptide. Several other DTIs 
were then developed including Bivalirudin, Dabigatran as well as, Ximelagatran 
(Raskob et al., 2001).  
2.8.2. Mechanical Prophylaxis 
Although mechanical prophylaxis methods are not as well researched as pharmacological 
prophylaxis, they have gained wide popularity especially since they are not associated 
with bleeding risk. Mechanical prophylaxis have therefore been primarily recommended 
as an alternative thromboprophylaxis method in patients subject to high bleeding risk, or 
as an adjunct to pharmacological prophylaxis (Geerts et al., 2008). As mentioned earlier, 
any factor inducing VTE can be characterised by the presence of one or more of the 
components of the Virchow’s triad. Therefore, any thromboprophylaxis method used 
produces their effect by targeting components of the Virchow’s triad; altering venous 
stasis, vessel wall damage, and/or hyper coagulability. Mechanical methods are further 
divided into two groups: compression methods and electrical stimulation. 
2.8.2.1. Compression Methods 
2.8.2.1.1. Graduated Compression Stockings (GCS) 
Generally accepted compression methods include Graduated Compression Stockings 
(GCS) and Intermittent Pneumatic Compression (IPC) devices. Graduated Compression 
Stockings are the most commonly used method of mechanical compression. They are 
available as full length extending up to the mid thigh, or below the knee. GCS exert their 
action, through applying a graduated pressure on the lower leg, with the pressure being 
the highest at the ankle. GCS compresses the leg, reducing the cross sectional area of the 
veins, which in turn reduces venous stasis by increasing blood flow velocity. The 
graduated pressure together with muscle activity in the lower limb, results in the 
movement of blood from the superficial venous system to the deep venous system 
reducing venous stasis and preventing clot formation, thereby potentially preventing 
DVT (Amaragiti and Lees, 2000).  
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In a systematic review, a 52% reduction in the relative risk of DVT was estimated 
following the use of graduated compression stockings as compared to no prophylaxis 
(Amaragiti and Lees, 2000). In addition to its moderate effectiveness in preventing DVT, 
graduated compression stockings offer the advantage of being used during recumbency, 
as well as during immobility. However, to exert their beneficial action, the correct 
measurements of the leg must be taken. As with other prophylactic measures, the use of 
GCS is also associated with some adverse effects. They are immensely uncomfortable to 
wear and difficult to apply, this often results in poor patient compliance. Compression 
stockings also give rise to a hygiene problem as they have to be washed regularly and 
replaced at least within six months of first usage. Frequent washing and wearing causes a 
loss of elasticity resulting in loss of adequate compression. Adverse effects such as 
hypersensitivity reactions are also possible. For example, in a multicentre controlled trial 
examining the effectiveness of thigh length graduated compression stockings in reducing 
DVT following stroke in 2518 patients, adverse effects such as skin breaks, ulcers, 
blisters, and skin necrosis were significantly more common in patients using compression 
stockings. In addition to the adverse effect, results from the CLOTS study, investigating 
the effectiveness of thigh length GCS, were discouraging, as GCS was not clinically 
effective in reducing the risk of DVT in patients with  stroke (CLOTS, 2009).  
2.8.2.1.2. Intermittent Pneumatic Compression (IPC) 
Intermittent Pneumatic Compression (IPC) is another form of mechanical compression 
prophylaxis. IPC devices operate by squeezing blood from the underlying deep veins, 
which if the valves are competent will be displaced proximally (Morris and Woodcock, 
2004). Compression is achieved through the action of a pump that inflates and deflates air 
bladders within cuffs that cover the whole leg, the calf or just the feet. The deflation 
action causes the refill of the veins, ensuring the periodic flow of the blood through the 
deep veins, thereby preventing venous stasis. Published data have shown that IPC action 
is not only targeted at preventing venous stasis, but has also been found to stimulate 
fibrinolytic activity (Christen et al., 1997, Comerota et al., 1997b, Labropoulos et al., 
1999). IPC have been found effective in reducing the risk of DVT by 60% in post 
operative patients, compared to patients receiving no pharmacological or mechanical 
Background 
Page 53 of 265 
 
prophylaxis (Urbankova et al., 2006). Despite their proven efficacy, IPC devices cannot 
be used during mobility, as they are often bulky and not portable. They can also be hot 
and induce sweating beneath the sleeves.  
2.8.2.2. Electrical Stimulation Methods 
Electrical stimulation is the third type of mechanical prophylaxis. Published data on the 
effectiveness of electrical stimulation dates back to the year 1972, where initial studies 
were performed investigating the use of electrical stimulation for the prevention of 
thromboembolic complications following surgery (Nicolaides et al., 1972). As the 
research presented in this thesis is based on the use of electrical stimulation technology, a 
detailed overview of the technique will be addressed in the following chapter.  
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Chapter 3. The Physiology of Neuro-muscular Electrical 
Stimulation 
The membrane of the living cell maintains different concentrations of positively and 
negatively charged ions, so that in effect each cell acts like a tiny battery (Mayor, 2007). 
The exterior of the cell is charged more positively than the interior.  
Information is transmitted around the body along the neuron, the functional unit of the 
nervous system in the form of electrical signals. Information is transmitted across gaps, 
called synapses in the form of neurotransmitter chemicals (Mayor, 2007). The nervous 
system consist of the brain and the spinal cord, which make up the central nervous 
system (CNS). The rest of the nervous system is termed the peripheral nervous system. 
Changes in the external and external environment are sensed by receptors in the form of 
impulses. The nerves that carry impulses from the receptors to the CNS, are termed 
sensory nerves or afferents. The nerves that carry impulses from the CNS to the muscles 
or glands are the motor nerves, or efferents (Premkumar, 2004).  
The neurons communicate with each other, by changing the electrical potential inside the 
cell. This takes place through the movement of ions in and out of the cell.  
3.1. Resting Membrane Potential  
Nerves exhibit a resting membrane potential, such that the nerve membrane is polarised, 
even in its resting state. Polarisation is achieved by the unequal movement of ions across 
the membrane, which uses energy to create this state. In its resting state, a potential 
difference of -70mV is maintained across a nerve cell refer to Figure 10. The 
concentration difference of ions as well as the difference in electrical charges, serve as a 
force to reinforce or oppose movement of ions hence, transmitting an action potential.  
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3.2. Action Membrane Potential  
Action potential occurs when a nerve is stimulated, resulting in a temporary change of 
state of the nerve membrane, altering the pump and ion channel activity of the 
membrane. The inside of the cell can then either become less negative, where the state is 
known as the depolarisation or more negative in a state termed hyperpolarisation. 
Following the stimuli action, the cell returns to its original resting potential state and this 
is known as repolarisation, refer to Figure 10. If the stimulus is repeated, another action 
potential takes place. In some neurons however, several action potentials are produced 
continuously, as long as the stimulus remains and the generation of action potential stops 
once the stimulus is terminated. Furthermore, the strength of the stimulus generated in the 
body is proportional to the frequency of the action potential generated per second and not 
amplitude.  
When considering this in relation to the use of electrical stimulation, a similar outcome is 
achieved (i.e. electrical stimulation generates action potential followed by repolarisation 
to return to the resting potential state). However, the only difference is that the action 
potential is ‘forced’ by a source outside the body for instance; using an electrical current 
or a pulse of electricity, refer to Figure 10.  
3.3. Nerve Membrane Threshold 
The threshold level at which an action potential will be produced varies from one neuron 
to another (Premkumar, 2004). Stimulating a nerve cell to produce an action potential, 
requires a stimulus that is sufficient enough to push the membrane potential over its 
threshold value. If a weaker stimulus is applied, the nerve threshold will not be reached. 
Thus, although membrane changes are taking place, no action potential will be produced. 
The use of a stimulus beyond the threshold level, is therefore essential to stimulate a 
nerve to produce an action potential. It does not matter how much stronger the 
stimulation is, as the stimulation strength might stimulate more nerves, but will not 
influence the magnitude of the action potential.  
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a) Unstimulated State 
 
b) Stimulated State 
 
c) Return to Unstimulated State 
Figure 10:  Nerve Membrane Potentials. Adapted from (Premkumar, 2004, 
Watson, 2010). a) Resting membrane potential is the unstimulated state, 
characterised by a potential difference of -70mV. b) Action potential takes 
place when the nerve is stimulated, resulting in a potential change of +30 
Mv with less negative ions inside the cell. c) Following Action potential, 
the stimulus is removed and the nerve cell returns to its original 
unstimulated state.  
 
stimulator 
stimulator 
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3.4. Electrical Stimulation 
Electrical stimulation is a vast area, as there appears a range of electrical stimulation 
devices with diverse properties. Novel electrical stimulation devices are available in the 
market. However, there appears a great confusion as to how each device operates, what 
they are best used for, and how effective they are in doing the job they are intended to do. 
The research described in the subsequent chapters, focuses on the development of a novel 
neuromuscular electrical stimulation device. Neuromuscular electrical stimulation 
(NMES) is the process of evoking an action potential in a nerve through the delivery of 
an electric charge to the skin. Neuromuscular electrical stimulation involves stimulating 
motor nerves to elicit muscle contraction. Electrical stimulation is achieved through the 
use of two electrodes that are connected to a stimulator by wires although; recent 
developments of implanted electrodes are available. Electrodes usually have a sticky 
conductive gel coating at the bottom that enables them to adhere to the skin and ensure 
effective transmission of the charge from the electrode to the skin. Electrical stimulation 
is conducted through the use of specialised equipment that includes a stimulus generator, 
electrodes, power source and a user control unit. Stimulation parameters (frequency, 
pulse duration, amplitude and waveform) are chosen in relation to the type of nerve or 
muscle being stimulated. The key issue is to set the device in such a way as to stimulate 
the target nerves as effectively and efficiently as possible (Watson, 2010). Stimulation of 
sensory nerves will bring about a sensory outcome. Similarly, stimulation of motor 
nerves will bring about motor effects.  
3.5. Applications of Electrical Stimulation  
Electrical stimulation was initially used for the prevention of DVT in the year1972 during 
operative procedures (Nicolaides et al., 1972). The electrical simulation was applied by a 
mains-operated Thrombophylactor (Stanley Cox Medical Equipment Division of Rank 
Precision Industries Ltd.), which is a device where electrodes can be connected to, 
consisting of a series of knobs for the selection of the desired intensity. The research 
performed demonstrated that calf muscle electrical stimulation using a single 50 
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millisecond wave current in the range of 12 to 15 pulses per minute under general 
anaesthesia is effective in eliminating stasis during operation, resulting in a 92% 
reduction in the incidence of DVT. In addition to the bulkiness of the electrical stimulator 
device, a key drawback in this study is that the stimulation cannot be used during 
postoperative periods on conscious patients, due to the high electrical stimulation 
intensities. Furthermore, the electrical stimulation cannot be used conveniently in patients 
undergoing orthopaedic surgery on their legs, as there will be issues regarding the 
positioning of the electrical stimulation (Nicolaides et al., 1972).  
Further evidence on the effectiveness of electrical stimulation in the prevention of DVT 
was documented by Lindstrom et al in 1982, who showed that stimulation of the calf 
muscles with groups of impulses giving short periods of tetanus, reduces peroperative 
venous stasis considerably more than single impulses in patients undergoing abdominal 
surgery (Lindstrom et al., 1982). The electrical stimulation was applied using pre-gelled 
electrodes, which are in turn connected to a stimulator device giving galvanic square 
wave electrical impulses. The current range used during the study was 40-50mA, that was 
applied to patients anaesthetised with barbiturate, N2O2 + O2 and morphine, and were 
given muscle relaxants (Lindstrom et al., 1982). Although the study further proves the 
effectiveness of using electrical stimulation in reducing venous stasis, the strength of the 
impulse used is still high and can only be used under general anaesthesia.  
The effectiveness of electrical stimulation in alleviating venous stasis was further 
demonstrated by (Faghri et al., 1997). Electrical stimulation to the calf and thigh muscle 
pumps was given to patients prior to and during total hip and knee arthroplasty under 
general anaesthesia. The stimulation was applied using carbonised rubber skin surface 
electrodes (Medtronic Inc.), which are connected through long wires to an eight-channel 
electrical stimulator that induced rhythmic pulsatile isometric contractions in the calf and 
thigh muscles. The electrical stimulation used had a pulse width of 300µs, a pulse current 
of 65mA and a pulse frequency of 35Hz (Faghri et al., 1997). Results of the study 
demonstrated the effectiveness of electrical stimulations in activating the skeletal muscle 
pumps to promote venous return as shown by the higher stroke volume and cardiac 
output. Thus, although the results of this study are in agreement with results of previous 
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studies using electrical stimulations, however, the problem of pain associated with the 
use of high intensities of electrical stimulations, which makes it usable only under 
general anaesthesia remains unsolved. Pain reduction is therefore an important issue that 
needs to be considered when developing an accepted method that can be used in clinical 
practice. 
Following those earlier studies, trials investigating the effectiveness of direct electrical 
stimulation technology in improving blood flow continued (Kaplan et al., 2002, Lyons et 
al., 2002, Morita et al., 2006). Various electrical stimulation devices have been tested in a 
variety of ways on various population groups, with various outcome measurements. 
Lyons et al. (2002) demonstrated that the use of calf neuromuscular electrical stimulation 
at a frequency of 25 to 35Hz and a pulse width setting of 200 and 300µs increases the 
popliteal venous flow velocity. Furthermore, Kaplan et al. (2002) demonstrated the 
effectiveness of using a neuromuscular electrical stimulation technology over an 
extended period. In their study, the femoral and popliteal venous flow velocities in the 
stimulated leg were significantly higher  than those in the non-stimulated leg throughout 
a period of 4 hours (Morita et al., 2006). Considering the studies mentioned above, the 
effectiveness of neuromuscular electrical stimulation in increasing venous blood flow, 
hence venous stasis is apparent. However, the intensity of the stimulation used is still 
high and restricts mobility as the effect of this type of stimulation is muscular tetanus. 
Also, data on the compliance of patients to those techniques is absent. Further research 
based on the use of electrical stimulation is therefore justifiable, in an attempt to develop 
a technology that is more effective in increasing blood flow, does not restrict mobility, is 
simpler in design, less painful and better tolerated.  
 
 
 
 
 
Novel Electrical Stimulation 
Page 60 of 265 
 
Chapter 4. Investigating a Novel Electrical 
Stimulation Device 
 
Using the preceding knowledge, an attempt was made to test and evaluate a novel 
technique that enhances blood flow via transcutaneous electrical nerve stimulation. The 
studies presented in this thesis investigated the effectiveness of a novel neuromuscular 
electrical stimulation technology in enhancing blood flow, which is believed to 
potentially prevent DVT. Initially, a custom built electrical stimulator device consisting 
of two geometrically corrected electrodes connected by wires to a stimulator box was 
developed by the Vascular Scientist Dr. Arthur Tucker and Biomedical Engineer Dr. 
Duncan Bain, refer to Figure 11. The device was termed THRIVE referring to 
thromboembolic prevention via electrical stimulation. The electrodes were placed over 
the common peroneal nerve (also called the lateral or medial popliteal nerves) located in 
the region of the popliteal fossa behind the knee. Stimulation of the peroneal nerve has 
the advantage of initiating contraction of both the posterior and anterior muscle groups. 
Simultaneous stimulation of such muscle groups results in a more stable isometric 
contraction that enhances blood flow from the lower limbs back to the heart, thus 
increasing venous return. A substantial increase in lower limb blood flow was 
demonstrated to improve venous return and thereby reduce venous stasis. As stasis is one 
of the compounding factors in the development of DVT, the risk of developing 
thrombosis should theoretically be reduced. Stimulation of the peroneal nerve also results 
in the contraction of the foot muscles (foot pump). This will further stimulate the 
emptying of the venous blood and enhance blood flow. Additional advantages of the 
selected stimulation of the peroneal nerve are that the resultant muscle stimulation is 
compatible with standing and walking.  
Preliminary studies carried out using this novel technique have demonstrated the efficacy 
of the device in enhancing blood flow at the distal and femoral vein (Tucker et al., 2010). 
It has also been found that a more efficient pumping action is achieved using a series of 
short pulses, rather than a series of prolonged contractions. Taking this into 
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consideration, the stimulation sequence of the novel device was adjusted using a series of 
single pulses as opposed to a series of prolonged pulses.  
 
Figure 11:  A Custom Built Electrical Stimulator Device. The custom built device 
(THRIVE) developed by Dr Arthur Tucker and Dr Duncan Bain consists 
of two geometrically corrected electrodes connected by wires to a 
stimulator box. 
In light of the promising results obtained by preliminary studies performed by (Tucker et 
al., 2010), further studies described in this thesis were carried out. The cardiac study, 
described in chapter 3 was the first study performed with the intention of further 
confirming the efficacy of the novel device in enhancing blood flow using different pulse 
width settings and evaluating the effect on specific cardiac parameters. The cardiac study 
was followed by the THRIVE study, described in Chapter 4, which was primarily 
designed to investigate the systemic effect of the electrical stimulation device on specific 
blood coagulation parameters. The THRIVE study also further investigated blood flow 
parameters to confirm previous findings obtained. 
Through conducting the Cardiac and the THRIVE studies, it was found that the combined 
use of single pulses together with the stimulation of the peroneal nerve not only improved 
comfort to the user, but also greatly reduced current consumption. However, the separate 
circuit boxes, cables and electrode placement was not convenient or clinically appropiate. 
This presented the possibility of further developing the THRIVE device, into a low 
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power device, powered by a single-button cell, similar to the type used to power wrist 
watches. As clinical investigations on the THRIVE device were taking place, work was 
in progress on improving the overall design and specification of the device. Further 
developments of the device took place, to develop a compact, integral device whereby the 
control and induction circuit, battery and electrodes were all contained on a single self 
adhesive strip. Such development presented advantages in terms of convenience, disposal 
and infection control. The integral construction of the THRIVE device also provided the 
potential for a fixed geometry and orientation of the electrodes; this overcomes the 
inconsistency associated with orienting the positive and negative electrodes.  
Following the completion of the cardiac and THRIVE study, the device was developed in 
collaboration with First Kind Ltd, High Wycombe UK into a complete integral, self 
adhesive unit comprising a battery, circuit and electrodes. The device was accredited with 
the widely recognised CE marking into a medical device named geko™ T-1 that is 
powered by OnPulse™ technology, refer to Figure 12. OnPulse™ is a software that 
ensures safe and controlled delivery of electrical impulses via the geko™ electrodes. The 
geko™ T-1 is a portable, compact device resembling a wrist watch. It is simple, self-
adhesive, disposable, battery powered, one-size-fits all device that allows unrestricted 
ambulation while active. The electrical current supplied by the device is limited to 27mA 
and the interval is constant and is regulated to repeat the cycle of blood movement every 
second. The geko™ T-1 device consists of 7 pulse width settings ranging from 70μs to 
560μs. The desired pulse width setting can be selected by the on/off switch button; refer 
to Table 3 for more specifications of the device and Appendix 25 for the device 
instruction manual. 
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Figure 12:  geko™ T-1 Electrical Stimulation Device. The (THRIVE) device was 
further developed by First Kind Ltd. High Wycombe UK, into geko™ T-1  
device that  is powered by OnPulse™ technology.  
Weight 18g 
Dimensions 149mm x 42mm x 11mm 
Stimulation Mode 7 selectable pulse width 
Pulse Width 70,100,140,200,280,400,560 µs 
Pulse Current 27 mA (± 15%) constant current 
Repetition Rate 1 Hz ( ± 5%) 
Table 3:  Specifications of the geko™ Device.  
After developing the CE marked geko™ device, further investigations were performed by 
carrying out the geko™ versus IPC comparison study, described in chapter 5. The 
intention of the study was to compare the effectiveness of the device in enhancing blood 
flow with the most commonly used mechanical prophylaxis device (intermittent 
pneumatic compression) used in hospitals.  
The studies described in this thesis were all performed by a research team that comprised 
of a chief investigator, clinical investigator ultrasonographer, independent accredited 
echocardiographers (Cardiac study), anaesthetists (THRIVE Study) and myself (PhD 
Student). The tasks carried out by each team member are summarised in Table 4.  
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Team Member Responsibility 
Chief Investigator Consenting and screening volunteers  
Blood withdrawal  
Fitting Devices (geko™, IPC, Laser Doppler 
Flowmetry, Pulse Oximetry and Transcutaneous 
Oxygen Saturation device (TcPO2) 
Ultrasonographer Colour Flow Duplex Ultrasound Measurements 
Anaesthetist Needle cannulation of the foot and arm 
Clinical Investigator Rotational Thromboelastometry Assessment 
Echo cardiographer Echocardiography Scans 
Myself (PhD Student) Protocol Design and Literature Review 
Laboratory Management 
Explaining Study Procedure 
Completing Case Report Forms 
Performing Automated Coagulation Timer 
Assessments  
Blood centrifugation, Laboratory Analysis using 
Enzyme Linked Immunosorbent Assay (ELISA), 
Statistical analysis of all parameters measured 
Table 4:  Research Team Responsibilities. 
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Chapter 5. The Effect of THRIVE Device on Cardiac 
Performance in Healthy Volunteers: A Pilot Study 
 
5.1. Introduction 
Heart failure is a clinical syndrome that occurs when the heart is unable to pump enough 
blood to meet the demands of the body (Petersen et al., 2002). Heart failure is the result 
of structural or functional abnormalities of the heart. The symptoms most commonly 
encountered are breathlessness, fatigue and peripheral oedema (NICE, 2010a). Heart 
failure can clinically present with predominantly systolic or diastolic dysfunction or both. 
Diastolic dysfunction is the state where the heart loses its ability to relax. The heart is 
therefore unable to fill with blood. Therefore, to compensate for this state, the heart 
sometimes pumps out higher volumes of blood than in normal situations. Systolic 
dysfunction on the other hand, occurs when the heart is unable to pump out sufficient 
blood, which results in more blood remaining in the ventricles. This state is also known 
as left ventricular systolic dysfunction (LVSD). There is a strong association between left 
ventricular systolic dysfunction and heart failure. About two-fifths of people with heart 
failure will have impaired left ventricular systolic function (defined as an ejection 
fraction of less than 40%), and around half of those with left ventricular systolic 
dysfunction have definite heart failure (Davies et al., 2001). 
In the United Kingdom, there are about 63 000 cases of heart failure each year, of whom 
around 34 000 are men and 29 000 are women. Hospital statistics have shown that in the 
last ten years, the number of heart failure hospital admissions in the UK has increased by 
around 5% in men and 4% in women aged 45 years and older (Davies et al., 2001). The 
prevalence of heart failure increases steeply with age in both men and women. While 
around one in 35 people aged 65 to74 years have heart failure, the number increases to 
about one in 15 of those aged 75 to 84 years, and just over one in 7 of those aged 85 and 
above. Considering all ages, heart failure is more common in men than women (Cowie et 
al., 1999, Davies et al., 2001). Mortality rates, although falling, figures are still high in 
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the UK. In the year 2000 just under 10 000 deaths due to heart failure were recorded 
(Davies et al., 2001). Furthermore, heart failure is also associated with severe morbidity. 
People with heart failure tend to have a poor quality of life relative to people with other 
chronic conditions. The main group of drugs used to treat heart failure are angiotensin 
converting enzyme (ACE) inhibitors, beta-adrenoceptor blocking drugs (beta-blockers) as 
well as diuretics. However, although these therapeutic agents have decreased the overall 
mortality associated with heart failure, the proportions of patients that are alive but have 
severe symptoms has increased.  
 
Heart failure patients can suffer from peripheral oedema due to the inadequate pumping 
action of the heart. As a result of this condition, blood tends to pool into the veins and 
subsequently in the capillaries under the influence of gravity. High pressure in the 
capillaries increases the hydrostatic pressure and causes fluid accumulation into the 
interstitial space (Casey, 2004). In addition to the severe discomfort, oedema can further 
lead to chronic skin ulceration, particularly if it occurs in combination with other 
illnesses such as diabetes and peripheral vascular disease. This further increases the 
burden on the patient and may lead to hospital admission and the need for special wound 
care.  
 
Reduction of peripheral oedema is possible through stimulating calf and foot muscle 
pumps, which will in turn decrease the venous pressure in the peripheral region and 
augment blood flow towards the heart. Initial experiments using an electrical nerve 
stimulation device (THRIVE) have been shown to increase venous return from the lower 
limb and significantly increase blood flow velocity at the capillary level (Tucker et al., 
2010). This increase potentially decreases the capillary blood pressure and hence the 
forces that lead to fluid leaking from the capillaries into the interstitial space, which as 
mentioned earlier is one of the presumed mechanisms for oedema.  
5.2. Objectives 
The key objective to carrying out this study is to investigate whether the known increase 
in venous return from the lower limb leads to an enhancement in cardiac performance in 
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healthy individuals. This is achieved through carrying out a comprehensive evaluation of 
cardiovascular function, by measuring cardiac output, left ventricular filling and ejection 
fraction. This will provide a clinical justification of the efficacy and safety of the device 
to be applied to patients with heart failure.   
5.3. Study Approval 
The study sponsored by Barts and The London School of Medicine and Dentistry and 
funded by Sky Medical Technology Limited was approved by the National Research 
Ethics Service (NRES), Brent Medical Ethics Committee, reference number 05/Q0408/14 
on 7
th
January 2009, see Appendix 1.  
5.4. Materials & Methods  
5.4.1. Volunteers 
Nine healthy volunteers (7 males and 2 Females) were recruited by advertisement to staff 
and students at Barts and The London, Queen Mary University, Barts and The London 
NHS Trust, and to the general community as approved by the Medical Ethics Committee, 
refer to Table 5. Of the nine subjects recruited, 5 were Caucasians, 2 were Asians and 2 
were from other ethnic origins. All subjects complied with the study protocol.  
Parameters Mean (SD) Median [range] 
Sex; M: F 7: 2  
Age; Years 37.33 (8.14) 33 [30-48] 
Body Mass Index (BMI) 25.07 (3.77) 24.2 [20.3 – 31.2] 
Table 5 : Demographic Data for Cardiac Study Volunteers. 
Volunteers were instructed to have a light breakfast, avoiding fatty foods and caffeine 
containing products. They were also asked to abstain from vigorous exercise from the 
previous evening onwards. All volunteers attended the Royal London Hospital, Barts and 
The London NHS Trust, where assessments were performed. Upon arrival they were 
provided with information sheets and written informed consent was obtained prior to the 
study refer to Appendix 2 & 3. A screening evaluation was performed to each participant, 
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which included a medical history, physical examination together with vital signs (blood 
pressure, heart rate and respiratory rate) and colour flow duplex ultrasound of the lower 
legs to exclude DVT. The specific inclusion and exclusion criteria are presented in Table 
6 and Table 7.  
Health Good general health 
Age Between 18 – 65 
Medical History  No abnormal findings, absence of DVT and haematological 
disorders 
Body Mass Index (BMI) Between 18 – 34 
Drugs No history of drug abuse (including alcohol) licit or iliicit 
Medication No medication usage during 30 days preceding the study or 
during the course of the study.  
Table 6:  Cardiac Study Inclusion Criteria. 
5.4.2. Electrical Nerve Stimulation Device 
A custom built electrical stimulation device (THRIVE) was fitted bilaterally to the 
common peroneal nerve. For each volunteer two different pulse width settings, 400µs and 
600µs were used consecutively. In both settings, the frequency used was 3Hz and the 
device was current modulated to provide a peak current of 20mA. The duration of each 
stimulation programme was 30 minutes for each setting. The stimulation device used 
consists of two electrodes connected to a stimulator box and placed over the common 
peroneal nerve, which is related to the reaction of the venous muscle pumps of the lower 
leg (foot and calf) refer to Figure 13. 
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Figure 13:  Positioning of Electrical Stimulation 
Device.  A custom built electrical stimulation device consisting 
of a pair of electrodes attached to a box was placed over the 
common peroneal nerve at the back of the knee.   
 
 
 
Health Organ dysfunction, any clinically significant 
deviation from normal in the physical 
determinations 
Age < 18 or > 65 years 
Medical History Haematological disorders, previous DVT/PE, 
varicose veins or lower limb ulceration, 
musculoskeletal disorders, recent surgery and 
recent trauma to lower limb; and history of 
gastrointestinal, hepatic, renal, cardiovascular, 
endocrine, neurological, dermatological, 
rheumatological, metabolic (including diabetes), 
psychiatric, or systemic disease judged to be 
significant 
Body Mass Index (BMI) Chronic obesity (BMI >34 kg/m
2
) 
Pregnancy Positive pregnancy test 
Ankle Brachial Pressure Index 
(ABPI) 
Peripheral arterial disease (ABPI < 0.9) 
Medication  Consumption  of any medication in the previous 
30 days 
Participation in other clinical study Participation in any clinical study during the 8 
weeks preceding the active period of the study 
Table 7:  Cardiac Study Exclusion Criteria.  
Common 
peroneal
nerve
Electrode
placement
+ -
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5.5. Study Procedure 
The study was carried out in a quiet, stable, draught free environment. After obtaining 
written consent and completing a screening evaluation, volunteers were clad in shorts, lay 
supine on a padded table with their head slightly tilted. Following 30 minutes of supine 
rest, baseline echocardiography assessments were performed by two independently 
accredited echocardiographers. Electrical stimulation using the THRIVE device, was then 
applied at a lower pulse width setting (400 µs), followed by a higher pulse width setting 
(600 µs). Each stimulation was active for a period of 30 minutes and 10 minutes resting 
period was used to separate each pulse width setting, to allow vascular re-equilibration. 
Echocardiography assessments were performed with the device still active, 5 minutes 
before the end of each stimulation period. 
Two dimensional, motion mode, together with Tissue Doppler Imaging echocardiography 
were performed to obtain a comprehensive evaluation of the cardiovascular function. 
Two dimensional imaging was used to assess ventricular and valvular movement. Motion 
mode, usually referred to as M-mode was used to measure dimensions and timing of 
specific cardiac events. Furthermore, tissue Doppler imaging was used to assess valvular 
flow patterns, left ventricular diastolic function, together with cardiac output (Kaddoura, 
2009).The imaging techniques were performed in six standard views;  parasternal long 
axis (PLAX), parasternal short axis (PSAX), apical 4 chamber (A4C), apical 2 chamber 
(A2C), apical 3 chamber (A3C), as well as arterial short axis (ASAX). To obtain two 
dimensional images and for quality purpose, a single focus was used, the frame rate was 
set at 75/s and three cardiac cycles were stored. 
Cardiovascular evaluation included testing the pumping action of the heart by measuring 
biplane left ventricular ejection fraction (EF), calculated using Simpson’s method. 
Simpson’s method treats the ventricles of the heart as a series of discs, where the 
ventricular length is divided into 20 equal sections. Calculations are then made using the 
length and diameters of the discs. Moreover, left ventricular filling was assessed by 
measuring the mitral inflow velocity as well as the left ventricular diastolic volume, 
which was also calculated using the Simpson’s method. In addition to those parameters, 
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assessment of the cardiac output was made by measuring the left ventricular outflow tract 
velocity time interval (LVOT VTI).  
Besides echocardiography, colour flow duplex ultrasound imaging (Philips IU 22; Philips 
Healthcare, USA) was performed on the femoral artery (15cm proximal to the patella) by 
an accredited vascular ultrasonographer. Parameters measured included femoral vessel 
diameter, peak velocity, blood volume flow together with cross sectional area. Owing to 
an excessive artefact caused by leg motion when the stimulation device is active, venous 
parameters were not measured. Both echocardiography and colour flow duplex 
ultrasound measurements were measured at baseline and 5 minutes before the end of the 
stimulation period. Measurements obtained were manually recorded in the subject’s case 
report form at the end of each study period. 
Furthermore, laser Doppler flowmetry (LDF) was used to measure microcirculatory 
blood flow through tissue capillaries, arterioles and venules. The laser Doppler flowmeter 
used in this study was (Laser Doppler Perfusion & Temperature Monitor DRT4; Moor 
Instruments Ltd, UK). Laser Doppler flowmetry works when a beam of laser light is 
directed through optical fibres to the probe, where it penetrates the skin to a depth of 1-
1.5 mm and is partly reflected and scattered. Light scattered back from the tissue by 
moving red blood cells, then undergoes a frequency shift that is proportional to the 
velocity of moving objects (Flux), and is expressed in volts (De Graaff et al., 2001). ). In 
this study, probes were attached bilaterally to the foot for each volunteer. Following zero 
calibration and stabilisation of LDF signals, skin blood flow was recorded for 5 minutes 
at baseline and at the end of the stimulation period, while the device is still active. LDF 
signals recorded for 5 minutes, were then processed by a computer analysis system, CED 
1401 using Spike 2 software (Cambridge Electronic Design Ltd., Cambridge UK), which 
averages the recordings, thereby reducing the effect of artefact. Using the data obtained 
from the LDF analysis, adjusted LDF was calculated by deducting the zero calibration 
values from the actual LDF measurements obtained.   
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5.6. Statistical Analysis  
All assessments were acquired at baseline and during the use of the electrical stimulation 
at different pulse widths. The baseline values obtained for each assessment were used as 
a reference range. Although reporting percentage change from baseline is often used to 
report results, this has been found to be statistically inefficient and does not correct for 
imbalance between groups at baseline (Vickers, 2001). For this reason the data were 
analysed untransformed. A comparison of the data before and after the use of the 
electrical stimulation device was then made. Statistical analysis was performed using 
Minitab 16 software (Minitab Ltd, UK). Analysis of variance using adjusted sum of 
squares followed by Dunnett’s Test was conducted for each parameter tested. A p-value 
of ≤ 0.05 was considered statistically significant. The data demonstrated in the results 
section represents the mean of data obtained from 9 volunteers.  
5.7. Results 
5.7.1. Doppler Ultrasound Assessments 
5.7.1.1. Arterial Volume Flow 
Analysis of the data using a linear model showed that there is a highly significant 
difference between the different pulse widths, 400µs and 600µs as compared to the 
baseline, p ≤ 0.05. The mean values of the femoral arterial volume flow, obtained 
following the use of the electrical nerve stimulation device were higher in comparison to 
the baseline values, refer to Figure 14. The highest mean value was obtained following 
the use of pulse width 600µs. The mean (SD) values were 174.1 mL/min (39.2) at 
baseline, 258.8 mL/min (65.6) following pulse width 400µs and 273.1 mL/min (97.1) 
following pulse width 600µs. Results obtained when calculating the average percentage 
change in comparison to the baseline, were approximately similar for both pulse widths. 
Blood volume flow increased by 55% and by 54 % following the use of pulse width 
400µs and 600µs respectively. This shows that both pulse width settings were equally 
effective in enhancing the arterial blood volume in comparison to the baseline.  
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Figure 14:  Cardiac Study Mean Arterial Volume Flow. Error bars represent 95% 
confidence interval of the difference from baseline, p ≤ 0.05.  
5.7.1.2. Peak Velocity  
Measurements of arterial blood velocity obtained following analysis of variance showed 
a highly significant difference between the different settings as compared to the baseline,  
p ≤ 0.05.  Peak blood velocity measurements increased following electrical stimulation. 
The mean (SD) values were 81.19 cm/sec (13.62) at baseline, 101.60 cm/sec (22.43) 
following pulse width 400µs and 100.90 cm/sec (26.37) following pulse width 600µs. 
The use of electrical nerve stimulation at both pulse widths gave rise to equal increases in 
blood velocity by 24% as compared to the baseline, refer to Figure 15.  
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Figure 15:  Cardiac Study Mean Arterial Peak Velocity. Error bars represent 95% 
confidence interval of the difference from baseline, p ≤ 0.05. 
5.7.1.3. Cross Sectional Area 
Unlike blood volume flow and peak velocity, analysis of the change in the femoral vessel 
cross sectional area following the use of electrical nerve stimulation was not significant, 
p > 0.05. The mean (SD) values obtained following analysis of variance were in the same 
range following the electrical stimulation when compared to the baseline. The values 
were 0.34 cm
2
 (0.10) for the baseline, 0.32 cm
2
 (0.14) and 0.33 cm
2
 (0.11) for pulse 
widths 400µs and 600µs respectively, refer to Figure 16. 
 
Figure 16:  Cardiac Study Mean Arterial Cross Sectional Area. Error bars represent 
95% confidence interval of the difference from baseline, p > 0.05. 
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5.7.1.4. Vessel Diameter 
Analysis of variance for the change in femoral vessel diameter was also not significant 
following electrical stimulation as compared to the baseline, p > 0.05. The mean (SD) 
values were again of similar range; 0.64 mm (0.10) was obtained at baseline, 0.63 mm 
(0.12) following pulse width 400µs and 0.64 mm (0.11) following pulse width 600µs, 
refer to Figure 17. 
 
Figure 17:  Cardiac Study Mean Vessel Diameter. Error bars represent 95% 
confidence interval of the difference from baseline, p > 0.05. 
5.7.2. Laser Doppler Flowmetry (LDF) Assessments 
A highly significant difference was reported following assessment of skin 
microcirculation measurements using LDF, p ≤ 0.05. A substantial increase was seen 
following the use of electrical nerve stimulation in comparison to the baseline. The use of 
pulse width 600µs was associated with a higher increase in LDF measurements in 
comparison to the use of pulse width 400µs. The mean (SD) obtained were 7.71 (3.39) at 
baseline, 107.5 (68.1) following pulse width 400µs and 117.9 (67.8) following pulse 
width 600µs. Moreover, when calculating the average percentage change in comparison 
to the baseline, LDF increased dramatically by 1186% following pulse width 400µs and 
1552% following pulse width 600µs, refer to Figure 18.  
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5.7.3. Echocardiography Assessments 
Echocardiography measurements were performed to assess the cardiac output, the 
percentage of ejection fraction as well diastolic function. Analysis of variance for cardiac 
output showed a significant increase in LVOT VTI by 6% following the use of electrical 
stimulation at pulse width 400µs and an increase of 4% following pulse width 600µs, p ≤ 
0.05. The mean (SD) obtained for LVOT VTI were 21.96 (3.23) for the baseline, 23.27 
(3.37) for pulse width 400µs and 22.79 (3.06) for pulse width 600µs, refer to Figure 19.  
Further analysis of variance showed a non significant change in ejection fraction as well 
as diastolic function parameters, p > 0.05. Parameters remained stable prior to and 
following electrical nerve stimulation, refer to Table 8.  
 
Figure 18:  Cardiac Study Mean Skin Microvascular Velocity. Error bars represent 
95% confidence interval of the difference from baseline, p ≤ 0.05. 
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Figure 19:  Cardiac Study Mean Left Ventricular Outflow Tract Velocity Time 
Interval (LVOT VTI). Error bars represent 95% confidence interval of the 
difference from baseline, p ≤ 0.05. 
Parameters Baseline  
Mean (SD) 
400µs 
Mean (SD) 
600µs 
 Mean (SD) 
P - Value 
Ejection Fraction (%) 59.9 (3.72) 60.3 (7.44) 62.6 (4.80) 0.09 
LV Diastolic Volume 
(mL) 
117.7 (37.10) 120.2 (32.30) 121.1 (27.86) 0.61 
E′ Velocity (m/s) 0.80 (0.16) 0.77 (0.12) 0.76 (0.08) 0.29 
A′ Velocity (m/s) 0.53 (0.13) 0.53 (0.09) 0.54 (0.12) 0.74 
Deceleration Time (ms) 187.4 (24.82) 194.1 (31.4) 187.9 (20.28) 0.59 
E′ Lateral (m/s) 3.76 (5.53) 3.79 (5.58) 3.89 (5.79) 0.75 
Table 8: Ejection Fraction and Diastolic Function Measurements prior to and 
Following Electrical Stimulation.  
5.8. Discussion  
The aim of the study presented was to investigate the effectiveness of a novel custom 
built electrical stimulation device (THRIVE) in increasing venous return of the lower 
limb, which in turn is believed to enhance cardiac performance. Echocardioghraphy was 
used in this study at different modes to evaluate the effect of applying electrical 
stimulation at two different pulse widths, 400µs and 600µs. Cardiac parameters measured 
were ejection fraction, cardiac output as well as diastolic function. Of all of the cardiac 
parameters assessed, a significant difference was only seen in the cardiac output, p ≤ 
0.05. Cardiac output  is the amount of blood ejected by the left ventricle in a time interval 
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of one minute (Nursecom, 2004). It is measured at the left ventricular out flow tract and 
is the product of heart rate and stroke volume, which is the amount of blood ejected with 
each contraction. The parameter used to measure cardiac output is LVOT VTI and the 
unit of measurement is cm. Heart rate and cardiac output have a direct relationship. Thus, 
as heart rate increases, so does cardiac output. In percentage terms, in comparison to 
baseline an augmentation in cardiac output by 6% was seen using pulse width 400µs and 
an augmentation of 4% was obtained using pulse width 600µs. The observed increase in 
cardiac output although minimal, it is still in agreement with the results of previous 
electrical stimulation studies performed by (Faghri et al., 1997). The electrical stimulator 
used in the study was an eight channel electrical stimulator device, which induced 
rhythmic pulsatile isometric contractions in the calf and thigh muscles. Following 
stimulation, a 26% increase in cardiac output was demonstrated. This was compared to a 
fall by 14% following the use of a sequential compression device (Faghri et al., 1997). 
The significant increase in cardiac output reported in our study, could be due to the direct 
activation of the calf muscle pump, which in turn causes the emptying of both venous 
beds and sinuses. Another reasoning for the increase in cardiac output, could be stress-
related and could be due to the exposure to a foreign sensation (electrical stimulation), 
which may have also resulted in an increase in heart rate. After exposure to the lower 
pulse width, the increase in cardiac output was 4% following the higher pulse width, 
which means that the volunteer may have become accustomed to the foreign sensation 
applied. However, as heart rate was not monitored throughout the study it is difficult to 
confirm this reasoning.  
Ejection fraction (EF), which is a measure of the amount of blood ejected out of the 
ventricles with each heart beat, was assessed at baseline and following the use of the 
different pulse widths. Ejection fraction is a predictor of congestive heart failure (Lavine, 
2003, Solomon et al., 2005). Although an augmentation of EF by 5% was seen following 
analysis of the results from our study, however this increase is not statistically significant, 
p > 0.05. Despite that, the increase seen is of interest and requires further investigation on 
a larger population. It is essential to note here that the subjects in this study are healthy, 
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thus it is possible that a greater effect may be seen when carrying out the same 
investigations on patients.  
In addition to ejection fraction, assessments of diastolic function parameters were also 
not statistically significant, p > 0.05. A series of diastolic function parameters were 
measured to assess the left ventricular filling pattern. Parameters include LV diastolic 
volume, which is the volume of blood available in the left ventricle at the end of diastole 
and just before systole, E- and A- wave diastolic velocities measured at the mitral valve 
that reflects the early and late diastolic filling. In addition to the deceleration time (DT) 
into the left ventricle, and E/E ratio, which is an assessment of the LV filling diastolic 
pressure. Analysis of the results suggests that electrical stimulation does not alter the 
filling pattern in the left ventricle.  
Furthermore, a statistically significant augmentation was observed when measuring 
vascular flow parameters both at the arterial and microvascular level, p ≤ 0.05. Using 
colour flow duplex ultrasound, arterial volume flow increased by more than 50% 
following electrical stimulation. Similarly, a lower but a significant increase in arterial 
peak velocity (24%) was reported. Of interest is the dramatic increase in microvascular 
velocity by 1186% following pulse width 400µs and 1552% following pulse width 
600µs. There are two possible mechanisms for the increase reported in both the arterial 
and microvascular measurements. The first mechanism may be that the increased vessel 
flow provided by the venous valve system when active provides direct auxiliary 
assistance to the heart, by reducing the pressure difference between inflow and outflow to 
the ventricle. However, further investigation is required to confirm this mechanism. An 
alternative mechanism is suggested by the striking increase in micro-vascular velocity as 
evidenced by the LDF results. This suggests a substantial up-regulation of the use of 
smaller vessels in the skin and possibly other organs. This represents a large increase in 
the total available cross sectional area and therefore a presumable drop in the vascular 
resistance. Hence, reducing the work component of the cardiac cycle.  
Findings of this study demonstrate the safety of the device with potential benefits in 
patients with heart failure; as confirmed by the increase in cardiac output reflected by the 
Cardiac Study  
Page 80 of 265 
 
increase in LVOTVTI. The novel device also enhances microcirculatory velocity, which 
results in the increase of peripheral vascular resistance. This is complimented by a 
significant enhancement in arterial blood flow volume and velocity. A key limitation in 
our study was the sample size and nature of the population. Further investigations are 
required in patients in order to confirm the responses and benefits of electrical 
stimulation in cardiac patients; particularly those in heart failure.  
However, before initialising trials on patients, further research will be performed 
exploring whether the novel device exhibits any systemic benefits, since studies have 
demonstrated the enhanced fibrinolytic effects of electrical stimulation (Nicolaides et al., 
1972). This will be achieved through performing invasive measurements to examine 
changes in specific coagulation parameters and explore the exact mode of action.  
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Chapter 6. The Systemic Effect of a Novel Electrical 
Stimulation Method 
6.1. Introduction  
Deep vein thrombosis (DVT) is the formation of a thrombus within the deep veins. 
Thrombus formation was thought to be only a complication of hospitalisation following 
surgery, or is associated with late stage terminal illness. However, studies in 1990s 
banished this myth by demonstrating that thrombus formation occurs not only in 
hospitalised patients, but also in a high proportion of patients who are not hospitalised 
nor recovering from major illnesses (Anderson and Spencer, 2003). Death can occur 
when venous thrombi break off forming pulmonary emboli that pass to the lungs and 
obstruct the arteries. Thrombus formation usually takes place in areas characterised by a 
disturbed blood flow in large venous sinuses and in the valve pockets. It has been shown 
that the majority of thrombi originate in the soleal veins and valve pockets following 
surgery (Nicolaides et al., 1971, Nicolaides et al., 1972). Thrombi also form in vein 
segments that have been subjected to direct trauma, or inflammatory processes. 
As described earlier, a number of risk factors have been well identified, all of which can 
be associated with an abnormality in one or more of the elements of Virchow’s Triad that 
includes venous stasis, endothelial damage of the veins and hypercoagulability. Some 
factors are considered strong risk factors that require prophylaxis such as general surgery, 
orthopaedic surgery, spinal cord injury, major trauma, malignancy, myocardial infarction, 
congestive heart failure and respiratory failure. Others are recognised as weak factors 
such as advanced age, hormone therapy, smoking and obesity that may require 
prophylaxis if present in combination with other risk factors (Anderson and Spencer, 
2003). Therefore, it is essential to assess the strength of individual risk factors and the 
combined effects of risk factors prior to selecting the appropriate prophylaxis.  
Despite the great advances in pharmacological prophylaxis, the bleeding risk associated 
with their use and the constant need of monitoring is a major hurdle. DVT still remains a 
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major public health problem; hence, improving ways of prevention is the key to tackling 
this issue.  
The underlying study referred to as Thromboembolic Prevention via Electrical 
Stimulation (THRIVE) investigated the use of a novel method for enhancing blood flow 
in the lower limb using electrical nerve stimulation. An increase in lower limb blood flow 
improves venous return and thereby reduces venous stasis. Since stasis is one of the 
compounding factors in the development of deep vein thrombosis, the risk of developing 
thrombosis should theoretically be proportionally reduced. The technique investigated 
may therefore, prove to be useful in preventing and reducing the incidence of deep vein 
thrombosis in both medical and surgical patients together with passengers undertaking 
significant travel.  
The proposed technique involves activation of the venous muscle pumps of the lower leg 
(foot and calf pump) via electrical stimulation of the lateral and/or medial popliteal 
nerves located within the popliteal fossa. This involves placing electrodes over the nerves 
in the lower thigh and locations anatomically distant from the calf and foot. In other 
studies, activation of the muscle pumps has been achieved by direct stimulation of the 
calf itself by placing the electrodes over the muscles themselves. In preliminary 
investigations in our laboratory, the technique has been shown to be effective in 
stimulating lower limb musculature contraction measured by strain-gauge 
plethysmography. Contraction of the lower limb and foot muscles has been demonstrated 
to enhance both blood flow velocity and flow volume in the lower limb as measured in 
dorsal foot veins by plethysmography and in the femoral vein using duplex ultrasound 
(Tucker et al., 2010).  
6.2. Objectives 
The key objective of this study was to investigate the effect of the electrical stimulation 
device (THRIVE) on specific blood coagulation factors. Secondary objectives were to 
evaluate the effectiveness of the THRIVE device in enhancing lower limb blood flow by 
assessing blood flow velocity and volume changes at the arterial and venous level using 
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colour flow duplex ultrasound and laser Doppler flowmetry. Furthermore, to assess the 
safety of the electrical stimulation applied, by monitoring oxygen saturation levels as 
well vital signs throughout the study period. In addition to this, to assess the acceptance 
and tolerance of healthy volunteers to the stimulation device applied using discomfort 
questionnaires.  
6.3. Study Approval 
The study sponsored by Barts and The London School of Medicine and Dentistry and 
funded by Sky Medical Technology Limited was approved by the National Research 
Ethics Service Committee (REC Number: 05/0408/14 Brent) refer to Appendix 4.   
6.4. Materials & Methods 
6.4.1. Volunteers 
Ten healthy volunteers (9 Males, 1 Female) were recruited by advertisement to staff and 
students at Barts and the London, Queen Mary University, Barts and The London NHS 
Trust and to the general community. The demographic data are displayed in Table 9 
below. Of the ten subjects recruited, 9 were White Europeans and 1 was from another 
ethnic origin. All subjects complied with the study protocol. The specific inclusion and 
exclusion criteria are outlined in Table 10 and Table 11.  
Volunteers were instructed to have a light breakfast, avoiding fatty foods and caffeine 
containing products. They were also asked to refrain from vigorous exercise from the 
previous evening onwards. All volunteers attended The Ernest Cooke Clinical 
Microvascular unit at St Bartholomew’s Hospital where assessments were performed. 
Upon arrival volunteers were provided with information sheets (Appendix 5) and written 
informed consent for screening and study participation was obtained prior to the study, 
see Appendix 6 & 7. Each volunteer had two visits; the first visit was to conduct a 
stimulation study where an electrical stimulation device was applied. The second visit 
was to carry out a control study were the same investigations were repeated without 
stimulation. 
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Parameters Mean (SD) Median[Range]   
Sex; M: F 9:1  
Age; Years 34.6 (6.88) 35 [26 – 45] 
Body Mass Index (BMI) 25.3 (2.86) 24.8 [20.1- 30.2] 
Table 9:  Demographic Data for THRIVE Study Volunteers. 
Health Good general health 
Age Between 18 – 65 
Medical History  No abnormal findings, absence of DVT and haematological 
disorders 
Body Mass Index (BMI) Between 18 – 34 
Drugs No history of drug abuse (including alcohol) licit or iliicit 
Medication No medication usage during 30 days preceding the study or 
during the course of the study  
Table 10: Inclusion Criteria for THRIVE Study. 
6.4.2. Electrical Nerve Stimulation Device (THRIVE) 
During the stimulation study, an in house custom built electrical stimulation device was 
applied transcutaneously to the common peroneal nerve in the popliteal fossa of one leg 
and compared to an un-stimulated contralateral control leg. The stimulation device used 
in this study is similar to that used in the cardiac study, which consists of two electrodes 
connected to a stimulator box refer to  
Figure 20. The electrical stimulation device was used at an amplitude of 25mA and a 
frequency of 3Hz with a pulse width of 600µs. Those settings were chose in relation to an 
optimum stimulation setting obtained from previous study results (Tucker et al., 2010). 
The stimulation was applied for 5 minutes every 15 minutes followed by a 10 minute 
recovery phase, to allow vascular re-equilibration.  
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Health Organ dysfunction, any clinically 
significant deviation from normal in the 
physical determinations 
Age < 18 or > 65 years 
Medical History Hematological disorders, previous DVT/PE, 
varicose veins or lower limb ulceration, 
musculoskeletal disorders, recent surgery 
and recent trauma to lower limb; and history 
of gastrointestinal, hepatic, renal, 
cardiovascular, endocrine, neurological, 
dermatological, rheumatological, metabolic 
(including diabetes), psychiatric, or 
systemic disease judged to be significant 
Body Mass Index (BMI) Chronic obesity (BMI >34 kg/m
2
) 
Pregnancy Positive pregnancy test 
Ankle Brachial Pressure Index (ABPI) Peripheral arterial disease (ABPI <0.9) 
Medication  Consumption  of any medication in the 
previous 30 days 
Blood  Contraindication to blood sampling, 
Donation of blood 8 weeks preceding the 
study 
Participation in other clinical study Participation in any clinical study during the 
8 weeks preceding the active period of the 
study 
Table 11:  Exclusion Criteria for THRIVE Study. 
 
 
Figure 20:  Custom Built  Electrical 
Stimulation Device. The Electrical stimulation device 
(THRIVE) was applied over the peroneal nerve located 
at the back of the knee to subjects seated in an airline 
seat.  
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6.5. Study Procedure 
6.5.1. Screening Evaluation  
After explaining the study procedure and following obtaining informed consent, 
volunteers were screened prior to starting the study. The screening evaluation included a 
medical history, physical examination together with vital signs (blood pressure and heart 
rate) and colour flow duplex ultrasound of the lower legs to exclude bilateral DVT. The 
ultrasound examination involved examining the deep veins (femoral, popliteal, 
gastrocnemial, soleal, posterior tibial, and peroneal) for vessel wall irregularities that 
might suggest a history of DVT. Furthermore, the superficial venous system (greater 
saphenous veins and lesser saphenous veins) were also examined for valvular 
incompetence (reflux) to exclude the presence of superficial vein thrombophlebitis.  
6.5.2. Study Methodology 
The study was carried out in a quiet, stable, draught free environment, where both the 
temperature and humidity were controlled (24 ± 1
0
C, relative humidity 30 – 40%). 
Following screening, eligible volunteers were cannulated by an anaesthetist in the vein at 
three sites: bilaterally in the foot (dorsum or medial malleolar region) and one arm (left 
arm). Volunteers lightly clad in shorts, then sat in an airline seat with their legs bent at 
the knees for a period of 4 hours. Changes in lower limb blood flow were then evaluated 
during the 4 hour study period using laser Doppler flowmetry (LDF), Colour Flow 
Duplex Ultrasound. Pulse oximetry was also used to measure the oxygen saturation and 
heart rate. Blood pressure was also monitored during the study period using a digital 
blood pressure monitor (UA- 767PC, A&D Tokyo, Japan). 
6.5.2.1. Laser Doppler Flowmetry (LDF) 
Microcirculatory blood flow was assessed using Laser Doppler Perfusion & Temperature 
Monitor DRT4; Moor Instruments Ltd, UK. Probes were attached bilaterally to the foot 
for each volunteer. Following zero calibration and stabilisation of the LDF signals, skin 
blood flow was recorded for 5 minutes at baseline and at the end of the stimulation 
THRIVE Study  
Page 87 of 265 
 
period, while the device is still active. LDF signals recorded for 5 minutes, were then 
processed as mentioned earlier by a computer analysis system, CED 1401 using Spike 2 
software (Cambridge Electronic Design Ltd., Cambridge UK), which averages the 
recordings, thereby reducing the effect of artefact. From the LDF signals generated, the 
average values of LDF signals were generated. Adjusted LDF were then calculated by 
deducting the zero calibration values from the actual LDF measurements.  
6.5.2.2. Colour Flow Duplex Ultrasound 
Colour flow duplex ultrasound (Phillips HDI 5000) was used to evaluate the effect of the 
electrical stimulation on blood flow in the superficial and deep venous system throughout 
the study. Ultrasound assessments of the arterial and venous femoral blood vessels were 
performed by an accredited vascular ultrasonographer at the end of each time interval i.e. 
Baseline, 1, 2, 3 and 4 hours and recorded manually in the subject’s case report form. The 
parameters measured include blood volume flow, peak velocity together with vessel wall 
diameter.  
6.5.2.3. Pulse Oximetry 
The percentage of haemoglobin saturated with oxygen, together with heart rate was 
measured using Pulse Oximetry. Readings were obtained through the use of a light sensor 
which contains two sources of light (red and infrared). Light is absorbed by haemoglobin 
and is transmitted through the tissue to the photo detector. The amount of light 
transmitted through the tissues is then converted to a digital value representing the 
percentage of oxygen saturation of the haemoglobin. Normal oxygen saturation values 
usually lie between 96-99% in healthy individuals, however values down to 90% are also 
normal but rarely occur (Minolta, 2006 ). Measurements using pulse oximeter (Datex 
Ohmeda 3900P, TruTrak+
®
) were made by placing a probe on the pulp of the second left 
toe of each volunteer. Percentages of oxygen saturation (SPO2) as well as, heart rate 
readings were then recorded manually from the pulse oximeter device immediately after 
the stimulation period. Pulse oximetry recording were not performed during the 
stimulation period, as unstable reading were given as a result of muscular contraction.  
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6.5.2.4. Blood Collection  
Blood was withdrawn from the three sites cannulated (bilaterally at each leg and left arm) 
at the start of the investigation and serially during the 4 hour study period. Approximately 
15mL of blood was collected at each site at each time point. Patency of each cannula was 
maintained by a saline flush preceding and following each collection. Prior to blood 
collection, 1-2mL of blood was withdrawn and discarded, as this represents blood and 
saline, which has been resident in the cannula or in close proximity to the cannula tip.  
As all parameters analysed were coagulation parameters, blood was collected into a 3.2% 
0.105M sodium citrate light blue top vacutainer tube (ratio 9:1) according to the Flow 
Chart presented in Appendix 8. Plasma was prepared by centrifugation for 10 minutes at 
2500g at room temperature. The platelet poor plasma that was aliquoted into pre-labelled 
2mL cryovials was immediately frozen. The cryovials were then placed in pre-labelled 
cardboard boxes and stored at -80
0
C until further analysis (Appendix 9). 
6.5.2.5. Assessment of Clotting Time 
As prolonged sitting is usually associated with clot formation in the lower limb, it was 
essential to analyse several parameters that are closely associated with the clotting time 
of blood throughout the different time intervals. This was carried out using two 
techniques: Medtronic Automated Coagulation Timer System (ACT) and Rotational 
Thromboelastometry (Rotem®). ACT is a microprocessor controlled electrochemical 
coagulation instrument, designed to determine coagulation endpoints in whole blood 
samples. Freshly drawn whole blood (2mL) was analysed at each time interval according 
to the standard operating instructions (Appendix 10). The clotting time of the whole 
blood was measured immediately following collection by placing 0.2mL of blood in a 
cartridge channel that has an activating agent (Kaolin). ACT detects clot formation by 
measuring the “falling time” of a plunger that is contained in each cartridge channel. The 
plunger-flag falls rapidly in an un-clotted sample, but as the fibrin forms, it delays the 
rate of descent, which is detected by a photo optical system. Simultaneous duplicate tests 
are being performed by using the provided two channels cartridges. The results for each 
channel are being displayed in seconds following the completion of the test.  
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Rotational thromboelastometry (Rotem®) is another technique used to assess blood 
coagulation. However, unlike ACT, thromboelastometry attempts a detailed graphical 
representation of the fibrin polymerisation process beginning with initial clot formation, 
followed by clot acceleration phase and ending with clot lysis. The Rotem® device 
consists of four measurement channels that allow simultaneous assays to be performed 
measuring the extrinsic coagulation pathway through ‘Extem Test’ and the intrinsic 
pathway through ‘Intem Test’. In the Extem coagulation is activated by tissue factor. This 
leads to the initiation of clot formation within 70 seconds. Thus, clot formation can be 
assessed within 10 minutes. In contrast, with the ‘Intem Test’, coagulation is activated 
via the contact phase (as in the ACT). Rotem® device is connected to a PC for automatic 
analysis as well as an electronic pipette for interactive test operation. Approximately 240 
µL of citrated blood sample was placed in a disposable cuvette with the addition of the 
appropriate reagent according to the standard operating procedure for Rotem® (Appendix 
11). A cylindrical pin is immersed, which in turn is connected to an optical detector. As 
soon as the blood clots, the clot restricts the rotation of the pin. The signal of the pin 
suspended in the blood sample, is then graphically displayed as a trace onto the PC, refer 
to Figure 21.  The key parameters measured at different stages of clot formation include:  
Clotting Time (CT): the time from the start of the measurement until initiation of 
clotting; units of measurement is seconds.   
Clot Formation Time (CFT): is the time from initiation of clotting until a clot firmness 
of 20 mm is detected; units of measurement is seconds.  
Maximum Clot Firmness (MCF): is the firmness of the clot, measured in mm. 
Maximum Lysis (ML): is the percentage reduction of clot firmness after MCF 
(breakdown of the clot) 
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Figure 21:  A Two- Sided Rotem® Trace Displaying The Important Parameters 
Measured  Throughout Time (Calatzis et al.) 
6.5.2.6. Assessment of Coagulation Factors  
Coagulation factors were assessed during the 4 hour sitting period to investigate the 
haematological effects of the electrical stimulation. The coagulation factors analysed 
were, Tissue Plasminogen Activator (t-PA) Antigen, von Willebrand Factor (vWF) and 
6-Keto Prostaglandin F1 alpha. Assessment of those factors was performed using 
Enzyme Linked Immunosorbent Assay (ELISA).   
6.5.2.6.1. Tissue Plasminogen Activator Antigen Assay 
Tissue plasminogen activator the primary initiator of fibrinolysis in the vascular system 
plays an important role in regulating the formation and removal of thrombi. Therefore, a 
deficiency in tPA can result in a reduction of the capacity to degrade a clot, hence 
predispose to thrombosis. Levels of tPA in the plasma were measured using a tPA ELISA 
Kit (IMUBIND
®
 tPA ELISA Kit, American Diagnostica Inc), refer to Appendix 12 for 
tPA ELISA Protocol. Frozen aliquots of the platelet-poor plasma were thawed and 
assayed using the tPA ELISA kit. 20µL of sample was added in duplicates to microwells 
coated with polyclonal anti human tPA antibody. The tPA antibody captures the tPA 
antigen during the incubation period. Unbound materials were then washed away and 
bound tPA antigen was identified using peroxidase enzyme substrate. The reaction was 
then terminated by the addition of 50µL of sulphuric acid, which turns the colour from 
yellow to orange. Absorbance of the solution was then measured at 490 nm using ELISA 
spectrophotometer reader (Wellcozyme, Wellcome Diagnostics, Analytical Services 
International Ltd, UK). A standard curve was then constructed by plotting the mean 
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absorbance value measured with each tPA standard versus its corresponding 
concentration. The standard curve was then used to extrapolate the tPA antigen 
concentrations of the plasma samples from the ELISA assay using the Windows Excel 
Program. To maintain quality control, plasma samples were selected and repeated with 
each new assay.  
6.5.2.6.2. von Willebrand Factor Assay 
Von Willebrand factor is a possible indicator of endothelial dysfunction, where raised 
levels are associated with increased thromboembolic events. Thus, it was essential to 
measure quantitatively vWF levels in the plasma of participants over time at the three 
different sites, in order to assess the effectiveness of the electrical stimulation in the 
prevention of thrombus formation. Frozen, stored aliquots of the platelet-poor plasma 
were thawed and analysed by Enzyme Linked Immunosorbent Assays (ELISA) vWF kit 
(IMUBIND
® 
vWF ELISA Kit, American Diagnostica Inc). Refer to Appendix 13 for 
vWF ELISA Protocol. 100µL of diluted sample was added in duplicates to microwells 
coated with polyclonal goat antibody. The antibody captures the vWF during the 
incubation period. After washing the unbound material, peroxidase conjugate detection 
antibody was added and incubated for a further period. Following incubation, wells were 
washed thoroughly again. 100µL of substrate was then added and the plate was further 
incubated for a short period (10 minutes) to allow blue colour to develop. The enzymatic 
reaction was then terminated by the addition of 50µL of sulphuric acid to each well, 
which changed the colour from blue to yellow. Absorbance was then measured at 450nm 
immediately. A standard curve based on a quadratic equation was plotted using Windows 
Excel Program and used to interpolate concentrations of vWF in the plasma sample. To 
maintain quality control, plasma samples were selected and repeated with each new 
assay.  
6.5.2.6.3. Prostacyclin Assay 
Prostacyclin, a major product produced by endothelial cells is responsible for inhibiting 
platelet aggregation. However, as prostacyclin has a short half-life in plasma, the 
production of PGI2 can be measured indirectly, through measuring the levels of its stable 
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product, 6 keto PGF1 F1α.  To do this, 50mg of indomethacin was first dissolved in 
3.5mL of H2O to yield a final concentration of 40mM. 100µL of the indomethacin 
solution prepared earlier was then added to citrated blood prior to centrifugation at 2500g 
for 10 minutes to block the metabolism of prostacyclin  (Webberley et al., 1993). The 
ELISA used to assay 6 keto PGF1α is based on a competitive technique. The ELISA kit 
used (Neogen Corporation), operates on the basis of competition between the enzyme 
conjugate and 6 keto PGF1α in the sample for a limited number of binding sites on the 
antibody coated plate. 6 keto PGF1α was first extracted using solid phase extraction 
method. Following extraction, 50µL of the diluted enzyme conjugate was then added to 
each well and incubated for an hour. Following incubation, the plate was washed 
thoroughly using diluted wash buffer to remove any unbound material. 150µL of 
substrate was then added to each well to detect the bound enzyme conjugate. Following 
an additional incubation period (30 minutes), colour is detected. The extent of colour 
development is inversely proportional to the amount of 6 keto PGF1α in the sample. For 
instance, the absence of 6 keto PGF1α in the sample will result in a bright blue colour, 
whereas its presence will result in a decreased or no colour development. The enzymatic 
reaction was then terminated by the addition of 100µL of stop solution to each well. 
Absorbance was then read at 450nm; refer to Appendix 14 for a detailed description of 
the protocol. From the absorbance values obtained a four parameter logistic calibration 
curve was constructed by plotting absorbance versus concentration in ng/mL using 
Windows Excel Program. The four parameter logistic curve constructed was based on the 
following equation:  
       
         
   (
 
    )
      
where:  
 x = Concentration  
NSB = The lower value of the curve (non-specific binding) 
TOP = The upper value of the curve (maximal binding) 
ED50 = The midpoint value of the curve 
Slope = Slope of the curve 
Y= Absorbance value 
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6.5.2.6.4. Endogenous Thrombin Generation and D-dimer Assay 
Further coagulation marker assessments were carried out by measuring levels of D-
dimer, the final degradation product of fibrinolysis and Endogenous Thrombin Potential 
(ETP), which is an indicator of the thrombin generating capacity. Both analysis were 
performed by an external laboratory (Haemostasis Laboratory, Blood Science 
Department, NHS, London).  
6.5.2.7. Tolerance and Acceptance  
Following electrical stimulation, the volunteers were provided with a discomfort 
questionnaire. Discomfort was compared to a blood pressure cuff inflated around the 
upper arm. Volunteers were asked to rate their level of discomfort using a Visual 
Analogue Scale (VAS), by marking the level of the perceived pain using a 100mm line, 
marked at one end “no sensation” and at the other end “severe discomfort”. Verbal 
Rating Score (VRS) was also used to categorise the rating of the discomfort pain as 
shown below, refer to Appendix 15 for a sample of VAS and VRS.  
1 = no sensation (other than muscles tensing and relaxing) 
2 = minimal sensation 
3 = mild discomfort 
4 = moderate discomfort 
5 = severe discomfort 
6.6. Statistical Analysis 
All assessments obtained during the stimulation and control study were acquired at 
baseline and after 1, 2, 3 and 4 hours. As mentioned in the previous chapter, the data 
were analysed untransformed. As all subjects were healthy and were not expected to have 
any abnormal pathological findings, the baseline values obtained for each assessment 
were therefore, used as a reference range. Statistical analysis was performed using 
Minitab 16 software (Minitab Ltd, UK) as in the previous chapter. Results obtained 
during the stimulation study were compared to those obtained during the control study at 
each time interval with the baseline values acting as reference. The data shown below 
represent the mean of the data obtained from the ten volunteers and are presented as 
mean (SD). 
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6.7. Results  
6.7.1. Colour Flow Duplex Ultrasound Assessments 
Colour flow duplex ultrasound assessments to the arterial and venous femoral blood 
vessel were performed at each time interval (Baseline, 1, 2, 3 and 4 hours) refer to Figure 
22  & Figure 23. Selected parameters were investigated, these include: blood volume 
flow (mL/min), peak maximum velocity (cm/sec) and femoral vessel wall diameter 
(mm). 
 
Figure 22:  Typical Colour Duplex Ultrasound Waveform of the Femoral Artery 
following 4 Hours of Stimulation. Red arrow highlights the femoral arterial 
diameter measured. Time Averaged Mean Velocity (TAMV) and Cross Sectional 
Area (Area) are then calculated by the software to produce the Volume Flow 
(Vol Flow) and Maximum Peak Velocity (Vel), outlined by the blue box. 
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Figure 23:  Typical Colour Duplex Ultrasound Waveform of the Femoral Vein 
following 4 Hours of Stimulation. Red arrow highlights the femoral vein 
diameter measured. Time Averaged Mean Velocity (TAMV) and Cross Sectional 
Area (Area) are then calculated by the software to produce the Volume Flow 
(Vol Flow) and Maximum Peak Velocity (Vel), outlined by the blue box. 
6.7.1.1. Mean Peak Maximum Velocity Assessments 
Analysis of the control study data using linear models, demonstrated a non significant 
difference in femoral velocity both at the arterial and venous level, p > 0.05 refer to 
Figure 24. The mean (SD) reported for the arterial and venous femoral blood vessel in 
the control study are summarised in Table 12. 
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Figure 24:  Mean Peak Maximum Velocity throughout the Control Study. Error 
bars represent 95% confidence interval of the difference from baseline; p > 0.05. 
Time Arterial Velocity (cm/sec) 
Mean (SD) 
Venous Velocity (cm/sec) 
Mean (SD) 
Baseline 58.01 (9.48) 11.28 (2.62) 
1 Hour 55.27 (12.69) 10.35 (4.34) 
2 Hours 55.66 (9.19) 10.72 (2.76) 
3 Hours  54.54 (8.22) 11.21 (4.33) 
4 Hours 57.21 (7.41) 10.26 (2.30) 
Table 12:  Mean Peak Maximum Velocity Measurements obtained throughout 
the Control Study, p > 0.05. 
Similarly following stimulation, no significant difference was reported at the arterial 
vessel, p > 0.05 refer to Figure 25. The mean (SD) measurements reported at the arterial 
vessel are summarised in Table 13. In contrast, a highly significant difference was 
reported at the venous vessel, p ≤ 0.001 as shown in Figure 25. The mean (SD) venous 
velocity measurements reported were 10.70 cm/sec (4.32) at baseline, which then 
increased by 158% to 24.09 cm/sec (8.30) after 1 hour and further increased by 169% 
with a mean (SD) of 26.82 cm/sec (6.57) after 2 hours. Similarly, an increase in venous 
velocity by 221% at 3 hours with a mean (SD) of 30.07 cm/sec (13.32) was 
demonstrated. This was followed by a small fall at 4 hours as indicated by an average 
percentage change of 162% and mean (SD) of were 25.67 cm/sec (5.54).  
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Figure 25:  Mean Peak Maximum Velocity throughout the Stimulation Study. 
Error bars represent 95% confidence interval of the difference from baseline; 
venous velocity   p ≤ 0.001, arterial velocity p > 0.05. 
Time Arterial Velocity (cm/sec) 
Mean (SD) 
Baseline 69.92 (21.32) 
1 Hour 70.47 (28.50) 
2 Hours 76.04 (16.47) 
3 Hours  83.69 (13.03) 
4 Hours 82.23 (15.56) 
Table 13:  Mean Arterial Peak Maximum Velocity Measurements obtained 
throughout the Stimulation Study, p > 0.05. 
6.7.1.2. Mean Blood Volume Flow Assessments 
Analysis of blood volume flow measurements obtained throughout the control study 
showed a significant drop in the arterial volume flow in comparison to the baseline, p ≤ 
0.05. This is in comparison to a non-significant difference in the venous blood vessel; p > 
0.05 refer to Figure 26. The mean (SD) measurements obtained for both arterial and 
venous blood volume flow are summarised in Table 14. Calculating the average 
percentage change from baseline showed a drop in arterial volume flow by 21% after 1 
hour, a small drop of 3% was then reported after 2 hours, followed by a greater drop of 
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14% after 4 hours that was interestingly followed by a small increase by 3% after 4 
hours.  
 
Figure 26:  Mean Blood Volume Flow throughout the Control Study. Error bars 
represent 95% confidence interval of the difference from baseline; venous 
volume flow: p > 0.05, arterial volume flow: p ≤ 0.05. 
Time Arterial Volume Flow (mL/min) 
Mean (SD) 
Venous Volume Flow (mL/min) 
Mean (SD) 
Baseline 125 (47.4) 62.23 (33.4) 
1 Hour 93.4 (35.2) 54.7 (38.7) 
2 Hours 112.9 (40.4) 61.5 (37.7) 
3 Hours  100.0 (45.5) 59.0 (44.3) 
4 Hours 111.20 (29.30) 77.0 (74.4) 
Table 14: Mean Blood Volume Flow Measurements obtained throughout the 
Stimulation Study. Arterial Volume Flow p ≤ 0.05, Venous Volume 
Flow p > 0.05. 
Further analysis using linear models for the stimulation study showed a significant 
difference in mean blood volume flow measurements at both the venous and arterial 
levels. In comparison to arterial blood flow results obtained in the control study, the 
mean arterial volume flow levels increased following stimulation, p ≤ 0.05 refer to 
Figure 27. The mean (SD) reported were 176.6 mL/min (65.6) at baseline, that increased 
substantially by 125% after 1 hour 288.7 mL/min (127.2), a slight increase by 62% was 
then reported at 2 hours 237.3 mL/min (81.7). Arterial volume flow then increased by 
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99% at 3 hours followed by 87% at 4 hours, with the mean (SD) values being 259.4 
mL/min (71.9) and 253 mL/min (100.1) for 3 and 4 hours.  
 
Figure 27:  Mean Arterial Blood Volume Flow throughout the Stimulation Study. 
Error bars represent 95% confidence interval of the difference from baseline; p ≤ 
0.05. 
Similarly, a highly significant increase was reported when measuring the venous blood 
volume flow in the femoral vessel, p ≤ 0.001 refer to Figure 28. The mean (SD) were 
59.4 mL/min (41) at baseline, which then increased dramatically after 1 hour to 233.76 
mL/min (114.5) followed by 224.6 mL/min (76.3) after 2 hours.  A further increase was 
then reported at 3 hours and the mean (SD) values were 253 mL/min (86.8) that was 
followed by a slight fall to 223 mL/min (76.9) after 4 hours. When considering the 
average percentage change in comparison to baseline for the venous volume flow 
measurements, a 489% increase was reported after 1 hour that further increased 
substantially by 374% after 2 hours. The increase was the highest at 3 hours where the 
average percentage change reported was 471% followed by an increase by 405% increase 
at 4 hours. 
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Figure 28:  Mean Venous Blood Volume Flow throughout the Stimulation Study. 
Error bars represent 95% confidence interval of the difference from baseline; p ≤ 
0.001. 
6.7.1.3. Femoral Vessel Wall Diameter Assessments 
No significant difference in mean vessel diameter at both the venous and arterial level 
was reported in the control and stimulation study, p > 0.05 refer to Figure 29, Figure 30 
and Figure 31. Measurements remained equally stable throughout the study. The mean 
(SD) obtained in both studies are summarised in Table 15 and Table 16.  
Time Arterial Blood Vessel (mm) 
Mean (SD) 
Venous Blood Vessel (mm) 
Mean (SD) 
Baseline 5.91 (2.01) 15.17 (22.04) 
1 Hour 5.76 (2.02) 16.94 (28.03) 
2 Hours 5.46 (2.17) 13.50 (17.76) 
3 Hours  5.70 (2.09) 12.79 (14.63) 
4 Hours 5.66 (1.94) 13.83 (17.51) 
Table 15:  Vessel Wall Diameter throughout the Control Study, p > 0.05. 
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Time Arterial Vessel Diameter (mm) 
Mean (SD) 
Venous Vessel Diameter (mm) 
Mean (SD) 
Baseline 1.27 (1.89) 1.91 (2.92) 
1 Hour 1.27 (1.90) 1.71 (2.38) 
2 Hours 1.23 (1.89) 1.76 (2.65) 
3 Hours  1.12 (1.52) 1.78 (2.70) 
4 Hours 1.17 (1.72) 1.74 (2.60) 
Table 16:  Vessel Wall Diameter throughout the Stimulation Study, p > 0.05. 
 
Figure 29:   Mean Arterial Vessel Wall Diameter throughout the Control Study. 
Error bars represent 95% confidence interval of the difference; p > 0.05. 
 
Figure 30:  Mean Venous Vessel Wall Diameter throughout the Control Study. 
Error bars represent 95% confidence interval of the difference from baseline; p > 
0.05. 
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Figure 31:  Mean Vessel Wall Diameter throughout the Stimulation Study. Error 
bars represent 95% confidence interval of the difference from baseline; p > 0.05. 
6.7.2. Skin Microcirculatory Assessments  
Analysis of the data obtained using laser Doppler flowmetry (LDF) showed a non 
significant difference in the control study at both sites measured (right leg and left leg), p 
> 0.05, refer to Figure 32. The mean (SD) obtained at both sites are summarised in Table 
17. 
 
Figure 32:  Mean LDF Measurements throughout the Control Study. Error bars 
represent 95% confidence interval of the difference from baseline; p > 0.05. 
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Time LDF Right Leg (Flux Units) 
Mean (SD) 
LDF Left Leg (Flux Units) 
Mean (SD) 
Baseline 4.43 (5.83) 8.58 ( 2.45) 
1 Hour 3.78 (5.52) 6.73 (2.13) 
2 Hours  3.79 (5.76) 6.74 (2.01) 
3 Hours 3.75 (6.40) 7.48 (3.01) 
4 Hours 4.27 (6.62) 9.84 (6.45) 
Table 17:  LDF Results at the Right and Left Leg.  
However, analysis of the data obtained from the stimulation study showed a highly 
significant difference in the stimulated leg as compared to passive, p ≤ 0.001. Mean LDF 
values remained stable throughout the study at the passive leg; p > 0.05 refer to Figure 
33. The mean (SD) recorded throughout the stimulation study is summarised in Table 18. 
Time LDF PassiveLeg (Flux Units) 
Mean (SD) 
LDF Stimulated Leg (Flux Units) 
Mean (SD) 
Baseline 7.35 (6.14) 4.66 (5.09) 
1 Hour 9.36 (6.52) 73.6 (62.4) 
2 Hours  7.74 (4.40) 70.4 (62.3) 
3 Hours 8.77 (6.42) 73.9 (56.5) 
4 Hours 7.79 (5.99) 75.8 (54.1) 
Table 18: LDF Results for the Passive and Stimulated Legs.  
 
Figure 33:  Mean LDF Measurements throughout the Stimulation Study. Error 
bars represent 95% confidence interval of the difference from baseline; passive 
leg: p > 0.05, stimulated leg: p ≤ 0.001. 
 
0
20
40
60
80
100
120
0 1 2 3 4
M
e
a
n
 L
D
F
, 
F
lu
x
 u
n
it
s
Time, Hours
Mean Laser Doppler Flowmetry (Stimulation Study)
Stimulated Leg Passive Leg
THRIVE Study  
Page 104 of 265 
 
6.7.3. Clotting Time Assessments 
Assessment of blood coagulation was performed using Automated Coagulation Timer 
(ACT) by measuring the clotting time at the three sites investigated (Arm, Passive Leg, 
Stimulated Leg). A significant drop in clotting time was reported throughout the control 
and the stimulation study, p ≤ 0.001; however no significant difference was reported 
between the sites investigated, p > 0.05 refer to Figure 34 & Figure 35. A comparison of 
the mean (SD) obtained using ACT in both the control and stimulation studies are 
summarised in Table 19.  
 
Figure 34:  Mean Clotting Time throughout the Control Study. Using an Automated 
Coagulation Timer System (ACT) a significant fall in clotting time was reported 
at the Arm, Right Leg & Left Leg: p ≤ 0.001. 
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Figure 35:   Mean Clotting Time throughout the Stimulation Study. Using an 
Automated Coagulation Timer System (ACT) a significant fall was reported at 
the Arm, Stimulated Leg & Passive Leg: p ≤ 0.001. 
Time  Arm  
Mean  (SD) 
Right Leg 
(Stimulated) 
Mean (SD) 
Left Leg  
(Passive) 
Mean (SD) 
Control Study    
Baseline 87.15 (20.93) 91.38 (14.75) 82.93 (11.49) 
1 Hour 79.95 (11.01) 74.38 (8.11) 71.36 (11.96) 
2 Hours 73.40 (16.14) 74.25 (11.85) 67.21 (14.07) 
3 Hours 78.30 (11.70) 74.94 (9.26) 71.50 (7.99) 
4 Hours 79.15 (11.11) 78.13 (10.48) 71.93 (6.04) 
Stimulation Study    
Baseline 101.15(10.69) 100.15(12.89) 95.05 (14.24) 
1 Hour 82.55 (14.75) 76.15 (14.45) 77.30 (15.35) 
2 Hours 79.80 (17.30) 71.80 (10.30) 75.30 (13.49) 
3 Hours 83.50 (17.07) 72.30 (13.08) 69.80 (13.88) 
4 Hours 77.06 (12.13) 74.25 (12.43) 76.00 (15.05) 
Table 19:  A Comparison of Clotting Time Measurements obtained using 
Automated Coagulation Timer System throughout Stimulation and 
Control Study.  
Further analysis of clotting time was performed using Rotem® to confirm the results 
obtained using the Automated Coagulation Timer System (ACT) in both the control and 
stimulation study. Since ACT assesses intrinsic coagulation, results were compared to 
Intem Rotem® results. As with ACT a significant drop in clotting time was obtained in 
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the stimulation study using Rotem®, p ≤ 0.05, however all values were in the normal 
range (100 to 240 seconds) suggesting no abnormal findings, refer to Figure 36 & 
Figure 37. Likewise, no significant difference between sites was reported, p > 0.05. 
Additional analysis of coagulation parameters using the Intem Rotem device, showed no 
significant difference in both CFT and MCF across all time points in both the stimulation 
and control study, p > 0.05. Similarly, results were all within the normal range for both 
CFT (35-110 sec) and MCF (53-72 mm), refer to Appendix 16.  
 
Figure 36:  Mean Clotting Time using Intem Rotem® throughout the Stimulation 
Study. A significant drop in clotting time was reported throughout the study 
period, p ≤ 0.05. 
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Figure 37:  Mean Clotting Time using Intem Rotem® throughout the Control 
Study. No significant difference in clotting time was reported throughout the 
study period, p > 0.05. 
Analysis of the same coagulation parameters using Extem Rotem device, showed a non 
significant difference in both the stimulation and control study when measuring clotting 
time and maximum clot formation time, p > 0.05 refer to Figure 38 & Figure 39. 
However, a statistically significant difference among the different sites investigated was 
reported, p ≤ 0.05 when measuring clot formation time. Despite that, no significant 
difference was shown in time throughout the study period, p > 0.05 refer to Appendix 16.   
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Figure 38:  Mean Clotting Time using Extem Rotem® throughout the Stimulation 
Study. No significant difference was reported throughout the study period, p > 
0.05. 
 
Figure 39:  Mean Clotting Time using Extem Rotem® throughout the Control 
Study, No significant difference was reported throughout the study period, p > 
0.05. 
6.7.4. Assessments of Coagulation Factors 
In addition to clotting time, further assessments of specific coagulation factors were 
performed. These include, measurements of tissue plasminogen activator (tPA) antigen 
levels, von Willebrand Factor (vWF) antigen, together with 6 keto PGF1α levels. 
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Analysis of those parameters was made using Enzyme Linked Immunosorbent Assay 
(ELISA) technique. Adjusted concentrations were then calculated by deducting the 
values at baseline from the actual measurements.   
6.7.4.1. Assessment of Tissue Plasminogen Activator Antigen  
Enzyme Linked Immunosorbent Assay (ELISA) was performed to obtain the 
concentration of tissue plasminogen antigen in the blood plasma that has been withdrawn 
at each time point. Tissue plasminogen antigen concentrations were extrapolated using 
the standard curve plotted following ELISA assay; refer to Appendix 17. Statistical 
analysis of the results demonstrated a highly significant reduction in tPA antigen levels 
over time at both the arm and stimulated leg in the stimulation study, p ≤ 0.001. This is in 
comparison to a non significant change in the passive leg; p > 0.05 refer to Figure 40. A 
comparison of the mean (SD) of both the stimulation and control studies are summarised 
in Table 20. Adjusted percentage change from baseline was then calculated using the 
actual tPA concentrations, which displayed a fall in tPA antigen levels by 14% in the 
stimulated leg in comparison to a fall by 10 % at the arm and 1% at the left leg. Further 
analysis of the tPA antigen data obtained from the control study showed a highly 
significant drop in the left leg (p ≤ 0.001) with no significant difference in both the right 
leg and the arm, p > 0.05 refer to Figure 41.  
Time Arm 
Mean (SD) 
Right Leg/Stimulated 
Mean (SD) 
Left Leg/Passive 
Mean (SD) 
Control Study     
Baseline 4.29 (4.44) 6.79 (3.92) 8.26 (5.61) 
1 Hour 3.54 (3.44) 6.42 (3.93) 7.86 (5.27) 
2 Hours 3.48 (2.80) 6.45 (3.61) 6.49 (4.63) 
3 Hours 3.87 (3.20) 6.21 (4.32) 6.75 (4.83) 
4 Hours 3.33 (3.66) 6.69 (4.10) 6.11 (4.22) 
Stimulation Study    
Baseline 7.65 (4.29) 11.43 (8.21) 11.67 (8.53) 
1 Hour 6.47 (3.11) 7.47 (3.07) 9.21 (3.64) 
2 Hours 6.28 (2.98) 7.13 (2.80) 9.28 (3.73) 
3 Hours 5.45 (2.74) 7.19 (2.50) 9.14 (3.29) 
4 Hours 5.15 (3.41) 7.49 (3.01) 8.67 (4.58) 
Table 20:  A comparison of tPA Measurements at the Arm, Right and Left Leg 
throughout the Stimulation & Control Study. 
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Figure 40:  Adjusted Mean tPA Antigen Concentration throughout the 
Stimulation Study. Arm: p ≤ 0.001; Stimulated Leg: p ≤ 0.001, Passive Leg: p 
> 0.05. 
 
Figure 41:  Adjusted Mean tPA antigen Concentration throughout the Control 
Study. Arm & Right Leg: p > 0.05. Left Leg: p ≤ 0.001. 
6.7.4.2. Assessment of von Willebrand Factor   
Further assessments of coagulation parameters were performed, by measuring levels of 
von Willebrand factor (vWF). Enzyme Linked Immunosorbent Assay (ELISA) was 
performed to obtain the concentration of von willebrand factor in the blood plasma 
withdrawn at each time point. Concentrations of vWF were extrapolated using the 
standard curve plotted following ELISA assay, refer to Appendix 18. Statistical analysis 
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of the data obtained from the ELISA in both the stimulation and control study 
demonstrated a non significant difference at all sites, p > 0.05 refer to Figure 42 & 
Figure 43. This suggests that electrical stimulation has no effect on vWF synthesis from 
endothelial cells.    
 
Figure 42:  Adjusted Mean vWF antigen Concentration throughout the 
Stimulation Study, p > 0.05. 
 
 
Figure 43:  Adjusted Mean vWF antigen Concentration throughout the Control 
Study, p > 0.05. 
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6.7.4.3. Assessment of 6 Keto PGF1α  
The effect of electrical stimulation on platelet aggregation was investigated through 
measuring the level of 6 keto PGF1α, the stable product of prostacyclin. Enzyme Linked 
Immunosorbent Assay (ELISA) was performed to obtain the concentration of 6 keto 
PGF1α in the blood plasma withdrawn at each time point. Concentrations of 6 keto 
PGF1α were extrapolated using the standard curve plotted following ELISA assay, refer 
to Appendix 19.  Analysis of the data obtained following the ELISA showed diverse 
results in both the stimulation and control study. A non significant change was obtained 
in the levels of 6 keto PGF1α at all sites throughout the stimulation study; p > 0.05 refer 
to Figure 44. This suggests that electrical stimulation displays no direct effect on 
prostacyclin synthesis. However, further assessments of 6 keto PGF1α levels throughout 
the control study were surprising, as a significant change was reported over time, p ≤ 
0.05 refer to Figure 45. This was mostly apparent in the left leg, were a highly significant 
difference was seen over time, p ≤ 0.001 in comparison to an insignificant difference in 
both the arm and right leg, p > 0.05. Concentrations of 6 keto PGF1α increased 
significantly in the left leg with the highest mean value reported at 3 hours (232.64 
ng/mL) that was followed by a significant drop to 17.5 ng/mL. This suggests that sitting 
for a period of 4 hours might have induced platelet aggregation, resulting in the release of 
prostacyclin from endothelial cells.  
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Figure 44:  Adjusted Mean Concentration of 6 keto PGF1α throughout the 
Stimulation Study. Arm, Stimulated Leg & Passive Leg: p > 0.05. 
 
 
Figure 45:  Adjusted Mean Concentration of 6 keto PGF1α throughout the 
Control Study. Arm & Right Leg: p > 0.05; Left Leg: p ≤ 0.001. 
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6.7.5. Assessment of Thrombin Generation & D-dimer Levels 
Assessment of the thrombin generating capacity was performed through measuring Lag 
Time, Endogenous Thrombin Potential (ETP), Peak Height and Time to Peak in blood 
plasma at each time point. No significant difference in ETP and peak height was reported 
throughout the different time intervals both in the control and stimulation study, p > 0.05 
refer to Appendix 20. Interestingly, a significant increase was reported for lag time in the 
control study as compared to the stimulation study, p ≤ 0.05. The right leg together with 
the arm, exhibited a greater lag time in comparison to the left leg, refer to Figure 46 & 
Figure 47.  
 
Figure 46:  Adjusted Mean Lag Time throughout the Control Study, p ≤ 0.05. 
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Figure 47:  Adjusted Mean Lag Time throughout the Stimulation Study, p > 0.05. 
Similarly, further data analysis of the control study showed a significant increase in the 
time to reach the maximum thrombin concentration in comparison to the baseline, p ≤ 
0.05. A gradual increase was observed throughout the study, with the greatest time to 
peak displayed in the right leg, refer to Figure 48. 
 
Figure 48:  Adjusted Mean Time to Peak throughout the Control Study, p ≤ 0.05. 
Furthermore, assessment of D-dimer levels the final products of fibrinolysis was 
performed. However, the data obtained from the stimulation study showed similar results 
at each time point. Based on that, no further statistical analysis was performed and further 
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assessments of D-dimer levels were not carried out in the control study, refer to 
Appendix 20 for the D-dimer results obtained.  
6.7.6. Safety Assessments 
Safety assessments were performed throughout both the control and stimulation study, by 
measuring oxygen saturation levels, heart rate as well as blood pressure. Data analysis 
showed no significant difference in oxygen saturation and heart rate compared to the 
baseline; p > 0.05 refer to Figure 49 & Figure 50. Mean oxygen saturation measured 
using pulse oximetry remained stable and always above 97% throughout the study. 
Similarly, heart rates remained stable and within the normal healthy range (above 65 
bpm) throughout the study.  
Interestingly, blood pressure measurements throughout the stimulation study illustrated a 
statistically significant drop in both systolic and diastolic pressure, p ≤ 0.001 refer to 
Figure 51; this is in comparison to a non significant change in the control study refer to 
Figure 52. A comparison of the mean (SD) values reported in both the control and 
stimulation study are summarised in Table 21.  
 
Figure 49:  Mean Oxygen Saturation Levels throughout the Control & 
Stimulation Study, p > 0.05. Error bars represent 95% confidence interval of 
the difference from baseline. Oxygen levels remained stable and above 97% 
throughout both the control and stimulation studies.  
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Figure 50:  Mean Heart Rate throughout the Control & Stimulation Study, p > 
0.05. Error bars represent 95% confidence interval of the difference from 
baseline. Heart rate remained stable and within the normal range throughout both 
the control and stimulation study.  
Time Systolic Blood Pressure  
Mean (SD) 
Diastolic Blood Pressure  
Mean (SD) 
Stimulation Study    
Baseline 131.60 (14) 83.10 (11.75) 
1 Hour 129.10 (17) 79.60 (14.25) 
2 Hours 124.50 (16.21) 75.60 (14.84) 
3 Hours 125.40 (16.56) 74.40 (14.28) 
4 Hours 126.10 (11.08) 72.30 (11.83) 
Control Study   
Baseline 127.70 (13.90) 76.80 (8.50) 
1 Hour 125.20 ( 11.10) 79.10 (15.01) 
2 Hours 119.80 (18.75) 74.10 (12.40) 
3 Hours 126 (10.18) 78.30 (15.33) 
4 Hours 125 (12.54) 73.60 (8.76) 
Table 21:  A comparison of Mean (SD) Blood Pressure Measurements 
throughout the Stimulation & Control Study 
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Figure 51:  Mean Blood Pressure Measurements throughout the Stimulation 
Study, p ≤ 0.001. Error bars represent 95% confidence interval of the 
difference from baseline. A small but a significant drop in both systolic and 
diastolic blood pressure was reported throughout the study period.  
 
Figure 52:  Mean Blood Pressure Measurements throughout the Control Study, p 
> 0.05. Systolic and diastolic blood pressure remained stable and within a 
normal range throughout the study period. 
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Analysis of the discomfort levels showed no significant difference following stimulation 
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characterised by a mean score of 2.6 out of 5 at all time points, refer to Figure 53. 
Moreover, electrical nerve stimulation was rated at minimal sensation, as the mean score 
reported at all time points was 35.8 out of 100 using the visual analogue score (VAS), 
refer to Figure 54.  
 
Figure 53:  Mean Visual Rating Score throughout Stimulation, p > 0.05. 
Discomfort pain was rated on a scaled between 1-5; 1 = no sensation (other than 
muscle tensing and relaxing and 5 = severe discomfort. A mild discomfort was 
perceived following stimulation at all time points 
 
Figure 54:  Mean Visual Analogue Score throughout Stimulation, p > 0.05.  The 
level of pain was marked using a 100mm line marked at one end ‘no sensation’ 
and at the other end ‘severe discomfort.’ A minimal sensation was perceived 
using the stimulation at all time points.  
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6.8. Discussion  
A number of commercially available mechanical prophylaxis devices exist however, they 
are associated with several drawbacks such as being uncomfortable and difficult to apply 
or use, cumbersome and restrict mobility. In the quest for alternative methods for 
thromboembolic prevention, electrical stimulation stands out as a method producing 
encouraging results for a variety of conditions especially the prevention of deep vein 
thrombosis (Velmahos et al., 2005). Its effectiveness in reducing the incidence of 
preoperative and postoperative DVT has been reported widely (Browse and Negus, 1970, 
Doran et al., 1970, Lindstrom et al., 1982, Nicolaides et al., 1972, Velmahos et al., 2005). 
However, as direct electrical stimulation is extremely painful, this method has only been 
applied in restricted situations, i.e. in a controlled hospital environment under general 
anaesthesia.   
Preliminary studies were carried out to examine the effectiveness of indirect electrical 
stimulation via the popliteal nerve and the resulting activation of venous muscle pumps 
of the lower leg (Tucker et al., 2010). Results obtained demonstrated that the novel 
electrical stimulation technique is safe, and significantly increases blood flow and 
velocity by magnitudes that have not been shown previously. Following the significant 
results obtained, the present study was carried out to further evaluate the efficacy of the 
novel electrical nerve stimulation technique from multiple perspectives. The effect of 
electrical stimulation on peripheral circulation, vital signs and multiple blood coagulation 
parameters was investigated.  
6.8.1. Electrical Stimulation Effect on Peripheral Circulation  
Adequate peripheral blood flow in the lower limb is essential to maintain haemostatic 
balance and prevent venous stasis. Colour flow duplex ultrasound assessments to the 
arterial and venous femoral blood vessel at different time points (Baseline, 1, 2, 3, and 4 
hours) were performed during the stimulation and control study.  A significant increase in 
velocity, as well as blood volume flow was reported.  
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To our knowledge, the technology studied is novel and to date none of the studies carried 
out on electrical stimulation devices used a similar mechanism of action. Therefore, 
comparison of the results will be based on similar parameters measured by different 
electrical stimulation techniques. For instance, although the magnitude of increase is 
different, the results obtained are in agreement with previous studies carried out by 
Kaplan et al, using direct muscle stimulation, as a significant increase in venous velocity 
was reported. (Kaplan et al., 2002). The increase in venous velocity has also been 
demonstrated in another study using foot impulse technology, where the peak venous 
femoral velocity reported was 59.79 cm/sec following the use of an inflation device in 
comparison to a baseline value of 13.25 cm/sec. Others studies have also shown a 
significant increase in peak venous velocity that ranged between 43 to 120 cm/sec when 
measured in the popliteal vein using a muscle stimulation device at a high frequency 
(50Hz) (Izumi et al., 2010). Thus, as with the previous studies, the results reported in our 
study demonstrates a significant increase in venous velocity measurements. The greatest 
peak venous velocity measurement obtained was 30 cm/sec that was reached at 3 hours, 
which is lower than that reported by the latter studies. However, it is important to 
consider the different mechanism of action and the different setting modes used. The 
THRIVE device used in this study stimulated the peroneal nerve. It was applied for 5 
minutes every 15 minutes period and the electrical stimulation displayed is constant and 
pulsatile with a very low frequency (3 Hz).  
Furthermore, a highly significant increase in blood volume flow was demonstrated in the 
femoral vein, p ≤ 0.001. The increase reported in venous volume flow is equivalent to 
that reported by other electrical stimulation studies. Following a baseline volume flow of 
59.4 mL/min the greatest volume was again reported at 3 hours were a volume flow of 
253.6 mL /min was obtained. This is similar to the increase reported at the popliteal vein 
(258mL/min) by (Izumi et al., 2010) and higher than the increase reported by (Griffin et 
al., 2010) (240mL/min) following electrical stimulation. Moreover, the average 
percentage increase from baseline demonstrated in this study, which ranges between 
405% and 489% is greater than that shown in another study using neuromuscular 
electrical stimulation (NMES) were the highest mean average change reported was 301% 
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following a 4 hour stimulation period (Broderick et al., 2010a). In addition to the increase 
in venous volume flow, a significant increase in arterial volume flow was reported 
following stimulation, this is compared to a significant fall reported in the control study, 
p ≤0.05. As with previous measurements, following stimulation, the highest increase in 
volume flow was reported at 3 hours were the blood volume obtained was 259.4 mL/min. 
On the contrary, arterial volume flow decreased from 124.99 mL/min at baseline to 111.2 
mL/min at 4 hours in the control study. This suggests a possible systemic effect of the 
stimulation device. As studies investigating electrical stimulation techniques are mostly 
concerned with the effect on venous blood vessel and do not measure arterial 
measurements, the arterial results obtained in the present study cannot be compared with 
others.  
The enhanced effect of electrical stimulation was also apparent when measuring skin 
perfusion bilaterally in the dorsum of the feet using laser Doppler flowmetry (LDF). The 
main findings of the present study are a statistically significant increase in LDF in the 
stimulated leg as compared to the passive leg in the stimulation study, as compared to an 
insignificant difference in the control study. The skin perfusion reported at baseline was 
4.66 flux units at baseline, which escalated to 73.59 flux units following 1 hour and 
continued to increase reaching 75.85 flux units at 4 hours. The results obtained in this 
study further confirm the enhanced effect of the electrical stimulation on the skin 
microcirculatory velocity as reported earlier in an preliminary study carried out by 
(Tucker et al., 2010).  
6.8.2. Electrical Stimulation Effect on Blood Coagulation Parameters  
The effect of the novel electrical stimulation on specific coagulation factors was 
investigated by measuring tissue plasminogen activator (tPA) antigen, von Willebrand 
Factor (vWF) and Prostaglandin PGF1 alpha throughout the study period. The systemic 
effects of electrical stimulation was reported earlier by (Nicolaides et al., 1972), where 
muscle contractions was shown to increase the fibrinolytic activity in the blood. Levels of 
tissue plasminogen activator antigen were significantly reduced throughout the 
stimulation and control study. However, the reduction level was greater in the stimulation 
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study than the control. Following stimulation, a highly significant reduction in tPA 
antigen levels was demonstrated in the stimulated leg and the arm (p ≤ 0.001). Tissue 
plasminogen activator antigen levels reflect both tPA and tPA bound to PAI-1 and do not 
represent tPA levels alone; also most of the circulating tPA is bound to PAI-1(Comerota 
et al., 1997a, Nordenhem and Wiman, 1998). A direct relationship exists between tPA 
antigen and PAI-1 levels. As mentioned earlier, a decreased fibrinolytic activity is 
associated with increased levels of PAI-1 hence, increased levels of tPA. Therefore, the 
drop in tPA concentration in the plasma might suggest an increased fibrinolytic activity, 
which may also be correlated with a drop in PAI-1. The increased fibrinolytic activity is 
beneficial to break down any clots formed. To confirm this, further assessments must be 
performed by measuring PAI-I levels. However, plasma samples were not sufficient to 
perform this. Many prospective studies have been published, indicating that a decreased 
fibrinolytic activity due to increased concentrations of tPA antigen and PAI-1 are 
predictors of myocardial infarction (Held et al., 1997, Juhan-Vague et al., 1996, 
Nordenham et al., 2005, Scarabin et al., 1998, Thogersen et al., 1998). This suggests that 
the drop in tPA antigen demonstrated by the electrical stimulation might be of beneficial 
use for cardiovascular patients. However, further tests are needed to confirm this.  
Interestingly, no significant change in plasma vWF was seen throughout the stimulation 
and control study, suggesting a minimal effect of electrical stimulation on endothelial cell 
activation. Raised levels of plasma vWF antigen is an indication of endothelial cell 
activation and dysfunction following venous occlusion (Scharrer and Vigh, 1993). Other 
earlier studies have also demonstrated that  increased vWF level represent a risk factor 
for DVT(Nilsson et al., 1986, Stead et al., 1983) However, these findings were 
challenged by a later study, where it has been found that vWF did not differ in patients 
with DVT versus healthy subjects (Koster et al., 1995). Thus, the non significant change 
in vWF is justified.     
Furthermore, prostacyclin was also assessed throughout the study by measuring its stable 
marker 6 keto prostaglandin F1α. Following stimulation, a non-significant change in 
plasma levels of 6 keto prostaglandin F1α was observed at all sites. This suggests that the 
electrical stimulation has no direct effect on the arachidonic acid metabolism that results 
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in prostacyclin synthesis. However, analysis of 6 keto prostaglandin F1α throughout the 
control study showed conflicting results, as a significant increase followed by a gradual 
drop in prostacyclin levels in the left leg. A possible explanation to the increase in 
prostacyclin shown, is that the sitting induced platelet aggregation, which has resulted in 
the release of prostacyclin to regulate the aggregation process. Following regulation, 
levels of prostacyclin then dropped at 4 hours.  
The effect of the novel electrical stimulation technique on blood coagulation was further 
investigated by assessing other coagulation parameters. For instance, clotting time was 
measured using two techniques, ACT and Rotem®. Contrary to our expectations, in both 
the stimulation and the control study a statistically significant drop in blood clotting times 
was demonstrated throughout the study period using the ACT technique. The results were 
further confirmed following the use of the Rotem® device, which unlike ACT, is a more 
sensitive technique that provides a complete evaluation of the process of clot initiation 
and structural characteristics of the clot formed and its stability (Mallett and Cox, 1992). 
A statistically significant drop in clotting time was demonstrated in the stimulation study 
using Rotem®. This suggests that there may be a systemic increase in coagulation taking 
place during the study period. Despite that, all values reported using both techniques 
were within the normal range.  
Further assessment of blood coagulation was performed by measuring the endogenous 
thrombin potential (ETP), which is one of the main determinants of haemostasis and 
thrombosis (Vlieg et al., 2007). An elevated level of ETP is usually associated with an 
increased risk for DVT (Eichinger et al., 2008, Vlieg et al., 2007). Assessment of other 
secondary components of the thrombin generation was also performed by measuring the 
peak height, lag time, and time to peak. However, according to Vlieg et al, none of those 
components are associated with an increased risk for DVT (Vlieg et al., 2007). Results 
obtained in this study showed no significant change in ETP levels together with peak 
height throughout the study period. Interestingly, a significant increase in lag time and 
time to peak was demonstrated throughout the study. This suggests that coagulation is 
taking place, however since other measurement techniques showed opposite results, it is 
difficult to confirm this. It must be remembered that this study has been conducted on 
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healthy volunteers and the sample number is small. So a better way of confirming the 
findings obtained, is to repeat the study on a greater patient population. 
6.8.3. Electrical Stimulation Effect on Vital Signs 
Safety of the novel electrical stimulation device was of prime concern in this study. The 
safety of the THRIVE device was evaluated by monitoring oxygen saturation (SPO2) 
levels, heart rate as well as blood pressure throughout the study. The majority of the 
studies published earlier report only the change in the heart rate following electrical 
stimulation and the reported data are conflicting. A lower heart rate was demonstrated 
when subjects lying supine were exposed to electrical stimulation (Faghri et al., 1997). 
On the other hand, an increase in heart rate was noted when subjects lying supine were 
exposed to another novel electrical stimulation device (Broderick et al., 2010b) 
suggesting discomfort. A non-significant change in mean oxygen saturation and heart 
rate was observed throughout both the stimulation and control studies. Both oxygen 
saturation and heart rate values were stable and within the normal range. Since, 
measuring vital signs using pulse oximetry requires adequate peripheral blood flow; the 
enhanced blood flow evoked by electrical stimulation was beneficial for the measurement 
of the vital signs.  
Unlike oxygen saturation and heart rate results, a small but statistically significant drop in 
both the systolic and diastolic blood pressure was demonstrated throughout the 
stimulation study. The systolic pressure dropped from 131 mmHg at baseline to 126 
mmHg at 4 hours. Similarly, the diastolic pressure dropped was 83 mmHg at baseline to 
72.3 mmHg at 4 hours. The drop demonstrated is not of clinical significance, as results 
were within the normal range. The fall of blood pressure could be due to the volunteer 
being seated for a prolonged period of time and hardly consuming a significant quantity 
of food. Such results could imply that the device may be of importance to hypertensive 
patients. However further investigations are needed to confirm this.  
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6.8.4. Tolerance and Acceptance to Electrical Stimulation 
Given the wide range of side effects associated with the currently available thrombo-
prophylaxis measures. Levels of discomfort was assessed following stimulation using the 
verbal rating score (VRS) and visual analogue scale (VAS). Subjects reported a mean 
rating score of 3 out of 5 using the verbal rating score, suggestive of mild discomfort 
sensations. Similarly, a mean score of 35.8 out of a 100 was reported using the visual 
analogue scale, suggesting a minimal sensation. The mild discomfort perceived following 
exposure to the novel electrical stimulation device, is similar to that reported by 
(Broderick et al., 2010b) following 4 hours of electrical stimulation.  
Results of this study, suggests further that contractions of the calf and foot pumps evoked 
by the novel electrical stimulation device are effective in improving lower limb perfusion 
at the vascular and micro-vascular level. The resulting effect is an improvement in 
venous return and prevention of venous stasis, thereby potentially preventing deep vein 
thrombosis. The device also enhances fibrinolytic activity, hence influencing blood 
coagulability. Thus, the electrical stimulation used targets two components of the 
Virchow’s triad; venous stasis and blood coagulability. Also, the electrical stimulation 
device has no profound effects on vital signs. It is well tolerated by healthy subjects as it 
is only associated with mild discomfort. It is clear from this study and previous studies 
carried out, that electrical stimulation is an effective thromboprophylaxis technique that 
might be useful in hospital settings. To prove this, further investigations must be carried 
out on patients to evaluate its clinical effectiveness. However, prior to initiating the trials 
on patients, it was of interest to evaluate how the device performs in relation to 
commonly used devices in hospital settings. This will further provide an idea of the 
potential usage of the novel device investigated. 
The two most commonly used prophylaxis methods in hospitals are the Graduated 
Compression Stockings (GCS) and Intermittent Pneumatic Compression (IPC) devices. 
Since the effectiveness of the GCS in the prevention of DVT was questionable (CLOTS, 
2009), IPC devices were selected for the comparison. Further research was therefore 
performed comparing the effectiveness of the novel device with the IPC devices. 
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Chapter 7. The Effectiveness of the geko ™ Medical 
Device versus Intermittent Pneumatic Compression: 
A Comparative Study 
7.1. Introduction  
Thromboprophylaxis measures fall into two categories, pharmacological and mechanical 
methods. Numerous studies validated the efficacy of pharmacological agents (Francis et 
al., 1997, Hull et al., 1979, Lensing et al., 1995, Lotke et al., 1996, Markel and Morris, 
2002). Despite that, the bleeding risk and the need of clinical supervision remains a major 
challenge (Cohen et al., 2007, NHS, 2012, Qaseem et al., 2011, Welch, 2010). In recent 
years, mechanical prophylaxis for the prevention of deep vein thrombosis (DVT) has 
enjoyed wide popularity, as its use is not associated with the adverse events seen with 
pharmacological prophylaxis (Morris and Woodcock, 2004).  
Intermittent pneumatic compression (IPC) devices are one of the most commonly used 
mechanical prophylaxis methods that are widely used both intra-operatively and post 
operatively to prevent DVT (Izumi et al., 2010). All IPC devices have the same general 
principle, to compress the limb, expel blood from the underlying superficial and deep 
veins, which if the valves are competent will be displaced proximally (Morris and 
Woodcock, 2004). Compression is achieved through a pumping action that inflates and 
deflates air bladders within cuffs that can cover the whole leg, the calf, or just the feet. 
The deflation action is responsible for the refill of the veins ensuring the periodic flow of 
the blood through the deep veins, hence preventing venous stasis. The major 
disadvantage associated with the IPC devices is their size, weight, and requirement for 
continuous attachment to a power supply that contribute to poor patient compliance. 
Patient compliance has been argued as one of the most important factors to consider 
when selecting a mechanical prophylactic device (Morris and Woodcock, 2004).  
Alternative prophylaxis measures for the prevention of DVT include direct electrical 
stimulation of the lower limb muscles, which proved to be an effective modality in 
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improving blood flow (Currier et al., 1986, Faghri et al., 1997, Kaplan et al., 2002). 
However, the elevated level of discomfort associated with their use at high intensities 
limited its practical use to anaesthetised patients only.  
Recently a novel electrical stimulation device (geko™ T-1) has been developed by 
Firstkind Ltd, High Wycombe UK. The system operates using OnPulse™ Technology, 
activating foot and calf pumps of the leg by low intensity neuromuscular electrical nerve 
stimulation of the common peroneal nerve located within the popliteal fossa (Tucker et 
al., 2010). The geko™ T-1 device has been CE marked and its intended use is to increase 
blood circulation for the prevention of venous thrombosis. It can generate 7 pulse width 
settings ranging from 70µs to 560µs. The desired pulse width can be selected by an on-
off switch button.   
7.2. Objectives 
The main objective of the present study was to compare the effectiveness of a novel 
medical device, geko™ T-1(Firstkind Ltd, UK) at low and higher pulse widths in 
enhancing lower limb blood perfusion with two leading IPC devices, Huntleigh Flowtron 
Universal™ (Huntleigh Healthcare Ltd, UK) and Kendall SCD Express™(Covidien plc, 
Ireland). Furthermore, subjects’ tolerance and acceptability to the devices will be 
compared using a discomfort questionnaire.  
7.3. Study Approval  
The study was approved by the North London Research Ethics Committee 1 (reference 
05/Q0408/14), on 7
th
 January 2011, refer to Appendix 21.  
7.4. Materials & Methods 
7.4.1. Volunteers 
Ten healthy volunteers (8 Males, 2 Females), were recruited by advertisement to staff and 
students at Barts and the London, Queen Mary University, Barts and The London NHS 
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Trust and to the general community refer to Table 22. The specific inclusion and 
exclusion criteria for volunteer selection are presented in Table 23 & Table 24. 
Volunteers were instructed to have a light breakfast and avoid fatty foods and caffeine 
containing products. All volunteers attended The Ernest Cooke Clinical Microvascular 
unit at St Bartholomew’s Hospital were assessments were performed. Volunteers were 
provided with information sheets, and written informed consent for screening and study 
participation was obtained prior to the study refer to Appendix 22 & 23.  
Parameters Mean (SD) Median [Range] 
Sex; M:F 8:2  
Age; years 39 (8.12) 40.5 [ 29- 50] 
Body Mass Index (BMI) 24.8(2.44) 24.8 [19.9 – 28.8] 
Table 22:  Demographic Data for geko™ vs. IPC Comparison Study.  
7.4.2. Study Procedure 
7.4.2.1. Screening Evaluation 
After explaining the study procedure and following obtaining informed consent, 
volunteers were screened prior to starting the study. The screening evaluation included a 
medical history, physical examination together with vital signs (blood pressure and heart 
rate). Ultrasound assessment to the lower limb was also performed, examining the 
perforators, deep and superficial venous systems to exclude the presence of thrombus.  
Health Good General Health 
Age Between 18 and 65 years 
Medical History No abnormal findings; absence of DVT and 
haematological disorders; 
Body Mass Index (BMI) Between 18kg/m
2
 and 34kg/m
2
 
Ankle Brachial Pressure Index (ABPI) Normal ABPI > 0.9 
Drugs No history of drug abuse (including 
alcohol) 
Medication  No medication during 30 days preceding or 
during the study 
Table 23:  Inclusion Criteria for geko™ T-1 vs. IPC Comparison Study.  
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Health Organ dysfunction, any clinically 
significant deviation from normal in the 
physical determinations 
Age <18 or >65 years 
Medical History Haematological disorders, previous 
DVT/PE, varicose veins or lower limb 
ulceration, musculoskeletal disorders, 
recent surgery and recent trauma to lower 
limb; and history of gastrointestinal, 
hepatic, renal, cardiovascular, endocrine, 
neurological, dermatological, 
rheumatological, metabolic (including 
diabetes), psychiatric, or systemic disease 
judged to be significant 
Body Mass Index (BMI) Chronic obesity (BMI >34 kg/m
2
) 
Ankle Brachial Pressure Index (ABPI) Peripheral arterial disease (ABPI <0.9) 
Medication  Any medication in the previous 30 days 
Participation in other clinical study Participation in any clinical study during 
the 8 weeks preceding the active period of 
the study 
Table 24:  Exclusion Criteria for geko™ T-1 vs. IPC Comparison Study. 
7.4.3. Study Methodology 
The study was performed in a room where the temperature and humidity was controlled 
(24 ±1
0
C, relative humidity 30-40%). Volunteers clad in shorts, lay supine on a padded 
table that could be tilted manually, with their heads supported by a pillow and tilted 
upwards to 45
0
. After 30 minutes of supine rest, baseline measurements were recorded. 
Devices to be tested were then fitted bilaterally to the subject’s limbs in accordance with 
the manufacturer’s instructions, in a sequential manner. 
The order of the device tested was made in accordance to a pre-set randomisation 
schedule refer to Appendix 24.  Each device was active for a period of 30 minutes 
followed by 10 minutes recovery phase, to allow vascular re-equilibration prior to 
switching on the next device. A series of non-invasive measurements were performed at 
baseline and at the end of each programme. Changes in blood flow and volume, together 
with microcirculatory velocity were measured using laser Doppler flowmetry (Laser 
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Doppler Perfusion & Temperature Monitor DRT4; Moor Instruments Ltd, UK) and 
colour flow duplex ultrasound (Philips IU22; Philips Healthcare, USA).  
Several safety assessments were also performed, these included measuring blood pressure 
using a digital blood pressure monitor (UA-767PC; A&D Instruments Ltd, UK), pulse 
oximetry (3900 TruTrack®+ Datex-Ohmeda Ltd, UK) together with transcutaneous 
tissue oxygen tension (TCM4 Tina; Radiometer Ltd, UK). Transcutaenous tissue oxygen 
tension is a non-invasive measurement for assessing the peripheral circulation (Byrne et 
al., 1984). It reflects the amount of oxygen that diffuses from the capillaries, through the 
epidermis to an electrode placed at the site of measurement. The general principle for the 
technique involves the application of heat to the skin, producing hyperaemia, which 
enhances blood perfusion thereby increasing oxygen pressure. Following calibration of 
the electrodes in buffer solution, the electrodes were attached bilaterally on the dorsum of 
the feet by an adhesive ring. Oxygen diffusion was then measured and displayed on a 
monitor as the transcutaneous oxygen pressure, TcPO2.   
7.4.3.1. Electrical Nerve Stimulation using the geko™T-1 Device 
Transcutaneous electrical nerve stimulation was performed using a novel device (geko™ 
T-1, FirstKind Ltd, UK), refer to Figure 55. The geko™ T-1 device is a small, 
disposable, internally powered, self adhesive device that is applied over the common 
peroneal nerve (also called the lateral or medial popliteal nerves) located within the 
popliteal fossa behind the knee. The specifications of the geko™ device are listed in 
Table 25. Stimulation of these nerves by the geko™ T-1 device result in isometric 
contraction of the muscles that enhance blood flow from the lower limbs back to the 
heart, thereby increasing venous return (Tucker et al., 2010). The device has 7 
stimulation settings relating to pulse width ranging from 70 to 560µs, set by the on-off 
switch and indicated by a flashing light (setting 1 = lowest; setting 7 highest).  Unlike 
many electrical stimulation devices, the device operates at a fixed frequency (1Hz) with a 
constant pulse current of 27mA. The geko™ T-1 was applied bilaterally to each subject 
according to the instruction manual supplied refer to Appendix 25. For each subject, the 
device was initially switched on at a low setting for a period of 30 minute followed by a 
10 minute rest. A low setting was defined as the lowest possible stimulation level that 
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results in a minor visible twitching movement of the calf and foot. Following the 10 
minute resting period, a higher pulse width was selected that was set to 3 additional 
levels to the previous low setting.  
 
 
 
 
 
 
 
 
 
Figure 55:  The geko™ T-1 Device.  
7.4.3.2. Intermittent Pneumatic Compression (IPC) 
The two intermittent pneumatic compression devices used in this study were Huntleigh 
Flowtron Universal™ (IPCHF) and Kendall SCD Express™ (IPCKendall). Each device 
was applied bilaterally to the calf as per the manufacturer’s instructions; refer to 
Appendix 26 & 27. The devices differ in their pumping cycle. The IPCHF device has a 
pumping cycle characterised by 13 seconds of inflation period and 47 seconds deflation 
period. In contrast, the IPCKendall device has approximately 12 seconds inflation and 48 
seconds deflation period; the periodicity of the cycling of this device is influenced by the 
venous refilling times. The compression pressure was kept the same for both IPC devices 
(40 mmHg). 
 
 
 
Topside of geko™ 
 Underside of geko™ 
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Weight 18g 
Dimensions 149mm x 42mm x 11mm 
Stimulation Mode 7 selectable pulse width 
Pulse Width 70,100,140,200,280,400,560 µs 
Pulse Current 27 mA (± 15%) constant current 
Repetition Rate 1 Hz (± 5%) 
Table 25:  Specifications of the geko™ T-1 Device. 
7.4.3.3. Ultrasound Assessments 
Ultrasound assessments were performed using colour flow duplex ultrasound (Philips 
IU22; Philips Healthcare, USA) by an accredited vascular ultrasonographer. 
Measurements to the femoral vessels (arterial and superficial venous) were taken 
bilaterally; at baseline and 5 minutes before the completion of each programme, while the 
device was still active. Parameters measured include, peak maximum velocity, vessel 
diameter, and volume flow. Estimations of these parameters were obtained for the entire 
waveform. Measurements were performed in duplicates to ensure reproducibility. Venous 
volume flow measurements using IPC devices are usually presented incorrectly 
accounting for the inflation cycle only, thereby significantly overestimating their true 
effect. Thus, taking into account the difference in the inflation/deflation cycle, 
calculations were performed for venous volume flow measurements according to the 
underlying formula, in order to obtain the exact volume flow per minute.  
                            
  
                           
                         
  
                           
                         
 
7.4.3.4. Tolerance & Acceptance 
At the end of each program, subjects were asked to evaluate their acceptance and 
tolerability to each device using a discomfort questionnaire, refer to Appendix 28. 
Discomfort was compared to a blood pressure cuff inflated around the upper arm.  
Subjects rated their discomfort levels using a visual analogue scale (VAS), by marking 
the level of the perceived pain using a 100 mm line, marked at one end “no sensation” 
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and at the other end “severe discomfort”. Verbal rating score (VRS) was also used to 
categorise the rating of the discomfort pain as: 
1 = no sensation (other than muscles tensing and relaxing) 
2 = minimal sensations 
3 = mild discomfort 
4 = moderate discomfort 
5 = severe discomfort 
 At the end of the assessments, the subject’s deep veins were re-examined with duplex 
ultrasound to exclude the development of DVT. 
7.5. Statistical Analysis  
All assessments were acquired at baseline and at the end of each programme (30 
minutes). As in the previous chapter, the baseline values obtained for each assessment 
performed was used as a reference range. Statistical analysis was performed using 
Minitab 16 software (Minitab Ltd, UK). Data shown in the results section represent the 
mean of data obtained from the 10 volunteers studied and are presented as median (IQR).  
7.6. Results  
7.6.1. Ultrasound Assessments 
7.6.1.1. Mean Blood Volume Flow  
Analysis of the data using linear models indicated that there is a highly significant 
difference in both venous and arterial blood volume flow between the devices (p ≤ 0.001) 
refers to Figure 56 & Figure 57. The values obtained for both venous and arterial blood 
volume flow of the devices tested are displayed as median (IQR) in Table 26. 
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Device Venous Volume Flow 
mL/min 
Median (IQR) 
Arterial Volume Flow 
mL/min 
Median (IQR) 
Baseline – Without any device 123.5 (73.4) 197.5 (135.8) 
geko™ T-1 High Pulse Width 163 (105.3) 244.5 (125) 
geko™ T1- Low Pulse Width 129 (42.7) 170 (107.5) 
IPCHF 118(72.7) 181.5 (70.5) 
IPCKendall 115 (60.2) 158 (73) 
Table 26:  Comparison of Venous and Arterial Blood Volume Flow for the 
geko™ T-1 and IPC Devices.  
 
Figure 56:  Mean venous blood volume flow measurement, p ≤ 0.001. Bottom of the 
box = 25th percentile, centre of the box = median (50th percentile), top of the 
box = 75th percentile, vertical lines = extremes of values within 1.5 times the 
IQR. Asterisks = outliers. Middle line across = Baseline median. 
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Figure 57:  Mean Arterial blood volume flow measurement, p ≤ 0.001. Bottom of 
the box = 25th percentile, centre of the box = median (50th percentile), top of the 
box = 75th percentile, vertical lines = extremes of values within 1.5 times the 
IQR. Asterisks = outliers. Middle line across = Baseline median. 
Considering the average percentage change in comparison to the baseline for venous 
blood flow measurements, the highest average percentage change was achieved following 
the use of the geko™ T-1 device at higher pulse widths (33%), followed by geko™ T-1 
device at a lower pulse widths (14%). Surprisingly, both IPC devices demonstrated 
similar values below baseline levels (-4%).  
Equally, when examining arterial blood flow the highest average percentage change was 
obtained following the use of the geko™ T-1 device at higher pulse widths (30%). 
However, unlike the venous volume flow measurements, the use of the geko™ T-1 
device at the lower pulse width reported a decrease in the percentage change below 
baseline (-7%) that was roughly similar to that reported following the use of IPCHF 
device (-9%); with the lowest percentage change reported for the IPCKendall device            
(-16%).  
7.6.1.2. Mean Blood Velocity  
Blood velocity measurements for IPC devices were made during both the inflation and 
deflation phase, taking into consideration the marked difference in the compression 
period between the geko™ T-1 device and the IPC devices. The geko™ T-1 device 
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accelerates consistently every second (1Hz) unlike the IPC devices, which accelerate 
only during the inflation period, refer to Figure 58, Figure 59 & Figure 60.  
(a)                                                                        (b) 
Figure 58:  Colour Flow Duplex Ultrasound of the geko™ T-1 Device at High and 
Low Pulse Width Settings. A consistent acceleration is demonstrated with the 
geko™ T-1 device at both pulse width settings. A greater augmentation in blood 
velocity is seen when using the geko™ T-1 device at a higher pulse width 
settings (b) in comparison to the lower pulse width setting (a).  
(a)                                                                  (b) 
Figure 59:  Colour Flow Duplex Ultrasound of IPC Kendall™ Device during 
Inflation and Deflation Period. The Kendall™ device displays a greater 
acceleration during the inflation period as shown in (a), marked by a greater 
mean velocity. This is compared to a lower velocity during the deflation period 
as shown in (b).   
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(a)                                                                         (b) 
Figure 60:  Colour Flow Duplex Ultrasound of IPC Huntleigh™ Device during 
Inflation and Deflation Period. The Huntleigh™ device accelerates only 
during the inflation period as shown in (a), marked by a greater mean velocity. In 
comparison, a lower velocity is seen during the deflation period as shown in (b).   
Results obtained following analysis of variance showed a highly significant difference in 
blood velocity between the devices, p ≤ 0.001. Analysis of venous velocity 
measurements, revealed a substantial increase by 174% following the use of the geko™ 
T-1 device at higher pulse widths, which was equivalent to the IPC devices; 166% and 
143% for IPCHF and IPCKendall respectively, refer to Figure 61. A 73% increase was 
reported following the use of geko™ T-1 at the lower pulse width. Although this is lower 
than the performance of both the geko™ T-1 device at higher pulse widths and IPC 
devices during the inflation period, it is still considered to be much better than the 
performance of the IPC devices during the deflation period. During the deflation period, 
there was only an 11% increase following the use of IPCHF and a decrease by -9% 
following the use of IPCKendall.  
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Figure 61:  Mean Venous Velocity, p ≤ 0.001. Bottom of the box = 25th percentile, 
centre of the box = median (50th percentile), top of the box = 75th percentile, 
vertical lines = extremes of values within 1.5 times the IQR.  Asterisks = outliers. 
Middle line across = Baseline median. 
The median values reported following the use of the geko™ T-1 device at high settings 
were equivalent to that of the IPC devices during the inflation phase. The median (IQR) 
for venous and arterial velocity measurements are displayed in Table 27.  
Device Venous Velocity cm/sec 
Median (IQR) 
Arterial Velocity 
cm/sec 
Median (IQR) 
Baseline – Without any device 13.8 (5.4) 83.15 (24.23) 
geko™ T-1 High Pulse Width 38.3 (10.35) 98.25 (27.70) 
geko™ T1- Low  Pulse Width 22 (12.75) 84.75 (22.10) 
IPCHF – Inflation Period 37 (14.25) 81.9 (20.40) 
IPCHF – Deflation Period 14.7 (8.35) 79.7 (17.15) 
IPCKendall- Inflation Period 33.7 (14.63) 80.3 (17.85) 
IPCKendall-Deflation Period 12.6 (5.2) 85 (15.2) 
Table 27:  Comparison of Venous and Arterial Blood Velocity for the geko™ T-1 
and IPC Devices. 
Similarly, when measuring the arterial velocity, the highest increase reported was 
following the use of the geko™ T-1 device at higher pulse widths, where the velocity 
increased by 24% compared to the baseline. A small increase was reported for the geko™ 
T-1 device (2%) when used at lower pulse width. In comparison, a decrease was 
observed following the use of the IPCKendall by -1% during the inflation phase, and a 
IP
C
KD
ef
la
te
IP
C
KI
nf
la
te
IP
C
H
FD
ef
la
te
IP
C
H
FI
nf
la
te
Ba
se
lin
e
ge
ko
Lo
w
ge
ko
Hi
gh
80
70
60
50
40
30
20
10
0
Device
M
e
a
n
 V
e
lo
c
it
y
, 
c
m
/s
e
c
13.8
Venous Velocity
geko™  vs. IPC Comparison Study 
Page 140 of 265 
 
further decrease was reported following the use of IPCHF device by -4% during the 
inflation phase, refer to Figure 62.  
 
Figure 62:  Mean Arterial Velocity, p ≤ 0.001. Bottom of the box = 25th percentile, 
centre of the box = median (50th percentile), top of the box = 75th percentile, 
vertical lines = extremes of values within 1.5 times the IQR.  Asterisks = outliers. 
Middle line across = Baseline median. 
7.6.1.3. Mean Vessel Diameter 
No significant difference in mean femoral vessel diameter was reported between the 
devices studied p > 0.05. Both venous and arterial measurements remained stable 
throughout the study refer to Figure 63 & Figure 64. The median (IQR) range obtained 
for both the arterial and venous vessel diameters is displayed in Table 28. 
Device Venous Vessel Diameter, 
mm 
Median (IQR) 
Arterial Vessel Diameter, mm 
Median (IQR) 
Baseline – Without any device 7.78 (2.04) 6.58 (1.07) 
geko™ T-1 High Pulse Width 7.61 (2.40) 6.43 (1.00) 
geko™ T1- Low Pulse Width 7.46 (2.46) 6.56 (1.30) 
IPCHF – Inflation Period 7.65 (1.8) 6.33 (0.86) 
IPCHF – Deflation Period 7.6 (1.52) 6.33 (0.80) 
IPCKendall- Inflation Period 7.18 (1.58) 6.17 (0.98) 
IPCKendall-Deflation Period 7.5 (1.81) 6.33 (0.92) 
Table 28:  Comparison of Venous and Arterial Vessel Diameter for the geko™ 
T-1 and IPC Devices. 
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Figure 63:  Mean Arterial Vessel Diameter, p > 0.05. Bottom of the box = 25th 
percentile, centre of the box = median (50th percentile), top of the box = 75th 
percentile, vertical lines = extremes of values within 1.5 times the IQR.  
Asterisks = outliers. Middle line across = Baseline median. 
 
Figure 64:  Mean Venous Vessel Diameter, p > 0.05. Bottom of the box = 25th 
percentile, centre of the box = median (50th percentile), top of the box = 75th 
percentile, vertical lines = extremes of values within 1.5 times the IQR.  
Asterisks = outliers. Middle line across = Baseline median. 
7.6.2. Skin Microcirculatory Assessments 
Microcirculatory assessments using Laser Doppler flowmetry (LDF) showed a highly 
significant difference between the devices, p ≤ 0.001. The geko™ T-1 device at both 
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higher and lower pulse widths showed a substantial increase in microcirculatory blood 
velocity by 394% and 345% respectively. This is compared to a 59% increase achieved 
following the use of IPCKendall and 44% increase following the use of IPCHF device, 
refer to Figure 65. The median (IQR) range obtained is displayed in  
Device Laser Doppler Flowmetry, 
flux units 
Median (IQR) 
Baseline – Without any device 9.45 (7.61) 
geko™ T-1 High Pulse Width 35.46 (24.26) 
geko™ T1- Low Pulse Width 27.13 (24.92) 
IPCHF  6.67 (7.89) 
IPCKendall 6.71 (12.58) 
Table 29: Comparison of Skin Microcirculatory Velocity obtained using Laser 
Doppler Flowmetry for the geko™ T-1 and IPC Devices. 
 
Figure 65:  Mean Laser Doppler Flowmetry, p ≤ 0.001. Bottom of the box = 25th 
percentile, centre of the box = median (50th percentile), top of the box = 75th 
percentile, vertical lines = extremes of values within 1.5 times the IQR.  
Asterisks = outliers. Middle line across = Baseline median. 
7.6.3. Safety Assessments 
No significant difference was reported between the devices following the measurement of 
blood pressure, transcutaneous tissue oxygen (TcPO2), tissue oxygen saturation (SPO2) as 
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well as heart rate, p > 0.05. All measurements remained equally stable throughout the 
study refer to Figure 66, Figure 67, Figure 68 & Figure 69. 
 
Figure 66:  Mean Blood Pressure, p > 0.05. Bottom of the box = 25th percentile, centre 
of the box = median (50th percentile), top of the box = 75th percentile, vertical 
lines = extremes of values within 1.5 times the IQR.  Asterisks = outliers. Middle 
line across = Baseline median. 
 
 
Figure 67:  Mean Transcutaneous Tissue Oxygen, p > 0.05. Bottom of the box = 25th 
percentile, centre of the box = median (50th percentile), top of the box = 75th 
percentile, vertical lines = extremes of values within 1.5 times the IQR.  
Asterisks = outliers. Middle line across = Baseline median. 
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Figure 68:  Mean Tissue Oxygen Saturation, p > 0.05. Bottom of the box = 25th 
percentile, centre of the box = median (50th percentile), top of the box = 75th 
percentile, vertical lines = extremes of values within 1.5 times the IQR.  
Asterisks = outliers. Middle line across = Baseline median. 
 
Figure 69:  Mean Heart Rate, p > 0.05. Bottom of the box = 25th percentile, centre of 
the box = median (50th percentile), top of the box = 75th percentile, vertical lines 
= extremes of values within 1.5 times the IQR.  Asterisks = outliers. Middle line 
across = Baseline median. 
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7.6.4. Discomfort Assessments 
Analysis of the discomfort levels reported following the use of each device was not 
significant using the visual analogue scale, p > 0.05, but showed a statistically significant 
difference using the verbal rating score, p ≤ 0.05 refer to Figure 70 & Figure 71. Using 
the verbal rating score, the discomfort level following the use of the geko™ T-1 device at 
a higher pulse width was rated at mild discomfort as compared to the other devices 
studied, which were rated at a minimal sensation. 
 
 
Figure 70:  Visual Analogue Scale, p > 0.05. Bottom of the box = 25th percentile, centre 
of the box = median (50th percentile), top of the box = 75th percentile, vertical 
lines = extremes of values within 1.5 times the IQR.  Asterisks = outliers. Middle 
line across = Baseline median. 
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Figure 71:  Verbal Rating Score, p ≤ 0.05. Bottom of the box = 25th percentile, centre of 
the box = median (50th percentile), top of the box = 75
th
 percentile, vertical lines 
= extremes of values within 1.5 times the IQR. Asterisks = outliers. Middle line 
across = Baseline median. 
7.7. Discussion  
The present study compares the effectiveness of a novel electrical nerve stimulation 
device with two leading IPC devices commonly used in hospital settings. Maintaining 
adequate peripheral blood flow in the lower limb is essential to prevent venous stasis, 
hence preventing the formation of DVT. The devices in this study may be considered 
effective in preventing venous stasis; however they differ in the magnitude of increase in 
lower limb blood perfusion (Morris and Woodcock, 2004, Tucker et al., 2010, Westrich 
et al., 1998). 
Based on the analysis of the data obtained from 10 healthy subjects, it can be inferred that 
the novel device studied (geko™ T-1), is superior to IPC Huntleigh Flowtron™ and IPC 
Kendall SCD™ devices in enhancing blood flow in the lower limbs. This is evident from 
the substantial significant increase in the femoral venous and arterial blood volume flow 
by ~ 30% following the use of the geko™ T-1 device especially at higher pulse widths. 
Although the volume flow increase following the use of the geko™ T-1 at lower pulse 
widths is less than that of the higher pulse widths (14%), it is still much greater than that 
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reported following the use of the IPC devices, where a decrease in volume flow was 
observed. The blood flow measurements performed in the majority of electrical 
stimulation studies are mostly for venous measurements hence, arterial data is absent. 
Thus, when comparing the venous volume flow results obtained in this study with results 
of recent studies performed investigating different electrical stimulation techniques, 
similar results were obtained. For instance, a greater volume flow was reported by 
(Broderick et al., 2010b) following stimulation using a novel skin surface electrodes 
placed over motor points of the calf muscle at a frequency of 36Hz. Similarly, an increase 
in volume flow was also demonstrated when investigating another novel electrical 
stimulation technique by (Griffin et al., 2010), however the increase was only significant 
at high stimulation rates with short contraction time intervals. Therefore, it appears that 
the stimulation evoked by the novel technology at lower frequencies compared with the 
available electrical stimulation techniques, is more efficient in driving a greater blood 
flow through the femoral blood vessel.  
Measuring arterial peak velocities, demonstrated that the use of the geko™ T-1 device 
especially at higher pulse widths is more effective than IPC devices in producing an 
increase in the femoral artery and vein. This is in comparison to a fall in arterial velocity 
following the use of IPC devices, which may be of concern especially in patients with 
peripheral arterial disease. Furthermore, our data shows that the geko™ T-1 device is as 
efficient as the IPC devices during the inflation period in increasing peak venous 
velocity. Those results are in agreement with the data obtained by (Izumi et al., 2010) and 
(Czyrny et al., 2010) where a higher increase in the femoral venous velocity was reported 
following electrical stimulation as compared to IPC. Although the use of the geko™ T-1 
device at lower pulse widths demonstrated lower increase (73%) as compared to an 
increase by 174% at higher pulse widths, it is still considered more effective than the IPC 
devices during the deflation period. The use of the IPC devices showed an increase by 
11% only for IPCHF and a fall by 9% for IPCKendall. The results obtained further 
confirm that the frequent acceleration in velocity for the geko™ T-1 device (every 
second) compared to an acceleration every minute by the IPC devices is more effective in 
enhancing blood flow, hence preventing venous stasis.  
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Peak venous velocities are considered a very popular measure by some of the 
manufacturers to indicate the efficacy of their systems. Although there is a scarce 
evidence that systems that produce higher velocities during compression, yield low DVT 
rates, a study published by Proctor et al suggested the opposite (Morris and Woodcock, 
2004, Proctor et al., 2001). Published data have shown that the use of IPC devices at 
pressures of 40 mmHg, achieves a calf compression between 35 to 60cm/sec (Flam et al., 
1996, Keith et al., 1992, Morris and Woodcock, 2004, Ricci et al., 1997, Whitelaw et al., 
2001). The results obtained from our study are in agreement with those figures, as the 
mean velocity range obtained following the use of IPCHF and IPCKendall during the 
inflation phase is 36 and 33cm/sec respectively.   
Laser Doppler flowmetry measurements, which reflect the microcirculatory blood 
velocity in the skin, increased substantially by ~ 370% following the use of the geko™ T-
1 device in comparison to a modest 59% and 44% increase following the use of the 
IPCHF and the IPCKendall devices respectively. Interestingly, studies have revealed the 
efficacy of electrical stimulation in wound care by increasing blood flow and enhancing 
tissue oxygenation, thereby targeting inflammation and proliferation phases of wound 
healing (Feedar et al., 1991, Mulder, 1991, Weiss et al., 1990). Thus, the vast increase in 
laser Doppler flowmetry values, together with the tissue oxygen results, suggests the 
potential benefits of the geko™ T-1 device in lower limb wound care. However, further 
studies are needed to confirm this.  
Furthermore, safety parameters were measured to compare the safety of the geko™ T-1 
device to the IPC devices. Pulse oximetry measurements confirmed a stable heart rate 
and saturated oxygen levels throughout the study. No significant differences (p > 0.05) in 
heart rate and mean oxygen saturation were reported between the geko™ T-1 device and 
IPC devices. The stable heart rate was also reported in a recent study using a novel 
electrical stimulation at a frequency of 36Hz (Broderick et al., 2010b). This further 
provides a non-subjective assessment of subject tolerance and potential compliance. 
Transcutaneous tissue oxygen levels also remained stable throughout the study. 
Furthermore, blood pressure measurements showed no differences. This again is a 
significant indicator of the safety of the device. Duplex ultrasound measurements of the 
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arterial and venous femoral vessel diameter, also showed no significant change in the 
mean vessel diameter throughout the study, which confirms the validity of the ultrasound 
volume and velocity measurements.  
Pain due to high intensity settings has been a major hurdle to the development of 
electrical stimulation technology, especially direct muscle stimulation. In many cases this 
has limited their application and clinical usage to the anaesthetised patient. Likewise, the 
immobilisation, discomfort, bulkiness, excessive heat and sweating associated with the 
use of IPC devices has always been a major drawback to their use despite their 
effectiveness in preventing DVT. Discomfort assessment by verbal rating score in this 
study demonstrated that the use of the geko™ T-1 at higher pulse widths is associated 
with only a mild discomfort. This is in comparison to a minimal sensation perceived 
following the use of IPC devices as well as the geko™ T-1 device at a lower pulse width. 
It is essential to note that the devices were active for a short period of time (30 minutes), 
thus the mild discomfort following the use of the geko™ T-1 device at higher pulse 
widths, could be minimal if the duration is increased as the subject might develop a 
greater tolerability.  
A key limitation to this study is the small population number. The present study was 
conducted on a small number of healthy subjects, so the results obtained can hardly be 
extrapolated to patients. Therefore, further studies are required on larger population of 
patients to confirm the results obtained. Moreover, as all examinations in the present 
study were performed with the subjects lying supine, it might be useful to conduct 
additional studies at different postures to further assess the compliance to the device and 
the effectiveness in enhancing blood flow.  
In conclusion, the present study is the first to compare the effectiveness of a portable self-
contained electrical stimulation device to the widely used intermittent pneumatic 
compression systems. The findings of the study demonstrate the potential benefits of 
using electrical nerve stimulation in improving circulatory dynamics in the arterial, 
venous and microcirculatory vasculature of the lower limb. The stimulation applied was 
perceived by healthy subjects as acceptable, as only a mild/minimal discomfort was 
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associated with its use. We propose that the novel device has a significant potential for 
the development into an easy-to-use, pain-free DVT prophylaxis device, with a potential 
use in the management of several other vascular disorders.  
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Chapter 8. General Discussion 
Deep vein thrombosis is a medical condition associated with the formation of a thrombus 
in the deep veins, usually in the lower leg. The main physiological contributing factors 
for the development of DVT as described by Virchow’s Triad are hyper-coagulability, 
endothelial damage and venous stasis. The natural mechanism for the prevention of 
venous stasis in an ambulatory healthy individual is the process of walking. Decreased 
mobility increases the risk of DVT due to inadequate pumping action resulting in 
insufficient venous return to the heart.  
Prophylaxis for DVT is divided into pharmacological and mechanical methods. 
Pharmacological methods are effective, but are contraindicated in certain cases where 
there is a high risk of bleeding. Mechanical methods are mainly graduated compression 
stockings, intermittent pneumatic compression devices and electrical stimulation. 
Published data on the effectiveness of neuromuscular electrical stimulation in preventing 
DVT dates back to 1972, where electrical impulses were shown to increase blood flow 
response in the lower extremities (Nicolaides et al., 1972). Studies on the usefulness of 
electrical stimulation continued in the subsequent years, increasing the scope of the 
technique not only in the prevention of DVT, but for a wide range of conditions(Currier 
et al., 1986, Czyrny et al., 2010, Faghri et al., 1997, Kaplan et al., 2002, Kostin, 1993, 
Velmahos et al., 2005). However, the unbearable pain associated with its use has limited 
its use to surgical procedures under general anaesthesia. Painless treatment was therefore 
an important goal considered during our investigations. 
The rationale for carrying out the studies described in this thesis was to investigate the 
effectiveness of a novel neuromuscular electrical stimulation device (geko™ T-1) that 
could be used potentially in the management of DVT as well other disorders associated 
with abnormal blood flow.  
The studies described in this thesis were all performed on healthy subjects. The primary 
objective of the studies was to investigate the effectiveness of the geko™ T-1 device in 
enhancing lower limb blood perfusion using colour flow duplex ultrasound and laser 
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Doppler flowmetry. The secondary objective was to investigate whether the enhancement 
of venous return results in an improved cardiac performance. Additionally, to assess the 
effect of the geko™ T-1 device on specific blood coagulation parameters such as clotting 
time, tissue plasminogen activator antigen, von willebrand factor antigen, prostacyclin 
and endogenous thrombin potential. Other objectives were to evaluate the safety of the 
geko™ T-1 device investigated by assessing blood pressure, heart rate, oxygen saturation 
and transcutaneous tissue oxygen tension. Furthermore, subjects’ acceptance and 
tolerance to, the novel device was assessed. Finally, an evaluation of the effectiveness of 
the device in relation to the most commonly used devices for mechanical prophylaxis 
(IPC devices) in hospital settings was preformed.  
8.1. Electrical Stimulation Effect on Cardiac Performance 
The effect of the novel device on cardiac performance was initially investigated on 
healthy subjects lying supine. Cardiac performance was evaluated using 
echocardiography by measuring cardiac output, ejection fraction, as well as diastolic 
function. Analysis of the data acquired from the first study demonstrated that, in 
comparison to the baseline measurements, the geko™ T-1 device significantly increased 
cardiac output. Although for statistical efficiency, the data were analysed untransformed, 
percentage changes can make the results more accessible (Vickers, 2001). In percentage 
terms, the geko™ T-1 increased cardiac output by 4 to 6%. These results compliment the 
results obtained by (Faghri et al., 1997), who demonstrated a 24% increase in cardiac 
output following electrical stimulation compared to a 14% fall following the use of a 
sequential compression device. The reported increase in cardiac output could be due to 
the direct activation of the calf muscle pump, which causes a complete emptying of both 
venous beds and sinuses (Faghri et al., 1997). Cardiac output, which  is the amount of 
blood ejected by the left ventricle in the time interval of one minute is directly 
proportional to heart rate (Nursecom, 2004). Thus, as heart rate increases, so does cardiac 
output. The increase in cardiac output obtained could be due to exposure to a foreign 
sensation, which could have resulted in the increase of heart rate. However, as heart rate 
was not monitored throughout the study period, it was difficult to confirm this. Findings 
from studies using electrical stimulation have demonstrated an increase in heart rate 
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(Broderick et al., 2010b). Contractions of the calf muscle evoked by electrical 
stimulation, stimulates the sympathetic nervous system that leads to increased heart rate 
and further increases the contractility of the heart muscle (Broderick et al., 2010b).  
Furthermore, the data acquired from this study also demonstrate that the geko™ T-1 
device investigated has a slight influence on ejection fraction, and does not alter the 
filling pattern in the left ventricle of the heart in healthy volunteers.  
8.2. Electrical Stimulation Effect on Tissue Perfusion  
Lower limb blood perfusion was of prime concern throughout all the studies. Initially, 
when performing the cardiac study, assessment of blood perfusion was made by 
measuring blood flow parameters in the femoral artery. Based on the results acquired 
from the study, in percentage terms a significant increase of greater than 50% was 
obtained when measuring arterial blood volume flow in comparison to the baseline.  
Further analysis of lower limb blood flow was performed throughout the subsequent 
studies by measuring blood perfusion in both the femoral artery and superficial femoral 
vein. Data obtained from the THRIVE study showed a significant augmentation in 
arterial blood volume flow following stimulation. Based on the data obtained from the 
stimulation study, the highest increase in arterial volume flow was noted at the first hour 
of the study, where a substantial increase from 177mL/min at baseline to 289mL/min was 
demonstrated. Arterial volume flow then decreased slightly throughout the study period, 
although values remained higher than the baseline. In contrast, a significant drop in 
arterial volume flow was demonstrated throughout the control study period, with the 
greatest drop (21%) seen at the first hour of the study. The change observed at the first 
hour of the study could be stress related. Therefore, it is clear from the results obtained 
that the application of the novel electrical stimulation device augments arterial volume 
flow, which suggests a reduction in peripheral vascular resistance. The augmentation in 
arterial blood volume flow was further confirmed when comparing the novel electrical 
stimulation device with IPC devices. An increase of 30% in arterial blood flow following 
the use of the geko™ T-1 device in comparison to the baseline was demonstrated, this 
was compared to a drop when using the IPC devices.  
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Similarly, the significant increase in blood volume flow was not only apparent in the 
artery, but also in the superficial femoral vein. Following stimulation venous blood 
volume flow increased significantly throughout the study period in comparison to the 
baseline. As compared to similar existing muscle electrical stimulation method (MEST) 
that show only 25% increase in the femoral venous blood flow (Zhao et al., 2004), the  
venous blood volume flow results obtained in our studies were exceptionally high. The 
highest increase was reported during the THRIVE study following 3 hours where the 
blood volume flow increase was close to six fold in comparison to the baseline. The 
significant augmentation reported was further confirmed when comparing the geko™ T-1 
device to the IPC devices, as the geko™ T-1 device was found to be superior in 
increasing venous blood volume flow by 33% in comparison to the baseline. This 
suggests that the geko™ T-1 device is highly effective in enhancing blood flow through 
the femoral vein. Similar results were reported in a study comparing a novel electrical 
stimulation technique with IPC devices. In this study, a greater increase in blood volume 
flow following electrical stimulation in comparison to IPC devices was demonstrated 
(Izumi et al., 2010).  
In addition to the significant augmentation in blood volume flow, the studies carried out 
demonstrated that the geko™ T-1 device increases peak venous velocities at the femoral 
vein that by far exceeds the baseline measurements. Data from the THRIVE study; 
demonstrated a substantial increase in venous velocity (221%) following stimulation. 
Furthermore, the geko™ T-1 device causes an equivalent increase (38 cm/sec) in venous 
velocity to that of the IPC devices during the inflation period. However, the geko™ T-1 
device was superior to the IPC devices during the deflation period in maintaining venous 
velocity. The findings of our study, although differing in the magnitude of the increase in 
velocities, are again similar to those reported by (Izumi et al., 2010), who also reported a 
greater increase in peak venous velocities (97 cm/sec) following electrical stimulation as 
compared to a lower increase using IPC (65cm/sec).  
Studies have shown that an increase in venous volume and velocity causes venous 
emptying and facilitates clearance within the soleal sinuses and valve cusps, which are 
the most common sites for DVT formation (Flanc et al., 1968, Nicolaides et al., 1971). 
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The soleus sinuses  are the largest veins draining the muscle and are responsible for the 
largest volume of flow from the muscle into the deep veins upon contraction (Broderick 
et al., 2010b). Published studies have reported that the IPC devices are not capable of 
entirely eliminating venous stasis, as the blood is being pushed past the venous sinuses 
via the deep veins, leaving behind pooled blood in the sinuses (Faghri et al., 1997, 
Laverick et al., 1990). The use of electrical stimulation methods may therefore be more 
effective than IPC devices, as the contractions of the calf muscle pump results in the 
complete emptying of the soleal sinuses (Laverick et al., 1990).  
In comparison to the venous velocity, arterial peak velocity was only significantly raised 
in the cardiac study and when comparing the geko™ T-1 device with IPC devices. 
Interestingly, in both studies, following the use of the geko™ T-1 device arterial velocity 
increased by 24%. This confirms the reproducibility of the measurements and suggests 
that the device might be useful in patients with peripheral arterial disease. However, 
further studies are needed to confirm this.   
Laser Doppler flowmetry, which is a reflection of the microcirculatory blood velocity in 
the skin, was another mean of confirming the effectiveness of the geko™ T1 device. The 
data acquired from all the studies presented, showed a substantial increase in 
microcirculatory velocity that by far exceeds the baseline measurements. For instance, in 
the first study, following stimulation, laser Doppler flowmetry increased from 7.71 flux 
units at baseline to 117.9 flux units. The increase was confirmed during the stimulation 
study, which unlike the control study showed a highly significant augmentation in 
microcirculatory velocity in the stimulated leg from 4.66 flux units at baseline to 75.8 
flux units. This was again confirmed when comparing the geko™ T-1 device to IPC 
devices, as a large increase of ~370% was reported when using the geko™ T-1 device in 
comparison to a modest increase of ~40% following the use of the IPC devices. The 
findings confirm the validity of the laser Doppler measurements obtained, and also adds 
to the potential benefits of the geko™ T-1 device in the reduction of peripheral vascular 
resistance. This might be of benefit in wound healing. It has been shown that electrical 
stimulation affects the inflammation and proliferation phases by increasing blood flow 
and enhancing tissue oxygenation. Hence, electrical stimulation has been widely used as 
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an additional therapy in wound care management for pressure, venous and ischemic 
ulcers (Feedar et al., 1991, Kloth and Feedar, 1988, Mulder, 1991).  
Based on the ultrasound and laser Doppler flowmetry findings in the studies presented in 
this thesis, a summary of the effect of the geko™ T-1 device on blood flow as it passes 
through the systemic circulation is displayed in Figure 72. Results demonstrated that the 
geko™ T-1 device causes an augmentation in blood velocity when measured at the 
femoral artery and superficial femoral vein. An augmentation was also demonstrated at 
the capillary level when measuring the microcirculatory velocity as confirmed by the 
laser Doppler flowmetry results. This suggests that the electrical stimulations increase 
capillary recruitment by enhancing the activity of resting capillaries.  
 
Figure 72:  The effect of geko™ T-1 Device on Blood Flow. The effect of the geko™ 
T-1 device (red line) on normal mean blood velocity (solid black line) and total 
cross sectional area (dashed line). The geko T-1 device also causes an 
augmentation at the capillary level as shown by the LDF measurements and the 
blue dashed curve, suggestive of an increased capillary recruitment. 
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8.3. Electrical Stimulation Effect on Blood Coagulation  
Blood coagulation factors investigated throughout the THRIVE study were, tissue 
plasminogen activator antigen (tPA), von willebrand factor (vWF) as well prostacyclin 
levels. The systemic effects of electrical stimulation was reported earlier by (Nicolaides 
et al., 1972), where muscle contractions was shown to increase the fibrinolytic activity in 
the blood. In the THRIVE study presented earlier, a significant difference was only 
reported with tissue plasminogen activator antigen. In comparison to baseline levels, a 
greater and a highly significant drop in tPA antigen levels was demonstrated throughout 
the stimulation study in comparison to the control. Tissue plasminogen activator antigen 
is usually present as a bound complex of active tPA and plasminogen activator inhibitor 
1, PAI-1 (Comerota et al., 1997a, Nordenhem and Wiman, 1998). A decreased 
fibrinolytic activity is associated with increased levels of PAI-1 hence, increased levels of 
tPA antigen. Therefore, the drop in tPA antigen concentration in the plasma might 
suggest an increased fibrinolytic activity to break down any clots formed, which may also 
be correlated with a drop in PAI-1. To confirm the above reasoning, further assessments 
must be performed by measuring concentrations of PAI-1. Furthermore, studies have 
shown that, a decreased fibrinolytic activity is a predictor of myocardial infarction (Held 
et al., 1997, Juhan-Vague et al., 1996, Nordenham et al., 2005, Scarabin et al., 1998, 
Thogersen et al., 1998). Thus, the drop in tPA antigen caused by the novel electrical 
stimulation might also be of beneficial use for cardiovascular patients. However, further 
investigations are needed to confirm this. 
Another blood coagulation factor assessed was von Willebrand factor (vWF), a protein 
secreted by endothelial cells. In comparison to the baseline, no significant difference in 
von Willebrand factor antigen levels was seen throughout both the stimulation and 
control study. Von Willebrand factor  antigen is an indication of endothelial cell 
activation and dysfunction following venous occlusion (Scharrer and Vigh, 1993). Raised 
levels of vWF in the plasma is an indication of DVT as reported by (Nilsson et al., 1986). 
It is important to note here that the volunteers investigated were healthy; hence, the non 
significant change in vWF is justified. The findings obtained are supported by similar 
results from (Comerota et al., 1997b), who reported a drop in tPA antigen and no 
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significant change in vWF antigen levels following the use of IPC devices. This suggests 
that the geko™ T1-1 device induces a non specific disturbance of the endothelium. 
Similarly, when assessing prostacyclin throughout the stimulation study by measuring its 
stable marker, 6 keto PGF1α, a non significant change was reported. This suggests that 
the electrical stimulation has no influence on prostacyclin sysnthesis.  
The effect of the geko T-1 device on blood coagulation was investigated further through 
measuring clotting time using automated coagulation timer technology (ACT) and 
rotational thromboelastometry (Rotem®). A significant drop in clotting time was 
observed using both techniques. This suggests that there might be a systemic increase in 
coagulation taking place during the study period. However, the values reported were 
within the normal healthy range. Additional blood coagulation assessments were 
performed by measuring the endogenous thrombin potential (ETP), which is one of the 
main determinants of haemostasis and thrombosis (Vlieg et al., 2007). Studies have 
shown that an elevated level of ETP is usually associated with an increased risk for DVT 
(Eichinger et al., 2008, Vlieg et al., 2007). Assessment of other secondary components of 
the thrombin generation was also performed by measuring the peak height, lag time, and 
time to peak. No significant change in ETP levels together with peak height throughout 
the study period. Interestingly, a significant increase in lag time and time to peak was 
demonstrated throughout the study. This suggests that coagulation is taking place, 
however since other measurement techniques showed opposite results, it is difficult to 
confirm this. 
8.4. Safety Evaluation of the Electrical Stimulation Device 
Several parameters were measured to evaluate the safety of the geko™ T-1 device. 
Colour flow duplex ultrasound measurements of the superficial femoral vessel, showed 
no significant change in mean vessel diameter in comparison to baseline throughout all 
the studies. This supports the safety of the geko™ T-1 device investigated and confirms 
the validity of the ultrasound measurements performed. Furthermore, pulse oximetry 
measurements ensured constant monitoring of heart rate and saturated oxygen levels. 
Mean oxygen saturation remained constant and always above 97% throughout the study 
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period. Similarly mean heart rate remained stable and within the normal healthy range 
between 60 and 90 beats per minute. Based on the data analysis, no significant difference 
in mean oxygen saturation and heart rate was demonstrated. Those findings are in 
agreement with the findings reported by (Broderick et al., 2010b), who demonstrated a 
stable heart rate following the use of a novel electrical stimulation at a frequency of 
36Hz. Similarly, when measuring transcutaneous tissue oxygen in the geko™ T-1 versus 
IPC comparison study, no significant difference between the devices was reported. The 
stabilised pulse oximetry and tissue oxygen results obtained are strong indicators for the 
potential use of the device in wound care. 
Blood pressure findings were of great interest in the studies performed. In comparison to 
the IPC devices, significant change in blood pressure was observed when comparing the 
geko™ T-1 device with the IPC devices. Both systolic and diastolic blood pressure 
remained stable throughout the study period. Interestingly, a small but a statistically 
significant drop in systolic and diastolic pressure was noted following stimulation 
throughout the stimulation study period. However, measurements where still within the 
normal range. This is in comparison to a stable and an insignificant change throughout 
the control study. Such findings could imply that the geko™ T-1 device may be of 
importance to hypertensive patients. Further investigations possibly on hypertensive 
patients are needed to confirm this.  
8.5. Tolerance and Acceptance of the Electrical Stimulation 
Device 
Selecting a mechanical prophylaxis method requires equal consideration of both patient 
compliance and hemodynamic performance. It was argued that patient compliance is an 
important factor to consider in the selection of mechanical prophylaxis (Morris and 
Woodcock, 2004). At the end of the day, for the device to be effective it must be used 
regularly by the patient. Non-compliance is most commonly the result of discomfort or 
inconvenience. Significant pain due to high intensity settings has been a major obstacle to 
the development of electrical stimulation technology. Hence, the application and clinical 
use of the electrical stimulation technique have been limited to anaesthetised patients. It 
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was therefore necessary to assess the tolerance and acceptance to the novel 
neuromuscular electrical stimulation device throughout the studies. Analysis of verbal 
rating score results, showed that the stimulation applied was associated with only a mild 
discomfort, and a minimal sensation was perceived when using visual analogue scale. 
Those findings were again similar to the findings of (Broderick et al., 2010b), who also 
demonstrated a mild discomfort sensation following the use of a novel electrical 
stimulation method. However, it is important to note here that the electrical stimulation 
device was only active for a short period throughout the studies conducted. Therefore, it 
is possible that subjects might develop a greater tolerance and acceptance to the device 
when used for longer periods.   
The non-compliance associated with the use of IPC devices has raised great concern. 
Intermittent pneumatic compression devices are usually cumbersome, expensive and 
require a fixed power source that confines the patient. In an observational study on the 
use of compression devices by traumatised patients, only 19% were fully compliant, and 
non compliance was associated with a higher rate of DVT (Cornwell et al., 2002). 
Compliance is not only associated with patients, but with nurses and other care providers 
who often disconnect the devices during the period of evaluation and fail to reconnect 
them again. (Bockheim et al., 2009). The geko™ T-1 device investigated is less 
susceptible to compliance issues, as the device is smaller, more discrete in comparison to 
IPC devices; it is also portable allowing the patient to ambulate freely without the need to 
disconnect the device. Recent assessments of the geko™ T-1 device on a number of post 
surgical patients in a specialised tertiary hospital in Australia, confirmed that the device 
is well tolerated by the patients and well received by the hospital staff (Medical, 2012).    
Conclusion  
Findings of the studies presented have demonstrated that the geko™ T-1 device is 
potentially beneficial. Firstly, due to its ability to increase blood flow at the venous, 
arterial as well as microcirculatory level. Secondly, due to exhibiting an enhanced 
fibrinolytic effect by decreasing levels of tissue plasminogen activator antigen. 
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Furthermore, the small size, portability and most importantly simplicity of use makes the 
geko™ T-1 device an essential prophylactic tool with a wide range of application 
possibilities. Although the study successfully reached its aims, the common limitation 
with all the studies presented in this thesis is the small numbers and the use of only young 
healthy volunteers. This might have influenced the degree of statistical significance of 
certain factors assessed in the study. Thus, there is a need to generalise and confirm the 
results obtained on a larger group of patients.  
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Chapter 9. Future Options  
Investigations on the use of electrical nerve stimulation of the lower leg using the novel 
device (geko™ T-1) were encouraging. Tthe geko™ T-1 device is believed to have 
significant implications for the prevention of DVT in hospitals, outpatients and 
community care settings. Furthermore, based on the findings obtained, there is a 
considerable potential for the device to be further applied to non DVT related 
applications to expand the range of indications.  
After performing trials on healthy volunteers and confirming the safety and efficacy of 
the novel neuromuscular electrical stimulation device in enhancing lower limb blood 
perfusion, trials on selected patient population can be initiated. The objectives for 
carrying out future studies is to further confirm the results obtained on patients who are 
believed to be at a greater risk for developing DVT, or who suffer from a vascular or 
micro-vascular disorders. Additionally, to explore the effectiveness of the device in the 
management of conditions characterised by an abnormality in blood flow in comparison 
to commonly used mechanical methods. A summary of the studies, which have been 
planned and are in the progress of being implemented, are outlined below.  
1. Study investigating the effectiveness of a novel electrical stimulation method on 
critical limb ischemic patients  
Analysis of the findings obtained in the studies performed has clearly illustrated that the 
device can significantly stimulate lower limb blood flow in the arterial, venous and 
microcirculatory systems. Furthermore, the device seems to be well tolerated and no 
adverse events were observed. Such observations, provide the framework to study the 
effects of the geko™ T-1 device on critical limb ischemic patients. The primary objective 
of this study is to evaluate the effectiveness of the novel device in enhancing lower limb 
perfusion in limb ischemic patients. The secondary objective is to evaluate using non 
invasive techniques such as duplex ultrasound and laser Doppler flowmetry, the blood 
flow velocity and volume changes associated with the use of the geko™ T-1 at higher 
pulse width settings. Additional objectives are to explore the patients’ acceptability and 
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tolerance through the use of a questionnaire and a scoring index. The geko™ T-1 device 
will be fitted bilaterally to their lower limbs in the supine position. During the stimulation 
period, non invasive blood flow and volume parameters will be measured. These include: 
colour flow duplex ultrasound scanning, pulse oximetry, laser Doppler flowmetry, 
transcutaneous tissue oxygen and transcutaneous carbon dioxide tension. Patients will 
also be asked to evaluate their acceptance and tolerance of the electrical stimulation 
sequences by the use of a Visual Analogue Scale and a Verbal Rating Score. Vital signs, 
including radial pulse, systolic and diastolic blood pressure will be performed prior 
commencing the stimulations.  
 
2. A comparative study of the cardiovascular effects of intermittent pneumatic 
compression therapy and the geko™ electrical stimulator device in hip and knee 
replacement patients 
As described earlier, patients undergoing orthopaedic surgery especially hip and knee 
replacement have an increased risk of developing DVT. This study is a multi-centred 
physiological response study. It is designed to be conducted in Stanmore, Middlesex, 
UK, at six sites involving a total of 72 patients (12 per site). The primary objective is to 
compare the effectiveness of the geko™ device with intermittent pneumatic compression 
in enhancing lower limb perfusion in patient volunteers prior to undergoing hip or knee 
replacement. The secondary objective is to compare and evaluate patients’ tolerability 
and compliance of both systems. Each device will be active for a period of 60 minutes, 
the sequence of application of IPC and geko™ will be randomly selected. Bilateral 
duplex ultrasound assessment to the femoral artery and superficial femoral vein will be 
performed at rest and with the device active at 30 and 60 minutes period. A final scan 
will also be performed 30 minutes following the removal of each device. Patients will 
then be aked to evaluate their acceptance and tolerability to the devices applied using a 
verbal rating score and a visual analogue scale.  
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3. A pilot study investigating the effectiveness of the geko™ device in post-operative 
total hip replacement patients 
The primary objective of the study is to compare the effectiveness of the geko™ device 
in improving venous circulation with A-V-Impulse foot compression device following 
orthopaedic surgery. The secondary objective is to compare and evaluate patients 
tolerability and compliance of both systems investigated. Furthermore, to observe and 
asses improvement in mobility following application of the devices investigated. The 
study is set to take place at the Freeman Hospital, Newcastle, UK. It will include 20 
patients who have undergone total knee replacement and 20 patients who have undergone 
hip replacement. In addition to the chemical prophylaxis treatment, each device will be 
applied bilaterally for a period not exceeding 4 hours. Comparative blood flow analysis 
using colour flow duplex ultrasound to the femoral blood vessels will be performed at 
baseline and hourly. Comparative acceptance and compliance will then be evaluated 
using verbal rating score and visual analogue scale.  
4. A randomised control trial to evaluate the effect of the geko™ T-1 device on measures 
of patient recovery following total hip replacement  
Patients recovery following surgical procedures such as total hip replacement involves 
minimising the negative impact of surgery, so that patients can be pain free and 
functionally able to return to their preoperative state as quickly as possible. This study is 
a parallel group randomised controlled trial. The primary objective of this study is to 
evaluate the effectiveness of using geko™ T-1 device in addition to standard treatment, 
in comparison to using standard treatment alone on measures of patient recovery 
following total hip replacement. The secondary objective is to evaluate patient 
tolerability and compliance when using the geko™ T-1 device. The study is set to take 
place at the Royal Bournemouth and Chrischurch Hospitals NHS Foundation Trust, 
Bournemouth, UK and will involve a total of 24 patients (12 per group). Patients will be 
randomised pre-operatively to receive either standard treatment alone or standard 
treatment with the addition of using the geko™ T-1 device. Patients on the intervention 
group will be instructed to use the geko™ T-1 device when resting supine or when sitting 
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for at least 4 hours per day following surgery and until 6 weeks. Markers of post 
operative stress response, recover, and function after surgery will be measured on every 
post-operative day whilst in hospital and also in the out-patient clinic following 2 and 6 
weeks post-operatively. Patients will also be asked to evaluate their tolerability and 
acceptance of using the geko™ T-1 device using verbal rating score and visual analogue 
scale.  
5. The efficacy of the geko T-1 device in promoting the blood flow in a plaster cast as a 
way of offering mechanical DVT prophylaxis 
Patients in a plaster cast are at risk of developing DVT. Chemical prophylaxis is 
traditionally used for those at highest risk. However, the daily administration of 
injections of heparin or warfarin can be quite exhausting and expensive. Mechanical 
devices available are also impractical and cannot be fitted with a cast. The geko™ T-1 
device is therefore believed to offer a new approach to thromboprophylaxis. The geko™ 
T-1 device causes calf muscle contraction, which expresses blood from the deep venous 
system. Improving venous flow is known to reduce the risk of DVT, which is a common 
problem in orthopaedic patients and can affect patients in a plaster cast. Thus, the geko™ 
T-1 device can be applied to patients with a below knee cast. The study is an open label 
single centred study. It is set to take place at the Southampton University Hospitals Trust, 
Southampton, UK and will involve 10 volunteers. The primary objective of this study is 
to examine the blood flow characteristics of the deep venous system in the leg using 
colour doppler ultrasound and to investigate how the flow is modified by the application 
of a plaster with a geko™ T-1 device in healthy volunteers. The secondary objective is to 
evaluate microcirculatory blood flow changes, using laser Doppler flowmetry and 
transcutaneous tissue oxygen monitors. Additional objectives are to explore the 
participants’ acceptability and tolerance through the use of verbal rating score and a 
visual analogue scale and to assess the pressure exerted on the leg at the points of contact 
during muscle contraction in order to understand any potential risk of tissue damage 
caused by repeated pulsing. A randomly selected leg will be immobilised by each of the 
following methods in sequence: Aircast-type boots (devices analogous to ski boots used 
to immobilise fractures), Plaster cast extending from the forefoot to above the knee and 
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plaster cast extending from the forefoot to below the knee. Bilateral blood flow 
measurements will be made to the lower limbs with the volunteer lying down, with legs 
elevated and standing. Assessments will be made after 10 minutes in each position with 
the geko™ T-1 device switched off and then repeated after the geko™ T-1 device has 
been active for 10 minutes.  
 
6. A new neuromuscular device to improve hemodynamic stability in critical care 
patients 
 
The study is at the final planning stage, it has been designed to investigate the potential 
use of the neuromuscular device in stabilising the vascular systems of patients under 
critical care. Such patients are at an increased risk of developing DVT. The aim of the 
study is to create and clinically evaluate a medical device employing OnPulse™ 
technology, which is believed to improve cardiovascular status of critical care patients 
whilst at the same time prevent DVT. This will significantly reduce the number of deaths 
in critical care patients and reduce the average time of stay in hospitals. The objective of 
the study is to develop a modified OnPulse™ device designed for critical care patients by 
demonstrating its efficacy on patients under general anaesthesia. Another objective is to 
investigate the systemic hemodynamic benefits of the novel technology, particularly at 
and soon after induction of general anaesthesia.  
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Appendix 2- Subject Information Sheet for Cardiac Study 
A study to determine the effects of a novel method for improving lower 
limb blood flow in Healthy Adult Subjects 
Lay Title: “THRIVE-1 – Cardiac Sub-Group” 
 
Part 1 
Invitation 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to 
others about the study if you wish.  
 
 Part 1 tells you the purpose of this study and what will happen to you if 
you take part.   
 Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. 
 
Queen Mary, University of London (QMUL) is the sponsor of this research. 
 
What is the purpose of the study? 
You are being asked to take part in this study because you are a healthy adult, 
aged between 18 and 65 years. 
 
Deep vein thrombosis (DVT) is the formation of a thrombus (clot) within the deep 
veins.  It is a relatively common condition in patients receiving medical or surgical 
treatment in hospital. Recently there has been much controversy and media 
interest regarding the development of deep vein thrombosis and its effects in 
passengers undertaking long haul air travel. This is also referred to as the 
‘economy class syndrome’ or ‘travellers thrombosis’ as it has also been 
associated with other modes of travel e.g. coach and car travel 
 
The THRIVE-1 study is examining a novel method for increasing blood flow in the 
lower leg using low level electrical stimulation. Increases in leg blood flow 
improve the return of blood towards the heart and thereby reducing accumulation 
of blood in the legs (venous stasis). Since stasis is one of the important factors in 
the development of deep vein thrombosis, the risk of developing thrombosis 
should be reduced.  This technique may prove to be a useful tool in preventing 
and reducing the incidence of deep vein thrombosis in both medical and surgical 
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patients together with passengers undertaking long duration travel (as travel-
related DVT is not exclusively related to flying). 
Following completion the first phase of 30 health Volunteers, we have found that 
the device can significantly increase leg blood flow in the arteries, veins and 
small blood vessels of the legs. The increases appear to be clinically valuable in 
relation to rest, but within normal ranges compared to exercise. Furthermore, 
there were no adverse events or causes for concern. 
This sub-study will allow us to study if these increases in blood flow in the legs 
have the effect of increasing the output of the heart in 10 healthy Volunteers. The 
value of this additional study will be to further confirm the safety of the device and 
to understand if the THRIVE system may have the additional potential to help 
patients with heart disease. 
Why have I been chosen? 
You are being asked to take part in this study because you are a healthy adult, 
aged between 18 and 65 years. 
 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You 
are still free to withdraw at any time and without giving a reason.  If you are 
employed by Barts & The London NHS Trust or Barts & The London School of 
Medicine & Dentistry, non-participation or dropping out of the study will not affect 
your training or career. 
Before you can begin the study 
You may read the full study protocol as well as this Information sheet, which 
gives you many details about the study. The recruiting Investigator will tell you 
about any potential adverse events that could occur in this study. You will be told 
exactly what the study entails and what will be required of you. You are 
encouraged to ask questions of the Investigators conducting the recruitment 
interview until you are satisfied that you fully understand the nature of the study 
and the requirements. 
 
What will happen to me if I take part? 
Screening 
If you agree to take part and sign a Consent for Study Screening you will be 
invited to a selection session. We will take a detailed medical history and a 
physical examination, including blood pressure, pulse rate and heart rhythm. 
Signs of drug and alcohol abuse will also be checked.  We will use an ultrasound 
machine to look at the blood vessels in your legs and your heart to check for any 
abnormalities, which might prevent you joining the study. This is entirely painless, 
and you will be required to attend with a pair of shorts. 
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Study 
If all results match our inclusion and exclusion criteria you will be invited to join 
the study and you will be asked to start within 7 days. The duration of your 
participation in the study will be around 2 hours in total. 
 
We hope to recruit 10 people to this part of the study.  On the day of the study 
you will need to attend the Cardiac Department of the Royal London Hospital 
with a pair of shorts to wear during the testing. You will be instructed to have a 
light breakfast, avoiding fatty foods, tobacco and caffeine and will be asked to 
abstain from vigorous exercise from the previous evening onwards. You will be 
asked to rest for 30m minutes to relax and get use to the environment. Your 
resting blood flow will then be measured in your legs and an ultrasound study of 
your heart will occur. These measurements are entirely non-invasive and 
painless.  
We will apply the stimulator electrodes to the back of each of your knees over a 
nerve. When switched on, the stimulation will make the muscles of your calf and 
foot gently contract. This will not hurt, but might feel a little strange and 
uncomfortable. The device will be turned on for the next 30 minutes, during which 
time the blood flow and heart measurements will be repeated. Also, during this 
time, we will ask you a series of questions about how the device feels and how 
comfortable you are compared to the discomfort you associate with having your 
blood pressure measured.  
After this point you will be discharged from the Study. 
 
Expenses and payments 
For attending the Screening session we will compensate you with £15-00. At the 
end of the study we will be pleased to pay you £60-00 for your time, commitment 
to the study and expenses (a total maximum payment of £75-00). 
If the study is stopped by the Investigator(s) prior to completion, if you withdraw 
or are withdrawn from the study before completion, a pro-rata payment will be 
made at the discretion of the Investigator(s). 
What are the possible benefits of taking part? 
This study will not benefit you directly, however it may lead to the development of 
a novel method for preventing deep vein thrombosis in patients and travellers 
alike; and may help in the future management of patients with heart disease 
 
Could I come to any harm if I take part in the study? 
You may be withdrawn from the study if the doctors feel it is best for you or if you 
do not comply with the requirements of the study. 
If during the health screening tests any abnormal results are found, you will be 
immediately referred for clinical review as appropriate. 
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If you feel unacceptable discomfort, or for any reason during the study you do not 
wish to continue, than we will stop the tests immediately. 
 
The blood flow measurements and ultrasound are non-invasive, painless and 
known to be entirely safe. 
 
All of the previous work using the system was found to be safe. When the device 
is applying an electrical stimulation, you may feel some muscle twitching and 
maybe tingling in your lower legs. 
 
There are very few risks involved in using this type of equipment and the device 
is commonly used for therapeutic purposes to exercise muscles under the 
supervision of a Physiotherapist, as well as by members of the public for “toning” 
purposes in their own homes.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  The detailed information on 
this is given in part 2. 
If you have a complaint please contact the following in the first instance: Dr. 
Arthur Tucker. 
If you feel any discomfort or distress during the investigations, you must say so 
and we will stop the tests immediately at any time. 
If you are employed by Barts & The London NHS Trust or Barts & The London 
School of Medicine & Dentistry, non-participation or dropping out of the study will 
not affect your training or career. 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on 
this is given in Part 2.    
A contact number for complaints will be given. 
Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept 
confidential.  The details are included in Part 2. 
 
Contact Details: 
If you require any further information please contact:   
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Dr Arthur Tucker 
The Ernest Cooke Vascular & Microvascular Unit, 
4th Floor Dominion House, 
St. Bartholomew’s Hospital, 
West Smithfield. 
London. EC1A 7BE. 
Tel Number: 0207 601 8498 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making any decision. 
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Part 2  
What if relevant new information becomes available?   
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied.  If this happens, your 
research doctor will tell you about it and discuss whether you want to or should 
continue in the study.  If you decide not to carry on, your research doctor will 
make arrangements for your care to continue.  If you decide to continue in the 
study you will be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study.  He/she will explain the 
reasons and arrange for your care to continue. If the study is stopped for any 
other reason, you will be told why and your continuing care will be arranged. 
 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study we will need to use the data collected up to your 
withdrawal.  
What if there is a problem? 
Queen Mary University of London has agreed that if you are harmed as a result 
of your participation in the study, you will be compensated, provided that, on the 
balance of probabilities, an injury was caused as a direct result of the intervention 
or procedures you received during the course of the study. These special 
compensation arrangements apply where an injury is caused to you that would 
not have occurred if you were not in the trial. These arrangements do not affect 
your right to pursue a claim through legal action. 
Complaints:  
If you have a concern about any aspect of this study, you should ask to speak 
with the Research Team who will do their best to answer your questions (Dr 
Arthur Tucker, telephone 020 7601 8498).  
 
If you remain unhappy and wish to complain formally you can do this by 
contacting: The Complaints Officer, c/o The Chief Operating Officer for the Barts 
and The London, Queen Mary School of Medicine and Dentistry, Wardens Office, 
32 Newark Street, Whitechapel, London E1 2AA, 020 7882 2259 
 
Will my taking part in this study be kept confidential? 
All the information obtained about you in the course of the study is confidential 
and will be kept in a secure locked room. The investigators performing the study 
and a study Monitor will have access to the data collected in this study.  They may 
also be looked at by representatives of regulatory authorities and by authorised 
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people from Queen Mary University of London Medical School to check that the 
study is being carried out correctly. All will have a duty of confidentiality to you as 
a research participant and nothing that could reveal your identity will be disclosed 
outside the research site. 
Involvement of the General Practitioner/Family doctor (GP)  
With your permission we will contact your General Practitioner to advise them of 
your potential participation in this study. 
 
What will happen to the results of the research study? 
The results of this study may be published or presented at meetings.  You will not 
be identified in any report / publication or presentation. 
Who is organising and funding the research?   
This research is being sponsored by Queen Mary, University of London Medical 
School. 
Who has reviewed the study?  
This study has been given a favourable ethical opinion for conduct in the NHS by 
Brent Research Ethics Committee reference 05 / Q0408 / 14. 
Before you sign this consent form please ask any questions you have about the 
study. 
Thank you for taking the time to read this information sheet. 
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Appendix 3- Screening Consent Form for Cardiac Study 
    Date    Signature 
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Appendix 3- Consent form for Study Participation for Cardiac Study 
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Appendix 4- Ethics Approval Letter for THRIVE Study 
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Appendix 5: Subject Information Sheet for THRIVE Study 
A study to determine the effects of a novel method for improving 
lower limb blood flow in Healthy Adult Subjects 
          EAST LONDON & The CITY HEALTH AUTHORITY 
 
Invitation to participate in a Research Project 
We invite you to take part in a research project, which we think may be important. 
The information, which follows, tells you about it. It is important that you 
understand what is in this leaflet. It says what will happen if you take part and 
what the risks might be. Try to make sure you know what will happen to you if 
you decide to take part. Whether or not you do take part is entirely your choice. 
Please ask any questions you want to about the research and we will try our best 
to answer them. 
Introduction 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with friends, relative and your GP if you wish. Ask if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not 
you wish to take part. Consumers for Ethics in Research (CERES) publish a 
leaflet entitled “Medical Research and You”. This leaflet gives more information 
about medical research and looks at some questions you may want to ask. A 
copy may be obtained from the Research Team. 
Why have we approached you? 
You are being asked to take part in this study because you are a healthy adult, 
aged between 18 and 65 years. 
 
Deep vein thrombosis (DVT) is the formation of a thrombus (clot) within the deep 
veins.  It is a relatively common condition in patients receiving medical or surgical 
treatment in hospital. Recently there has been much controversy and media 
interest regarding the development of deep vein thrombosis and its effects in 
passengers undertaking long haul air travel. This is also referred to as the 
‘economy class syndrome’ or ‘travellers thrombosis’ as it has also been 
associated with other modes of travel e.g. coach and car travel.  
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The THRIVE-1 study will examine a novel method for increasing blood flow in the 
lower leg using electrical stimulation. Increases in leg blood flow improve the 
return of blood towards the heart and thereby reducing accumulation of blood in 
the legs (venous stasis). Since stasis is one of the important factors in the 
development of deep vein thrombosis, the risk of developing thrombosis should 
be reduced.  This technique may prove to be a useful tool in preventing and 
reducing the incidence of deep vein thrombosis in both medical and surgical 
patients together with passengers undertaking long duration travel (as travel-
related DVT is not exclusively related to flying). 
 
The aim of this second phase of the study is to effectiveness and tolerability of an 
electrical stimulation protocol developed in the first phase of investigations. 
 
Before you can begin the study 
You may read the full study protocol as well as this Information sheet, which 
gives you many details about the study. The recruiting Investigator will tell you 
about any potential adverse events that could occur in this study. You will be told 
exactly what the study entails and what will be required of you. You are 
encouraged to ask questions of the Investigators conducting the recruitment 
interview until you are satisfied that you fully understand the nature of the study 
and the requirements. 
What would I do in the study, if I took part? 
Screening 
If you agree to take part and sign a Consent for Study Screening you will be 
invited to a selection session. We will take a detailed medical history and a 
physical examination, including blood pressure, pulse rate and heart rhythm. 
Signs of drug and alcohol abuse will also be checked.  We will use an ultrasound 
machine to look at the blood vessels in your legs to check for any abnormalities, 
which might prevent you joining the study. This is entirely painless, and you will 
be required to attend with a pair of shorts. 
With your permission we will contact your General Practitioner to advise them of 
your potential participation in this study. 
 
Study 
If all results match our inclusion and exclusion criteria you will be invited to join 
the study and you will be asked to start and complete your participation within a 
2-day period. 
 
We hope to recruit 20 people to this part of the study.  On the day of the study 
you will need to attend the Clinical Microvascular Unit with a pair of shorts to 
wear during the testing. You will be instructed to have a light breakfast, avoiding 
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fatty foods, tobacco and caffeine and will be asked to abstain from vigorous 
exercise from the previous evening onwards. Before we start the blood flow 
measurements, we will insert 3 cannulae: one in a vein in each foot and one in 
your arm. By using the cannula we will be able to take small samples of blood 
without having to keep using a needle each time. At regular intervals:  At the 
start, 1, 2, 3, and 4 hours we will take blood samples, twenty millilitres (four 
teaspoons) from each site at each time point. The total amount of blood we will 
collect for analysis is about 240mL, which is less than you would donate at the 
blood bank. 
You will sit in an airline chair for a period of 4 hours. After sitting comfortably, we 
will ask you to move your toes up and down ten times to give us a baseline 
measurement of your natural system for moving the blood in the legs. Following 
this baseline, we will apply the stimulator electrode to the back of one of your 
knees over a nerve. When switched on, the stimulation will make the muscles of 
your calf and foot contract. This will not hurt, but might feel a little strange. Your 
other leg will not be stimulated and we will compare the responses of both legs. 
After each 5 minutes stimulation sequence we will take repeated measurements 
of the blood flow in your legs. Your blood flow will then be allowed to recover 
before the next sequence. These measurements are entirely non-invasive and 
painless. Also, during the 4 hours, we will ask you a series of questions about 
how the device feels and how comfortable you are compared to the discomfort 
you associate with having your blood pressure measured. During the study we 
will provide you with soft drinks (no alcohol) and a light snack. We hope to offer 
an ‘in flight’ movie, but you may prefer to work or read quietly. 
 
After the 4-hour assessment period, we will rescan your legs with an ultrasound 
to check that there is no evidence of significant clotting. Our experience strongly 
indicates that this is not a significant risk to you. 
 
After this point you will be discharged from the Study. 
 
What payment will I receive for doing this study? 
For attending the Screening session we will compensate you with £25-00. At the 
end of the 4-hour flight we will be pleased to pay you £90-00 for your time and a 
further £10-00 for each additional ultrasound for your time, commitment to the 
study and expenses (a total maximum payment of £135-00). 
If the study is stopped by the Investigator(s) prior to completion, if you withdraw 
or are withdrawn from the study before completion, a pro-rata payment will be 
made at the discretion of the Investigator(s). 
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Will this study help me? 
This study will not benefit you directly; however it may lead to the development of 
a novel method for preventing deep vein thrombosis in patients and travellers 
alike. 
 
 
Could I come to any harm if I take part in the study? 
You may be withdrawn from the study if the doctors feel it is best for you or if you 
do not comply with the requirements of the study. 
If during the health screening tests any abnormal results are found, you will be 
immediately referred for clinical review as appropriate. 
 
If you feel unacceptable discomfort, or for any reason during the study you do not 
wish to continue, than we will stop the tests immediately. 
 
Previous work using the system was found to be safe. When the device is 
applying an electrical stimulation, you may feel some muscle twitching and 
maybe tingling in your lower leg. 
There are very few risks involved in using this type of equipment and the device 
is commonly used for therapeutic purposes to exercise muscles under the 
supervision of a Physiotherapist, as well as by members of the public for “toning” 
purposes in their own homes.  
 
There are very few risks involved in inserting a catheter into a vein in the arm. 
You may feel some discomfort and sometimes there may be a small bruise 
around the area, which may sore and last for a couple of days.  
Due to the time you are sat in the chair, there is a very small statistical risk of 
microthrombi (clot) forming in your veins. The chance of this happening is similar 
to the risk accepted by any airline passenger. You have been selected as a 
group of people who should be at the lowest risk of developing a problem. 
However, the Volunteers will benefit from ultrasound monitoring by expert staff 
before and after each sitting session allowing early identification of any problems, 
and appropriate measures to be taken. 
 
Symptoms of a clot can include: swelling of the leg, warmth and redness of the 
leg; pain that is noticeable; or worse when standing or walking; shortness of 
breath; chest pain which may be worsened by deep breaths; and coughing up 
phlegm, possibly flecked with blood. 
 
Anyone with these symptoms should seek emergency medical treatment 
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Any concerns during the Study? 
If you have any problems before, during or after the study you should contact: 
Dr Arthur T. Tucker (020) 76018498. Outside working hours you can contact us 
via the hospital switchboard (0207) 3777000. The study has been seen and 
approved by the Brent Medical Research Ethics committee. Any personal 
information will remain strictly confidential. 
If you feel any discomfort or distress during the investigations, you must say so 
and we will stop the tests immediately at any time. 
If you are employed by Barts & The London NHS Trust or Barts & The London 
School of Medicine & Dentistry, non-participation or dropping out of the study will 
not affect your training or career. 
 
Are there any factors, which would exclude me from taking part in the 
research? (And which are not known by the investigators) e.g. Other 
medications. 
You may not join the study if you have ever had a deep vein thrombosis, 
significant injury to either of your legs or have any circulatory problems. 
We need to know whether you are taking any medication as this may also 
exclude you from the study, this includes oral contraceptives and the so-called 
“morning-after pill”. There are no known interactions with any other medications 
but you must inform one of the Investigators of any new medications or changes 
in your general health during the study.  
You should not take part in this study if you are already involved in any other 
study. 
 
You will also not be able to take part in the study if you are taking drugs of abuse, 
either short or long term. 
How will confidentiality be protected? 
All the information obtained about you in the course of the study is confidential 
and will be kept in a secure locked room.  
The investigators performing the study, Queen Mary University of London (study 
Sponsor) and the Barts & The London NHS Trust will have full access to the data 
collected in this study. Official representatives of the Drug Regulatory Authorities 
may at some stage in the future request access to the data collected in this study. 
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You don’t have to join the study. You are free to decide not to be in this trial or to 
drop out at any time. 
What happens if you are worried or if there is an emergency? 
You will always be able to contact an investigator to discuss your concerns 
and/or to get help 
Dr Arthur T. Tucker 
The Ernest Cooke Clinical Microvascular Unit, 
4th Floor Dominion House, 
St. Bartholomew’s Hospital, 
London. EC1A 7BE. 
Tel. No: 020 76018498 
Mobile No: 07887 852995     
 
What happens if something goes wrong? 
We believe that this study is basically safe and do not expect you to suffer any 
harm or injury because of your participation in it. However, we carry insurance to 
make sure that if your health does suffer as a result of your being in the study, 
then you will be compensated. In such a situation, you will not have to prove that 
the harm or injury, which affects you, is anyone’s fault. If you are not happy with 
any proposed compensation, you may have to pursue your claim through legal 
action. 
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Appendix 6 -Screening Consent Form for THRIVE Study  
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Appendix 7 – Consent Form for Participation in THRIVE Study 
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Appendix 8- Flow Chart for Blood Collection 
Blood sample taken from [a] Left foot [b] Right foot [c] Arm of each subject at 0,1,2,3, and 4 hours goes to: 
 
 
                                                                                                                                             
                                                         
                                                                                                       
                                                                                                                                 
ACT  
0.4 ml/channel 
1) 1 ml Syringe 
1.8 ml light - blue tube  2) 
ROTEM 
6PG F1 α        
250 µL aliquots 
(3) 
Indomethacin 
(10µg/ml)  
1.8 ml light - blue tube                                                                                                                           
Double Centrifuge 
3) 
2500g for 10 mins 
Double Centrifuge 
 D-Dimer & ETP         
 600 µL aliquots (1) 
4.5 ml light - blue tube                                                    
2500g for 10 mins 
4) 
VWF & tPA 
250 µL aliquots (7) 
5) 
Double Centrifuge 
4.5 ml light - blue tube                                                    
2500g for 10 mins
+ 
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Appendix 9-Cryo-vial Arrangement Plan per Patient 
 
A1: Start of D-Dimer & ETP (0 - 4 hrs)                       Arm (A)           
G2: Start of PGF1 alpha (0 - 4 hrs)                            Right Leg (RL) 
G7: Start of vwf & Tpa (0 - 4hrs)                                Left Leg (LL) 
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Appendix 10- Standard Operating Instructions for ACT 
 
Operating Instructions for the Medtronic Hemotec ACT II 
machine. 
Low Range ACT Tests 
1) Connect power cable and turn on at rear of machine. The machine automatically runs 
through a self-check test.  The temperature displayed should read between 36 – 37 0C 
(body temperature) this initially takes about 10 mins. 
 
Do not turn on the Incubation switch.  This option is not required for Low Range ACT 
tests. 
 
2) Place the test cartridges in the machine for 3 minutes prior to collecting 
sample of blood.  This step will heat the cartridges up to 36-37 C (body temp.). 
These cartridges can be left heating in the machine for up to 12 hours. 
 
3) Collect your blood sample when ready to perform test.  Approx. 0.5 ml required. 
 
4) Tap the test cartridges to mix the reagents in lower reagent chamber. 
 
5) When using Low Range test cartridges (product code 402-01) Inject .2ml of blood 
sample into each upper reaction chamber of test cartridge, this should fill to between the 
fill lines.  Allow the sample to flow down the back of the chamber taking care to avoid 
getting sample on the black flag. (we recommend using a syringe with blunt tip needle to 
dispense the sample in the cartridge). 
 
6) Insert the test cartridge into the machine (actuator heat block) and push forward 
toclosed position.  The test will commence immediately. 
 
After clot formation has been detected, an audible tone sounds and the actuator heat 
block automatically springs forward to open position. The result is displayed (in seconds) 
on the front panel, until the next test is commenced. If wished - new cartridges can be 
inserted to prepare for next test. 
 
The results have two display formats controlled by the front panel Display switch. When 
the display switch is depressed so that “Channel 1” and “Channel 2” are illuminated, 
the individual clotting times are displayed. 
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Channel 1 or the left –hand channel is the upper display, and channel 2 or the right-hand 
Channel is the lower display. When the Display switch is depressed so that “Average” 
and “Difference” are illuminated, the upper display shows the average of the clotting 
times of channels 1 and 2, and the bottom display shows the difference between the 
clotting times of channels 1 and 2. 
 
NB: The Duplicate channel results should fall within 12% of each other for extended or 
heparinised blood samples.  If the values do not fall within 12% of each other please 
retake the test with a fresh blood sample. 
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Appendix 11- Standard Operating Procedures for Rotem® 
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Appendix 15 – Discomfort Questionnaire for THRIVE Study 
 
Volunteer Number:      Time Point:  
Date:         
 
Discomfort Questionnaire 
 
When compared to a blood pressure cuff inflated around your upper arm, how does the 
stimulation feel? 
 
Q: “How uncomfortable was the last stimulation sequence?”  
Select one answer by circling the number. 
 
     
[1] No sensation (other than muscles tensing and relaxing) 
[2] Minimal sensations 
[3] Mild discomfort 
[4] Moderate discomfort 
[5] Severe discomfort 
 
Fold Here ----------------------------------------------- Fold Here 
 
Q: “What did the last stimulation sequence feel like?” 
Make a vertical line across the line below, which relates to the intensity of any 
discomfort experienced by the procedure. 
 
9.1.1.1.  No Sensations    Severe Discomfort 
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Appendix 16 - Clotting Time Assessment using Rotem® Device 
 
A. Clot formation time using Intem Rotem® throughout the control and Stimulation Study 
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B. Maximum Clot Firmness using Intem Rotem® throughout the Control and Stimulation 
Study  
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C. Clot Formation Time using Extem Rotem® throughout the Control and Stimulation Study 
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D. Maximum Clot Firmness using Exem Rotem® throughout the Control and Stimulation 
Study 
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Appendix 17 - Tissue Plasminogen Activator Antigen Data 
Standard Curves for Plates 1 & 2 (Stimulation Study) 
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Standard Curves for Plates 3 & 4 (Stimulation Study) 
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Standard Curves for Plate 1 & 2 (Control Study)  
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Standard Curves for Plate 3 & 4  (Control Study)  
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Appendix 18– von Willebrand Factor Antigen Data 
Standard Curves for Plates 1 & 2 (Stimulation Study)  
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Standard Curves for Plate 3 & 4 (Stimulation Study) 
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Standard Curves for Plate 1 & 2 (Control Study) 
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Standard Curves for Plate 3 & 4 (Control Study) 
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Appendix 19 - 6 Keto PGF1α Data   
 
Standard Curve for Plate 1 & 2 (Stimulation Study)  
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Standard Curve for Plate 3 & 4 (Stimulation Study) 
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Standard Curve for Plate 1 & 2 (Control Study)  
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Standard Curve for Plate 3 & 4 (Control Study) 
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Appendix 20: Thrombin Generation Data 
 
Thrombin Generation – Control Study  
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Thrombin Generation – Control Study  
 
 
 
Thrombin Generation – Stimulation Study  
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Thrombin Generation – Stimulation Study  
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Thrombin Generation & D-dimer Results- Stimulation Study 
Subject Site Time D-dImer 
ETP 
(nM.min) 
Peak height 
(nM thrombin) 
Time to peak 
(mins) 
Lag time 
(mins) 
1 Arm 0 <100 3417 552 6.67 3.33 
1 Arm 1 <100 3259 539 6.67 3.33 
1 Arm 2 <100 4269 649 8.00 4.00 
1 Arm 3 <100 3708 593 7.33 3.33 
1 Arm 4 <100 2283 370 6.67 3.33 
1 Lleg 0 <100 2292 379 7.33 3.33 
1 Lleg 1 <100 2374 377 7.33 4.00 
1 Lleg 2 <100 2591 417 6.67 3.33 
1 Lleg 3 <100 2256 365 7.33 3.33 
1 Lleg 4 <100 2494 386 7.33 4.00 
1 Rleg 0 <100 2324 375 7.33 4.00 
1 Rleg 1 <100 2070 339 6.67 3.33 
1 Rleg 2 <100 2253 349 7.33 4.00 
1 Rleg 3 <100 2243 350 7.33 4.00 
1 Rleg 4 <100 2201 359 7.00 4.00 
2 Arm 0 <100 2293 339 8.33 4.67 
2 Arm 1 <100 2521 362 9.00 5.00 
2 Arm 2 <100 2503 363 9.00 5.00 
2 Arm 3 * * * * * 
2 Arm 4 * * * * * 
2 Lleg 0 <100 2398 360 9.00 5.00 
 Appendix 20 
Page 240 of 265 
 
Thrombin Generation & D-dimer Results- Stimulation Study 
Subject Site Time D-dImer 
ETP 
(nM.min) 
Peak height 
(nM thrombin) 
Time to peak 
(mins) 
Lag time 
(mins) 
2 Lleg 1 <100 2829 388 9.33 5.33 
2 Lleg 2 <100 2780 379 9.33 5.33 
2 Lleg 3 <100 2516 343 8.67 4.67 
2 Lleg 4 <100 2634 372 9.33 5.33 
2 Rleg 0 <100 2417 353 9.33 5.33 
2 Rleg 1 <100 2329 321 8.67 4.67 
2 Rleg 2 <100 2465 342 9.00 5.00 
2 Rleg 3 <100 2465 345 9.33 5.33 
2 Rleg 4 <100 2280 329 8.33 4.67 
3 Arm 0 <100 2627 402 8.67 5.33 
3 Arm 1 <100 2637 408 8.67 5.33 
3 Arm 2 <100 2560 416 8.67 5.33 
3 Arm 3 <100 2629 417 8.67 5.33 
3 Arm 4 <100 2883 440 9.33 5.33 
3 Lleg 0 <100 2403 411 8.33 5.33 
3 Lleg 1 <100 1544 275 6.67 3.33 
3 Lleg 2 <100 1667 276 7.33 4.00 
3 Lleg 3 <100 1730 285 7.33 4.00 
3 Lleg 4 <100 1903 321 7.67 4.00 
3 Rleg 0 <100 2452 380 8.67 4.67 
3 Rleg 1 <100 2749 419 8.67 5.33 
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Thrombin Generation & D-dimer Results- Stimulation Study 
Subject Site Time D-dImer 
ETP 
(nM.min) 
Peak height 
(nM thrombin) 
Time to peak 
(mins) 
Lag time 
(mins) 
3 Rleg 2 <100 2540 418 8.67 5.33 
3 Rleg 3 <100 2742 429 8.67 5.33 
3 Rleg 4 <100 2676 423 8.67 5.33 
4 Arm 0 <100 1528 264 6.00 3.00 
4 Arm 1 <100 1586 278 6.00 3.00 
4 Arm 2 <100 1627 286 6.67 3.67 
4 Arm 3 <100 1548 296 6.33 3.33 
4 Arm 4 <100 2058 367 7.00 3.67 
4 Lleg 0 <100 2158 399 7.00 4.00 
4 Lleg 1 <100 2041 388 6.67 3.33 
4 Lleg 2 <100 2472 444 7.33 4.00 
4 Lleg 3 <100 2627 459 8.00 4.67 
4 Lleg 4 * * * * * 
4 Rleg 0 <100 2280 392 7.00 4.00 
4 Rleg 1 <100 2226 366 7.00 3.67 
4 Rleg 2 <100 2127 368 7.00 4.00 
4 Rleg 3 <100 2161 376 7.33 4.00 
4 Rleg 4 <100 2090 371 7.33 4.00 
5 Arm 0 <100 3820 476 9.33 5.33 
5 Arm 1 <100 3577 466 9.33 5.33 
5 Arm 2 <100 3668 468 9.33 5.33 
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Thrombin Generation & D-dimer Results- Stimulation Study 
Subject Site Time D-dImer 
ETP 
(nM.min) 
Peak height 
(nM thrombin) 
Time to peak 
(mins) 
Lag time 
(mins) 
5 Arm 3 <100 3704 492 9.33 5.33 
5 Arm 4 <100 3508 501 8.67 5.00 
5 Lleg 0 <100 2391 351 8.00 4.00 
5 Lleg 1 <100 2529 358 7.67 3.67 
5 Lleg 2 <100 2262 331 7.67 3.67 
5 Lleg 3 <100 2037 306 7.00 3.33 
5 Lleg 4 <100 2482 356 8.33 4.33 
5 Rleg 0 <100 3198 437 8.67 4.67 
5 Rleg 1 <100 2110 322 6.67 3.00 
5 Rleg 2 <100 2415 349 7.67 4.00 
5 Rleg 3 <100 2213 332 7.67 3.67 
5 Rleg 4 <100 2267 336 7.33 3.67 
6 Arm 0 <100 2577 358 8.00 4.00 
6 Arm 1 <100 2254 337 8.00 4.33 
6 Arm 2 <100 2317 344 8.00 4.33 
6 Arm 3 <100 2314 346 8.00 4.33 
6 Arm 4 <100 2309 350 8.00 4.00 
6 Lleg 0 <100 2319 348 8.00 4.67 
6 Lleg 1 <100 2207 322 8.67 4.67 
6 Lleg 2 <100 2184 327 8.67 4.67 
6 Lleg 3 <100 2137 327 8.33 4.33 
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Thrombin Generation & D-dimer Results- Stimulation Study 
Subject Site Time D-dImer 
ETP 
(nM.min) 
Peak height 
(nM thrombin) 
Time to peak 
(mins) 
Lag time 
(mins) 
6 Lleg 4 <100 2037 329 7.67 3.67 
6 Rleg 0 <100 2230 345 8.00 4.00 
6 Rleg 1 <100 2114 326 8.00 4.00 
6 Rleg 2 <100 2177 333 8.00 4.33 
6 Rleg 3 <100 2282 341 8.67 4.67 
6 Rleg 4 <100 2351 342 8.67 4.67 
7 Arm 0 <100 1675 298 6.67 3.33 
7 Arm 1 <100 1898 318 7.33 3.67 
7 Arm 2 <100 1904 325 7.00 3.67 
7 Arm 3 <100 1822 317 7.33 4.00 
7 Arm 4 <100 1851 321 7.33 4.00 
7 Lleg 0 <100 1755 297 6.67 3.33 
7 Lleg 1 <100 1769 311 7.33 4.00 
7 Lleg 2 <100 1847 314 7.33 4.00 
7 Lleg 3 <100 1777 311 7.33 4.00 
7 Lleg 4 <100 1792 313 7.33 4.00 
7 Rleg 0 <100 1849 308 7.33 4.00 
7 Rleg 1 <100 1813 315 7.00 3.67 
7 Rleg 2 <100 1743 307 6.67 3.33 
7 Rleg 3 <100 1749 318 6.67 3.33 
7 Rleg 4 <100 1925 322 7.33 4.00 
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Thrombin Generation & D-dimer Results- Stimulation Study 
Subject Site Time D-dImer 
ETP 
(nM.min) 
Peak height 
(nM thrombin) 
Time to peak 
(mins) 
Lag time 
(mins) 
8 Arm 0 <100 3118 477 6.00 3.33 
8 Arm 1 <100 3249 483 6.00 3.33 
8 Arm 2 <100 3102 439 6.67 3.33 
8 Arm 3 <100 3102 450 6.67 3.33 
8 Arm 4 <100 3272 466 6.67 3.33 
8 Lleg 0 <100 3492 543 6.33 3.33 
8 Lleg 1 <100 3358 516 6.33 3.33 
8 Lleg 2 <100 3431 516 6.67 3.33 
8 Lleg 3 <100 3257 501 6.67 3.33 
8 Lleg 4 <100 3442 512 6.33 3.33 
8 Rleg 0 <100 3122 456 6.67 3.33 
8 Rleg 1 <100 3079 453 6.67 3.33 
8 Rleg 2 <100 2917 458 6.33 3.33 
8 Rleg 3 <100 2779 457 6.00 3.33 
8 Rleg 4 <100 2997 477 6.00 3.00 
9 Arm 0 <100 2492 354 8.33 4.33 
9 Arm 1 <100 2531 363 8.00 4.00 
9 Arm 2 <100 2491 357 8.33 4.00 
9 Arm 3 <100 2780 372 8.67 4.67 
9 Arm 4 <100 2868 386 8.00 4.00 
9 Lleg 0 <100 2473 336 8.00 4.00 
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Thrombin Generation & D-dimer Results- Stimulation Study 
 
  
Subject Site Time  D-dImer 
ETP 
 (nM.min) 
Peak height  
(nM thrombin) 
Time to peak 
(mins) 
Lag time 
 (mins) 
9 Lleg 4 <100 2279 305 8.67 4.00 
9 Rleg 0 <100 2724 347 9.33 4.67 
9 Rleg 1 <100 2833 395 8.33 4.33 
9 Rleg 2 <100 2715 376 8.67 4.67 
9 Rleg 3 <100 2502 344 8.67 4.00 
9 Rleg 4 <100 2387 343 8.00 4.00 
10 Arm 0 148 2258 411 6.67 4.00 
10 Arm 1 402 2180 378 7.00 4.00 
10 Arm 2 <100 2108 398 6.67 4.00 
10 Arm 3 <100 1900 367 7.00 4.00 
10 Arm 4 <100 2151 406 7.00 4.33 
10 Lleg 0 118 2105 409 6.67 4.00 
10 Lleg 1 <100 2241 406 7.33 4.00 
10 Lleg 2 <100 2390 446 7.33 4.67 
10 Lleg 3 <100 2306 400 8.00 4.67 
10 Lleg 4 <100 2255 410 7.67 4.67 
10 Rleg 0 140 2265 405 6.67 4.00 
10 Rleg 1 <100 2190 386 6.67 3.67 
10 Rleg 2 <100 2320 411 7.33 4.33 
10 Rleg 3 <100 2190 394 7.33 4.33 
10 Rleg 4 <100 2166 413 7.33 4.33 
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Appendix 21 – Ethics Approval Letter for geko™ versus IPC Comparison Study 
 
 
 Appendix 21 
Page 247 of 265 
 
 
 
 Appendix 22 
Page 248 of 265 
 
Appendix 22 – Subject Information Sheet for geko™ vs. IPC Comparison Study 
A study to determine the effects of a novel method for improving 
lower limb blood flow in Healthy Adult Volunteers 
Lay Title: “THRIVE-1 – IPC Sub-Group” 
 
Part 1 
Invitation 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to others 
about the study if you wish.  
 
 Part 1 tells you the purpose of this study and what will happen to you if you 
take part.   
 Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part. 
 
Queen Mary, University of London (QMUL) is the sponsor of this research. 
 
What is the purpose of the study? 
You are being asked to take part in this study because you are an adult, aged 
between 18 and 65 years. 
 
Deep vein thrombosis (DVT) is the formation of a thrombus (clot) within the deep 
veins.  It is a relatively common condition in patients receiving medical or surgical 
treatment in hospital. Recently there has been much controversy and media interest 
regarding the development of deep vein thrombosis and its effects in passengers 
undertaking long haul air travel. This is also referred to as the ‘economy class 
syndrome’ or ‘travellers thrombosis’ as it has also been associated with other modes 
of travel e.g. coach and car travel 
 
The THRIVE-I study is examining a new device and method for increasing blood flow 
in the legs using very low level electrical stimulation. The device is called GEKO™ 
and is made by Sky Medical Technology Ltd. We know that increases in leg blood 
flow improve the return of blood towards the heart and thereby reducing accumulation 
of blood in the legs (venous stasis). Since stasis is one of the important factors in the 
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development of deep vein thrombosis, the risk of developing thrombosis should be 
reduced.  This technique may prove to be a useful tool in preventing and reducing the 
incidence of deep vein thrombosis in both medical and surgical patients. 
Following completion of the first phase of 50 healthy Volunteers, we have found that 
the device can significantly increase leg blood flow in the arteries, veins and small 
blood vessels of the legs. The increases appear to be clinically valuable in relation to 
rest, but within normal ranges compared to exercise. Furthermore, there were no 
adverse events or causes for concern. 
One of the existing methods used in hospitals for the prevention of deep vein 
thrombosis is intermittent pneumatic compression (IPC) which consists of calf length 
garments which are pneumatically inflated by a pump for approximately twelve 
seconds every minute. By gently inflating cuffs placed around the calves, IPC mimics 
the process of walking by squeezing the calf muscle and forces blood back to the 
heart. This active compression on the limb stops blood from pooling in the lower 
limbs and aims to generate continual movement of blood through the veins. It has 
been found that IPC devices are effective in reducing the risk of DVT by 60% when 
compared to patients receiving no medical device or drug. 
This sub-study will allow us to compare the effect of the geko® device with IPC 
devices to study the increases in blood flow in the legs in 10 healthy Volunteers and 
10 Patient Volunteers with Venous Insufficiency. Chronic venous insufficiency is 
impaired venous return, sometimes causing lower extremity discomfort, swelling, and 
skin changes.  The value of this additional study will be to further confirm the safety 
and potential of the devices for future studies. 
Why have I been chosen? 
You are being asked to take part in this study because you are a healthy adult, aged 
between 18 and 65 year; with or without Venous Insufficiency of your legs. 
 
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part.  If you do, you will be given 
this information sheet to keep and be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason.  As a patient, non-participation or 
dropping out of the study will not affect your clinical management in any way. If you are 
employed by Barts & The London NHS Trust or Barts & The London School of 
Medicine & Dentistry, non-participation or dropping out of the study will not affect your 
training or career. 
Before you can begin the study 
You may read the full study protocol as well as this Information sheet, which gives 
you many details about the study. The recruiting Investigator will tell you about any 
potential adverse events that could occur in this study. You will be told exactly what 
the study entails and what will be required of you. You are encouraged to ask 
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questions of the Investigators conducting the recruitment interview until you are 
satisfied that you fully understand the nature of the study and the requirements. 
What will happen to me if I take part? 
Screening 
If you agree to take part and sign a Consent for Study Participation you will be 
invited to a selection session. We will take a detailed medical history and a physical 
examination, including blood pressure, pulse rate and heart rhythm. Signs of drug 
and alcohol abuse will also be checked.  We will use an ultrasound machine to look 
at the blood vessels in your legs to check for any abnormalities, which might prevent 
you joining the study. This is entirely painless, and you will be required to attend with 
a pair of shorts. 
 
Study 
If all results match our inclusion and exclusion criteria you will be invited to join the 
study and you will be asked to start within 7 days. The duration of your participation in 
the study will be around 3½ hours in total. 
 
We hope to recruit 20 people to this part of the study.  On the day of the study you 
will need to attend the Microvascular Unit at St. Bartholomew’s Hospital with a pair of 
shorts to wear during the testing. You will be instructed to have a light breakfast, 
avoiding fatty foods, tobacco and caffeine and will be asked to abstain from vigorous 
exercise from the previous evening onwards. You will be asked to rest for 30m 
minutes to relax and get use to the environment. Your resting blood flow will then be 
measured in your legs. These measurements are entirely non-invasive and painless.  
We will apply the IPC cuffs around your calves and run the inflation device for 30 
minutes and then repeat the measurements. You will have a ‘rest period’ of ten 
minutes of rest before the next device is tested after 30 minutes. We will study two 
routine IPC devices (Huntliegh Flowtron® and the Kendle ICD Express®). After a 
further ten minutes of rest, we will remove the cuffs from your legs and apply the 
GEKO® device to the back of each of your knees over a nerve. When switched on, 
the stimulation will make the muscles of your calf and foot gently contract. This will 
not hurt, but might feel a little strange and slightly uncomfortable. The device will be 
turned on for the next 30 minutes, during which time the blood flow measurements 
will be repeated with a ten minute rest period before repeating. We will test two 
different settings of the GEKO® device. Also, during these times, we will ask you a 
series of questions about how each device feels and how comfortable you are 
compared to the discomfort you associate with having your blood pressure 
measured.  
After this point you will be discharged from the Study. 
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Expenses and payments 
 
For attending the Screening session we will compensate you with £15-00. At the end 
of the study we will be pleased to pay you £85-00 for your time, commitment to the 
study and expenses (a total maximum payment of £100-00). 
If the study is stopped by the Investigator(s) prior to completion, if you withdraw or 
are withdrawn from the study before completion, a pro-rata payment will be made at 
the discretion of the Investigator(s). 
What are the possible benefits of taking part? 
This study will not benefit you directly, however it may lead to the development of a 
novel method for preventing deep vein thrombosis in patients and travellers alike; and 
may help in the future management of patients to prevent DVT. 
Could I come to any harm if I take part in the study? 
You may be withdrawn from the study if the doctors feel it is best for you or if you do 
not comply with the requirements of the study. 
If during the health screening tests any abnormal results are found, you will be 
immediately referred for clinical review as appropriate. 
If you feel unacceptable discomfort, or for any reason during the study you do not wish 
to continue than we will stop the tests immediately. 
 
All of the previous work using these devices was found to be safe. When the geko® 
device is applying an electrical stimulation, you may feel some muscle twitching and 
maybe tingling in your lower legs. There are very few risks involved in using this type 
of equipment and the device is commonly used for therapeutic purposes to exercise 
muscles under the supervision of a Physiotherapist, as well as by members of the 
public for “toning” purposes in their own homes. 
 
When the IPC devices are inflating, you will feel the cuffs gently squeezing your 
calves. 
The blood flow measurements and ultrasound are non-invasive, painless and known to 
be entirely safe. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed.  The detailed information on this is 
given in part 2. 
 Appendix 22 
Page 252 of 265 
 
If you have a complaint please contact the following in the first instance: Dr. Arthur 
Tucker. 
If you feel any discomfort or distress during the investigations, you must say so and 
we will stop the tests immediately at any time. 
If you are employed by Barts & The London NHS Trust or Barts & The London School 
of Medicine & Dentistry, non-participation or dropping out of the study will not affect 
your training or career. 
 
As a patient, non-participation or dropping out of the study will not affect your clinical 
management in any way 
 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2.    
A contact number for complaints will be given. 
Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept confidential.  
The details are included in Part 2. 
 
Contact Details: 
If you require any further information please contact:   
Dr Arthur Tucker 
The Ernest Cooke Vascular & Microvascular Unit, 
4th Floor Dominion House, 
St. Bartholomew’s Hospital, 
West Smithfield. 
London. EC1A 7BE. 
Tel Number: 0203 4656773 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are considering participation, 
please continue to read the additional information in Part 2 before making any 
decision. 
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Part 2  
What if relevant new information becomes available?   
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied.  If this happens, your 
research doctor will tell you about it and discuss whether you want to or should 
continue in the study.  If you decide not to carry on, your research doctor will make 
arrangements for your care to continue.  If you decide to continue in the study you will 
be asked to sign an updated consent form. 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study.  He/she will explain the reasons 
and arrange for your care to continue. If the study is stopped for any other reason, 
you will be told why and your continuing care will be arranged. 
 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study we will need to use the data collected up to your 
withdrawal.  
What if there is a problem? 
 
Queen Mary University of London has agreed that if you are harmed as a result of 
your participation in the study, you will be compensated, provided that, on the 
balance of probabilities, an injury was caused as a direct result of the intervention or 
procedures you received during the course of the study. These special compensation 
arrangements apply where an injury is caused to you that would not have occurred if 
you were not in the trial. These arrangements do not affect your right to pursue a 
claim through legal action. 
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Complaints  
If you have a concern about any aspect of this study, you should ask to speak with 
the Research Team who will do their best to answer your questions (Dr Arthur 
Tucker, telephone 0203 4656773).  
 
If you remain unhappy and wish to complain formally you can do this by contacting: 
The Complaints Officer, c/o The Chief Operating Officer for the Barts and The 
London, Queen Mary School of Medicine and Dentistry, Wardens Office, 32 Newark 
Street, Whitechapel, London E1 2AA, telephone 020 7882 2259. 
 
Will my taking part in this study be kept confidential? 
All the information obtained about you in the course of the study is confidential and 
will be kept in a secure locked room. The investigators performing the study and a 
study Monitor will have access to the data collected in this study.  They may also be 
looked at by representatives of regulatory authorities and by authorised people from 
Queen Mary University of London Medical School, Barts & The London NHS Trust, 
Sky Medical Technology or the Regulatory Authorities to check that the study is being 
carried out correctly. All will have a duty of confidentiality to you as a research 
participant and nothing that could reveal your identity will be disclosed outside the 
research site. 
What will happen to the results of the research study? 
The results of this study may be published or presented at meetings.  You will not be 
identified in any report / publication or presentation. 
Who is organising and funding the research?   
This research is being sponsored by Queen Mary, University of London Medical 
School. 
Who has reviewed the study?  
This study has been given a favourable ethical opinion for conduct in the NHS by 
North London REC 1 (formerly known as Brent) Research Ethics Committee 
reference:05 / Q0408 / 14. 
Before you sign this consent form please ask any questions you have about the 
study. 
Thank you for taking the time to read this information sheet. 
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Appendix 23 – Participation Consent Form for geko™ vs IPC Comparison Study  
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Appendix 24 – Randomisation Sequence for Device Fitting 
Subject Device Sequence 
 
1 IPC 1, IPC 2, geko™ 1, geko™ 2 
2 geko™ 1, geko™ 2, IPC1, IPC 2 
3 IPC 1, IPC 2, geko™ 1, geko™ 2 
4 geko™ 1, geko™ 2, IPC1, IPC 2 
5 IPC 1, IPC 2, geko™ 1, geko™ 2 
6 geko™ 1, geko™ 2, IPC1, IPC 2 
7 IPC 1, IPC 2, geko™ 1, geko™ 2 
8 geko™ 1, geko™ 2, IPC1, IPC 2 
9 IPC 1, IPC 2, geko™ 1, geko™ 2 
10 geko™ 1, geko™ 2, IPC1, IPC 2 
11 IPC 1, IPC 2, geko™ 1, geko™ 2 
12 geko™ 1, geko™ 2, IPC1, IPC 2 
13 IPC 1, IPC 2, geko™ 1, geko™ 2 
14 geko™ 1, geko™ 2, IPC1, IPC 2 
15 IPC 1, IPC 2, geko™ 1, geko™ 2 
16 geko™ 1, geko™ 2, IPC1, IPC 2 
17 IPC 1, IPC 2, geko™ 1, geko™ 2 
18 geko™ 1, geko™ 2, IPC1, IPC 2 
19 IPC 1, IPC 2, geko™ 1, geko™ 2 
20 geko™ 1, geko™ 2, IPC1, IPC 2 
21 IPC 1, IPC 2, geko™ 1, geko™ 2 
22 geko™ 1, geko™ 2, IPC1, IPC 2 
23 IPC 1, IPC 2, geko™ 1, geko™ 2 
24 geko™ 1, geko™ 2, IPC1, IPC 2 
25 IPC 1, IPC 2, geko™ 1, geko™ 2 
Device Code  
IPC Huntleigh = IPC 1 
IPC Kendle = IPC 2 
geko™ Lower Setting = geko™ 1 
geko™ Higher Setting 2 = geko™ 2 
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Appendix 25 – geko™ T-1 device Manual  
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Appendix 26 – Huntleigh Flowtron™ Instruction Manual  
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Appendix 27 – Kendall SCD Express™ Instruction Manual  
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Appendix 28 – Discomfort Questionnaire for geko™ vs. IPC Comparison Study 
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